Method for engineering synthetic cis-regulatory DNA

The method generates cell type-specific expression cassettes using synthetic cis-regulatory DNA (sLCR) based on gene expression profiles and genomic data, addressing the limitations of prior knowledge-dependent methods by enabling flexible and specific gene expression in any cell type.

JP2024156849AInactive Publication Date: 2024-11-06MAX DELBRUECK CENT FUER MOLEKULARE MEDIZIN
View PDF 11 Cites 0 Cited by

Patent Information

Application Number
JP2024126042
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2018-09-05
Filing Date
2024-08-01
Publication Date
2024-11-06
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current methods for generating cell type-specific gene expression rely on prior knowledge of regulatory elements, limiting their application to complex cell types and requiring extensive characterization, making them inefficient for unbiased and flexible cell type-specific expression.

Method used

A method that utilizes gene expression profiles and genomic sequence data to identify and assemble a set of genomic subregions containing transcription factor binding sites, forming a synthetic cis-regulatory DNA (sLCR) that allows cell type-specific expression without prior knowledge of regulatory elements.

Benefits of technology

Enables highly specific and condition-dependent expression of reporter or effector genes in any given cell type, facilitating applications in gene therapy, drug discovery, and diagnostics by distinguishing between cell types and states without requiring prior knowledge of regulatory elements.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024156849000001_ABST
    Figure 2024156849000001_ABST
Patent Text Reader

Abstract

To provide alternative and / or improved means for the generation of genetic tracing cassettes or vectors based on synthetic cis-regulatory DNA that allow for a cell-type or developmental stage specific expression of reporter genes or functional effectors.SOLUTION: A systems biology approach is employed to generate an expression cassette by identifying a set of endogenously occurring cis-regulatory elements from a given transcriptional signature of the cell type of interest and placing these cis-regulatory elements before a reporter or an effector gene.SELECTED DRAWING: Figure 1-1
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to methods for generating cell type specific expression cassettes and reporter vectors, as well as nucleic acid constructs that can be generated by such methods. The cell type specific expression cassettes and reporter vectors are characterized synthetic cis-regulatory DNAs, also called synthetic locus regions (sLCRs). The sLCRs allow cell type specific expression of reporter or effector genes. The present invention further relates to various applications of reporter vectors, including the determination of cell characteristics, preferably cell type, state or fate transition, in gene and viral therapy, drug discovery or validation. [Background technology]

[0002] Expression cassettes and reporter vectors have a wide range of applications in basic research, drug screening diagnostics or gene therapy.

[0003] Selectively identifying cell type-specific identities is crucial to understanding the biological processes by which different cell types contribute to tissue homeostasis. Ideally, this approach will also inform disease situations involving alterations in tissue homeostasis, including metabolic, immune, neurological or psychiatric disorders, as well as inflammation and cancer. In developmental settings, this is traditionally achieved using lineage tracing. 1 .

[0004] Among the best-known examples, lineage tracing of Fbx15 expression led to the discovery of a defined factor capable of reprogramming fibroblasts into pluripotent cells. 49 Lineage tracing of Lgr5 expression allows identification of bona fide colonic and small intestinal stem cells. 2 These have later been shown to mark stem cells in several other adult tissues. 3 Parallel development of sophisticated reporter strategies allows single-cell analysis in multiple lineages.

[0005] Previously, several gene tracing approaches have been utilized to generate reporter mice for cell type-specific genetic manipulation and cell labeling (e.g., LacZ, mGmT, Brainbow and Confetti systems, Mosaic Analysis with Dual Labeling (MADM), etc.). These strategies have enabled the elucidation of complex neuronal connectivity patterns. 4 This could address unsolved questions such as the cell of origin of tumors in vivo. 5 Recently, optogenetic and CRISRP / Cas9-based strategies have provided additional flexibility in obtaining more quantitative readouts.

[0006] The use of reporter strategies based on adult stem cell biology can simultaneously inform about the origin of a tissue and its pathological homeostasis. 6,7,8 Gene reporters reflecting well-characterized pathways allow for a better understanding of the complex signaling dichotomy, such as transforming growth factor versus bone morphogenetic protein (BMP) signaling in hair follicle homeostasis. 9 .

[0007] In cancer, this approach may reveal that abnormal homeostasis may contribute to therapy resistance. 10 or that regenerative capacity and tumor susceptibility may be shared in some organs and differ significantly in others. 11 Quantitative spatiotemporal patterning dynamics can be revealed by designing synthetic reporters based on transcription factor binding sites. 47 As can be inferred from these and several other studies, the choice of genetic reporter is a critical factor to reliably address sophisticated and complex biological questions. This is particularly useful in developmental or disease situations governed by multiple factors and complex interactions. 12 In these situations, the ability to flexibly design synthetic reporters that disrupt multiple pathways in a single gene cassette would certainly prove to be a major advantage, but current approaches remain limited.

[0008] For example, currently used gene tracking vector approaches rely on the use of cell type-specific, pathway-specific or synthetic promoters or enhancers linked to reporter genes or functional effectors.

[0009] The use of cell type specific promoters is based on placing a reporter gene or a functional effector behind the minimal promoter of a signature gene of the cell type of interest. This allows specific transcriptional activation of a given reporter or effector mediated by the promoter of a given gene. Cell type specific vectors offer the possibility to use a given gene as a surrogate for a cell state or developmental stage.

[0010] One example is the use of the nestin promoter to mark neural progenitor cells. This approach is widely used and allows researchers to induce the activation of specific reporters or effectors in undifferentiated cells.

[0011] A major limitation of these approaches is that they require prior knowledge of the signature genes and assume that the regulatory elements of said genes are known and close to the transcription start site. Moreover, these approaches are insufficient to represent single-gene specificity complex regulatory systems. A cumbersome solution to this problem requires cell-type specific identification of all specific enhancers for any given cell type of interest, followed by selection of one such element and cloning it upstream of a minimal viral promoter. However, this approach is technically demanding and relies on supervised selection. 48 Both limitations limit the application of such approaches to very selective situations.

[0012] An alternative approach uses pathway-specific promoters to place reporters or effectors behind artificially constructed transcription factor binding sites specific for a given pathway, so that specific transcriptional activation can be controlled through the mediation of regulatory elements known to be essential for that pathway.

[0013] One example is the BMP response element (BRE), which is specific for the nuclear activity of SMAD1 / 5 / 8, which represents the activation of the BMP pathway. Although the BRE robustly represents canonical pathway activation, it misses non-canonical activation, resulting in a reporter system that is insufficiently sensitive to feedback loops.

[0014] Limitations of the use of pathway-specific promoters include the need to rely on the assumption that the minimal set of regulatory elements used is sufficient to be informative about pathway activation. Furthermore, a priori knowledge of such regulatory elements and their extensive characterization and isolation from their native environment is required, preventing application to complex, less well-characterized cell types.

[0015] A further approach has been proposed, which involves placing a reporter of interest after multiple artificially constructed transcription factor binding sites in front of a minimal promoter. However, these methods also rely on a priori knowledge of transcription factor binding sites known to be associated with a cell type or developmental stage.

[0016] Both methods suffer from the problem that they rely on a priori knowledge or precise discovery and validation of regulatory elements specific to the cell type or stage of interest. Moreover, in many cases, not all regulatory elements are covered, necessitating the use of multiple markers to ensure reliable cell type characterization, which complicates the construction of reporters and the evaluation of any experimental results.

[0017] The characterization of cells based on the expression of cell-specific surface molecules by flow cytometry has also been described in the art.This is a common method, but it is limited in that the corresponding markers must be known in advance, and not all cell types have characteristic surface proteins.In addition, the in vivo tracking of cell types using this approach is not possible or is very difficult.

[0018] Alternative gene expression reporter vectors have been developed to utilize multiple transcription factor binding sites to regulate expression of the reporter gene.

[0019] Patent document 1 (Korea Institute of Biotechnology and Life Sciences) discloses a cancer-specific gene expression vector that contains a promoter that has, in addition to the binding site for the E2F transcription factor (EF2bs) expressed in the cancer gene, additional binding sites for further transcription factors (e.g., SP1, AP1, NF1 or C / EFB). However, this approach still relies on a priori knowledge of TF binding sites (e.g., EF2bs) that have already been identified to be associated with a particular cancer type.

[0020] Patent document 2 (Libre Universiteit Brussel / University of Ghent) discloses a computational method to identify cardiac and skeletal muscle specific regulatory elements by enrichment of transcription factor binding sites (TFBS), and discloses different regulatory regions (CSk-SH1 to CSk-SH6; Sk-SH1) of 300 bp to 500 bp in length, each containing multiple (3 to 10) conserved TFBS. However, this technique focuses on using evolutionarily conserved TFBS and relies on genomic conservation of regulatory sequences to enhance expression in muscle.

[0021] US Patent No. 5,999,366 discloses a computational method for identifying transcription factor regulatory elements (TFREs) active in cells of interest, where the TFREs have a length of at least 6 bp to 100 bp, and six or more TFREs can be combined in a promoter element of an expression vector. However, this technique uses the fusion of the same preselected minimal promoter with additional TFREs identified under any given condition, i.e., supervised merging of cis elements with known function.

[0022] Non-Patent Document 1 reviews some viral vectors and transcriptional regulatory elements. Non-Patent Document 2 discloses the identification of cis-acting elements for cell-specific expression of vitelline membrane protein gene 32 (VMPE) in the follicular epithelium of Drosophila melanogaster, in which the expression vector contains various segments of regulatory genomic regions.

[0023] Despite these advances in the field, such alternative approaches rely on disadvantageous strategies for the generation of reporter vectors, such as relying on a priori knowledge of relevant promoters, focusing on the genetic / evolutionary conservation of TFBSs, or using single promoters modified by cis-elements with known function.

[0024] Thus, there is a need in the field of synthetic reporters for alternative or improved methods and constructs based on an unbiased de novo approach to decipher and reconstruct the regulatory information for any given cell type or condition. [Prior art documents] [Patent documents]

[0025] [Patent Document 1] International Publication No. 2001 / 49868 [Patent Document 2] International Publication No. 2015 / 110449 [Patent Document 3] International Publication No. 2008 / 107725 [Non-patent literature]

[0026] [Non-Patent Document 1] Guo et al. (Trends in Mol. Medicine, 14:410-418) [Non-Patent Document 2] Gargiulo et al. (Mechanisms of Development, 35:193-203) Summary of the Invention [Problem to be solved by the invention]

[0027] Considering the prior art, the technical problem underlying the present invention is to provide alternative and / or improved means for the generation of gene tracking cassettes or vectors based on synthetic cis-regulatory DNA allowing cell type or developmental stage specific expression of reporter genes or functional effectors. [Means for solving the problem]

[0028] The object is achieved by the features of the independent claims. Preferred embodiments of the invention are provided by the dependent claims.

[0029] Thus, the present invention provides a) providing a gene expression profile of a cell type of interest; b) providing genomic sequence data for said cell type of interest; c) selecting a set of signature genes from said gene expression profile; wherein the signature genes are (i) differentially regulated compared to a reference cell type, or (ii) selected according to gene expression levels; d) identifying genes encoding transcription factors in the set of signature genes selected in c); e) determining a set of genomic regions from the genomic sequence data; wherein each genomic region comprises a sequence encoding a signature gene identified in c) and an additional genomic sequence adjacent to the sequence encoding the signature gene; f) identifying a plurality of genomic subregions of comparable limited size, preferably the same size, in the set of genomic regions determined in e); wherein the genomic subregion comprises one or more binding sites for one or more of the transcription factors identified in d); g) selecting a minimum set of preferably 2 to 10 genomic subregions from the genomic subregions determined in f); wherein the set of genomic subregions is selected to contain transcription factor binding sites for a predetermined percentage of all transcription factors identified in d); h) generating a cell type specific expression cassette comprising the set of genomic subregions selected in step g) operably linked to a reporter gene or an effector gene; wherein the genomic subregion is configured to regulate expression of the reporter gene or effector gene; The present invention relates to a method for generating a cell type specific expression cassette, comprising:

[0030] The methods allow for the generation of expression cassettes that, when introduced into a cell of a subject, result in expression of a reporter gene or an effector gene in a highly specific manner for a particular entity or state, such as the cell type or state that the reporter is designed to indicate, without the need for prior knowledge of the regulation of gene expression in the entity or state of interest.

[0031] In contrast to the prior art, the methods and constructs of the present invention are based on an unbiased de novo approach to decipher and reconstruct regulatory information for any given cell type / state. The present invention is a completely new approach based essentially on the clustering of cell type / state specific TFBSs with cell type / state specific signature genes. The present invention also features the advantage of using quantitative and / or statistical enrichment of relevant TFBSs for any given cell type / state.

[0032] In some embodiments, the method essentially uses a systems biology approach to generate expression cassettes by identifying a set of cis-regulatory elements that occur endogenously from a given transcriptional signature of a cell type of interest and placing these cis-regulatory elements in front of a reporter or effector gene. This approach is independent of any pre-conceived information about the specific properties of the cell type of interest and allows for a standardized, unbiased and straightforward generation of reporter constructs for any given cell type.

[0033] To this end, the method identifies genomic subregions that contain transcription factor binding sites characteristic of a cell type and assembles them into a set of genomic subregions that contain relevant portions of transcriptional regulatory sequence information in the cell type of interest, sometimes referred to as "synthetic cis-regulatory DNA," "synthetic regulatory regions," or "synthetic locus control regions (sLCRs)."

[0034] When introduced into a cell, the reporter or effector gene expression occurs because the transcription factor corresponding to the characteristic transcription factor binding site is present in the cell type and initiates the expression of the reporter or effector gene.Therefore, the level of expression is associated with a specific cell type.Each cell type essentially produces a different set of genes depending on the signature gene set, and each cell type shows a different level of reporter expression depending on the combination of the transcription factor present and the regulatory region assembled in the sLCR.

[0035] Advantageously, the method is not limited to a particular cell type, but can be applied to virtually any cell type, and can further distinguish cell states or fate transitions in a particular cell type, and no a priori knowledge of gene regulation in the cell type of interest is required for this purpose.

[0036] Instead, the methods rely solely on the provision of gene expression profile and genomic sequence data for a given cell type, which can be obtained using standard biomolecular techniques or consulting public databases.

[0037] Gene expression profile reflects the level of gene expression in the cell type of interest.For this purpose, for example, RNA-SEQ or other sequencing or microarray-based methods can be used to quantify the level of RNA transcripts in the cell type of interest.However, gene expression profile can also be inferred by quantifying the expression of proteins or peptides present in the cell type of interest, potentially using proteomics, for example, which can be matched to gene expression profile.

[0038] From the gene expression profile, signature genes are selected that are characteristic of the cell type, cell state or entity of interest. The selection of signature genes can be tailored to the desired application.

[0039] For example, signature genes can be selected according to gene expression level by ranking the genes of the cell type of interest according to their gene expression level and selecting the genes that are above or below a certain threshold, or by selecting the genes with the highest or lowest expression of a certain number.For the selection of such signature genes, the absolute expression level of the genes of the cell type of interest is taken as reference.This allows the resulting expression cassette to faithfully report the presence of the cell type of interest in various assays, independent of the cell type being investigated.

[0040] However, in certain applications, it may be desirable to generate an expression cassette that distinguishes between a cell type of interest and a reference cell or cell state with particularly high specificity. In such applications, differentially regulated signature genes are selected by identifying genes that are up-regulated or down-regulated compared to their expression levels in the reference cell type. In these embodiments, gene expression profiles of the cell type of interest and the reference cell type are provided. By selecting differentially regulated genes, the expression cassette can be fine-tuned for assays that require the differentiation of a cell type (or state or fate) of interest from a certain reference type (or state or fate).

[0041] From the selected signature genes, all genes encoding transcription factors within the set of signature genes are identified. For this purpose, the method may utilize publicly accessible annotated databases such as ENCODE, mENCODE (the mouse version of the ENCODE project), JASPAR, Ensemble, EntrezGene, Genebank, etc. This identifies a set of transcription factors for the cell type of interest that are characteristically expressed. The skilled person can identify the transcription factors by their functional annotation in publicly available databases. Furthermore, the target sequences, i.e. the transcription factor binding sites, for each transcription factor are usually known to the skilled person and / or can be obtained using appropriately annotated databases as described above. Preferably, in some embodiments, the method is carried out for the use of transcription factors whose binding sites (in the form of DNA sequences or sequence motifs) are already known and / or preferably annotated in public databases.

[0042] Further, using the set of selected genes, a set of genomic regions is determined from the genomic sequence data of the cell type of interest, each genomic region comprising a sequence encoding a signature gene and additional genomic sequences adjacent (preferably immediately adjacent) to the sequence encoding the signature gene. This genomic sequence, such as non-coding reference DNA (although cis-regulatory elements may be present in the coding region), is intended to include regulatory sequences that may be located upstream of the coding region, downstream of the coding region, or within the coding region, usually but not limited to adjacent to the transcription start site. The size of the additional genomic sequences adjacent to the signature gene may vary, since the method is advantageously not overly sensitive to the presence of additional portions of additional genomic sequences.

[0043] For this purpose, the additional genomic sequence is large enough to encompass cis-regulatory elements (particularly transcription factor binding sites or enhancers or silencers) that regulate the expression of the signature genes. Such cis-regulatory elements may be structurally close to the coding regions, but it is known that cis-regulatory elements may be located at considerable distances in linear genomic sequences, given the 3D structural distribution of genomes in the nucleolus. In preferred embodiments, the regulatory genomic sequence is selected based on the folded three-dimensional state of DNA within chromatin in the cell type, using topological associating domains as boundaries. Preferably, in some embodiments, cell type-specific non-coding CTCF binding sites are envisaged in the method as a surrogate for the topological associating domains. CTCF binding sites (in the form of DNA sequences or sequence motifs) are generally known to those skilled in the art and / or are generally annotated in public databases.

[0044] In a preferred embodiment, after determining a set of genomic regions, the method searches for multiple genomic subregions of similar or comparable size (e.g., the same size) that contain one or more, preferably several, binding sites for the transcription factors encoded by the signature genes. Thus, all of the genomic subregions identified in step f) of the method contain DNA binding sites for transcription factors that are characteristically expressed in the cell type of interest. When the genomic subregions are assembled into a sLCR and the sLCR is introduced into the cells of the interest, the characteristically expressed signature transcription factors can bind to the sLCR and regulate the expression of downstream reporter or effector genes. Typically, more genomic subregions are identified than make up the sLCR, which are redundant for the binding sites of the characteristic transcription factors. The assembly of a limited number of all identified genomic subregions is sufficient to represent the entire regulatory complexity, and including all elements does not increase specificity, but rather results in unnecessarily large expression cassettes.

[0045] Thus, the method further comprises selecting a minimal set of genomic subregions that contain transcription factor binding sites for a predetermined percentage of all transcription factors encoded by the selected signature genes.

[0046] As an example, one can assume that in a set of signature genes, 100 transcription factors with 100 known transcription factor binding sites may be identified. However, in some embodiments, the number of transcription factors encoded by the selected signature genes is not necessarily the same as the number of transcription factor binding sites. In some selected embodiments, not all transcription factors may have known binding sites, or multiple transcription factor binding site matrices may be associated with some transcription factors.

[0047] In order to use as few genomic subregions as possible in the assembly of sLCR, for example to keep the resulting regulatory sequence compact, the method preferably ranks genomic subregions according to the number of transcription factor binding sites in addition to the diversity of transcription factor binding sites.For example, the highest ranked genomic subregion may contain 35 transcription factor binding sites for the transcription factor of step d), but three of these binding sites are represented five times in the same genomic subregion, and the remaining binding sites are only present once.In this case, this highest ranked genomic subregion contains 23 different (unique) transcription factor binding sites, which represent the binding sites of the 23 transcription factors of the signature gene.Therefore, this highest ranked genomic subregion covers 23% of the characteristic transcription factors of step d).

[0048] For example, if the predefined percentage is set to 50%, then a second (potentially third) genomic subregion(s) is searched for, preferably for genomic subregions that encompass transcription factor binding sites not already included within the 23 binding sites of the first genomic subregion, and so on, with the further genomic subregion(s) containing at least 7 binding sites for transcription factors not already covered by the first highest-ranked genomic subregion. Typically, a minimum set of 2-10 genomic subregions contains transcription factor binding sites that are binding targets for at least 50% of the transcription factors encoded by the signature genes.

[0049] When the expression cassette is introduced into a cell type of interest, the minimal set of genomic subregions acts as synthetic cis-regulatory DNA to which characteristic transcription factors can bind. Thus, the minimal set of genomic subregions selected in step g) of the method is referred to herein as synthetic locus control regions (sLCRs). Thus, in some embodiments, the cassette comprises a regulatory region (sLCR) enriched for regulatory sequences to which transcription factors that are expressed or highly expressed in the cell type of interest bind, for example. Thus, this regulatory region is unique / compatible with this particular cell type and results in an expression level of the reporter gene that is unique to this cell type.

[0050] Considering that the total amount of characteristic transcription factors identified in d) reflects the regulatory mechanism of the target cell type, a given percentage of transcription factor coverage can be regarded as the "percentage of regulatory information" covered by a minimum set of genomic subregions. In theory, the more regulatory information is covered, the more specific the expression of reporter or effector genes is to cell type. However, advantageously, a percentage of at least 30%, preferably at least 40% or 50% regulatory information coverage provides superior results in terms of cell type-specific expression profile as determined by experimental validation.

[0051] In step h) of the method, a cell type specific expression cassette is generated by assembling the set minimal of genomic subregions selected in step g) together with a reporter or effector gene to which they are operably linked, i.e. such that the genomic subregions containing transcription factor binding sites as cis-regulatory elements are configured to regulate the expression of the reporter gene or effector gene.

[0052] The high coverage of regulatory information by the assembled genomic subregions opens up a great possibility of using the methods and constructs described herein without the need for prior information. The expression cassettes as part of reporter vectors can be used in vitro and in vivo as reporters of intrinsic cell states, adaptive responses to external signaling or chemical inputs, cell fate transitions, reprogramming, forward and chemical genetic screens. Furthermore, by combining cell type-specific sLCRs with endonucleases or suicide genes, the vectors can be used to deplete cell type, developmental stage or disease specific populations in gene therapy or other genetic modification situations. In these other genetic modification situations, the sLCR can induce tumor-specific expression of oncolytic virus components and / or costimulatory molecules to increase the specificity and efficacy of oncolytic therapy.

[0053] In a preferred embodiment of the invention, the method further comprises the step of: According to step c)(i), a gene expression profile of a reference cell type comprising expression levels of genes in the reference cell type is prepared, and differentially regulated signature genes are selected by identifying genes that are up-regulated or down-regulated relative to their expression levels in the reference cell type, preferably by selecting genes that are up-regulated by 3-fold to 10-fold or more in the cell type of interest; or According to step c)(ii), the genes of the cell type of interest are ranked according to their gene expression levels and signature genes are selected based on expression of a predetermined level or a predetermined number of signature genes, such as the 100-1000 most highly expressed genes or the 100-1000 least expressed genes in the cell type of interest.

[0054] A second alternative allows the selection of signature genes based on a comparison of the expression levels of genes of said cell types, derivable from gene expression profiles. Such an embodiment is particularly suitable for the generation of expression cassettes representing a cell type of interest in different experimental contexts. For this purpose, the selection of genes that are upregulated 3-fold to 10-fold or more above the average expression level has given good results.

[0055] The first alternative allows for the expression cassette to be adjusted to distinguish a cell type of interest relative to a reference cell type. By way of example, the cell type of interest may be a certain tumor cell, and the reference cell type typically refers to normal cells of the tissue type infiltrated by the tumor or the cell type from which the tumor cell originates.

[0056] However, the reference cell type may also refer to the same cell type but before or after a different cell state or fate transition. The gene expression profile of the cell type of interest may refer to the gene expression profile of cancer cells in a mesenchymal state after epithelial-mesenchymal transition (EMT), and the gene expression profile of the reference cell type may refer to the gene expression profile of cancer cells of the same type but in an epithelial state, i.e., before epithelial-mesenchymal transition (ETM). In this case, the expression cassette makes it possible to distinguish between cells that have undergone EMT and cells that have not undergone EMT.

[0057] Expression cassettes that can be derived by selecting signature genes based on their relative regulation compared to a reference cell type are characterized by a particularly high specificity and allow the discrimination between the reference cell type and the cell type of interest without the need for any additional markers.

[0058] In a preferred embodiment of the invention the method is characterized in that the predefined percentage of transcription factors covered is greater than or equal to 30%, preferably greater than or equal to 40%, most preferably greater than or equal to 50%.

[0059] In a further preferred embodiment of the invention the method is characterized in that the genomic region determined in e) corresponds to the genomic sequence of a topologically associated domain containing said differentially regulated genes, preferably said topologically associated domain corresponds to the genomic sequence between two CTFC binding sites.

[0060] By selecting the size of the genomic region based on the topological association domain, optimal coverage of potential cis-regulatory elements governing the transcription of the signature genes can be achieved. In the topological association domain, DNA sequences physically interact with each other more frequently than sequences outside the topological association domain, thereby forming a three-dimensional chromosomal structure accessible to the transcription machinery. Particularly good results can be achieved by selecting a genomic sequence between two CTFC binding sites. Such an embodiment provides an optimal balance between computer battery capacity, specificity of non-coding cis-regulatory DNA for the genes it is most likely to regulate, and the size of the flanking DNA that covers the characteristic transcription factor binding sites.

[0061] In a preferred embodiment of the method, the identification of comparable, e.g. same sized, genomic subregions in step f) is performed by a sliding window algorithm on the genomic regions determined in e), preferably said window having a length between 500 bp and 5000 bp, preferably between 700 bp and 2000 bp, more preferably between 800 bp and 1200 bp, most preferably between 1000 bp, and a sliding step having a length between 100 bp and 1000 bp, preferably between 120 bp and 300 bp, more preferably between 130 bp and 170 bp, most preferably between 150 bp. In one embodiment, the sliding window is fixed at a size of 1000 bp sliding in steps of 150 bp, but the size of the genomic subregions resulting from the scanning can be of different sizes, depending on the statistical scores and the distribution of the TFBSs.

[0062] Further preferably, a sliding window algorithm is used to calculate the statistical enrichment of motifs of transcription factor binding sites from a relevant database (e.g. JASPAR) restricted to the transcription factor binding sites corresponding to the transcription factors identified in step d). This generates a list of significant enrichments of characteristic transcription factor binding sites in a particular region, which is used to identify comparable, preferably similarly sized genomic subregions that contain at least one transcription factor binding site for at least one characteristic transcription factor encoded by a signature gene. Preferably, and most likely, several tens (10-200, preferably 20-180) of TFBSs are contained in a comparable sized genomic subregion.

[0063] According to the invention, the multiple genomic subregions of equivalent limited size, preferably the same size, in the set of genomic regions determined in e) (according to step f) are usually of the same size, but may be different. Equivalent in this context refers to multiple genomic subregions preferably representing any window size between 500 bp and 5000 bp.

[0064] In a further preferred embodiment of the invention, the genomic subregion is between 100 bp and 1000 bp, preferably between 120 bp and 300 bp, more preferably between 130 bp and 170 bp, most preferably 150 bp in length. When using a sliding window algorithm, the length of the genomic subregion preferably correlates with the sliding step. In other embodiments, the sliding window approach can use any given step size from 1 bp to the step sizes indicated for the window sizes above. The preferred length was determined by using a method that differentiates between cell types and assay systems and reflects optimal results in terms of expression specificity and total size of the expression cassette.

[0065] In a further preferred embodiment of the invention, the method further comprises the steps of: selecting a set of genomic subregions in g) comprising, for each genomic subregion identified in f), d) enrichment of binding sites for transcription factors in said genome sequence data; A diversity score for the transcription factors for which binding sites exist; The method is characterized in that it is performed by calculating the genomic subregions are ranked according to the cumulative percentage of transcription factors for which they have binding sites; A minimal set of genomic subregions is selected that contains binding sites for a given percentage of all transcription factors identified in d).

[0066] For example, the number and type of transcription factor binding sites are generated after identifying genes encoding transcription factors in the set of signature genes selected in c). Furthermore, a list of genomic subregions generated in step f) is provided. This information can be used to calculate the number of transcription factor binding sites (TFBS) per genomic subregion (e.g., TFBS=35), which represents the enrichment for the binding sites of the transcription factors according to d) in the genome sequence data. Furthermore, it is preferred to calculate the diversity of the transcription factor binding sites per genomic subregion. For example, 3 TFBSs out of 35 TFBSs are present 5 times, and the remaining TFBSs are present only once, resulting in a TFBS number of 35 for said genomic subregion, and a diversity score of 23.

[0067] In a further step, the preferred method ranks the genomic subregions based on the highest number of TFBSs and the best diversity score. In one example of the number 1 ranked genomic locus chr10:6019558-6019708, there are 20 TFBSs associated with mesenchymal GBM status by the above method, some of which are repeated 2-6 times. After the best ranked genomic subregion is determined, the second best can be calculated for the remaining total genomic subregions, excluding the TFBSs present in the first genomic subregion from the ranking. By iteration, the number of different genomic subregions required to cover the entire set of transcription factor binding sites or a given percentage can be calculated. If a percentage of the total regulatory potential (TFBSn x TFBSd) is required, two independent LCRs can be generated. Usually, four or five elements are sufficient to reach up to 50% of the regulatory potential, which has been demonstrated to be sufficient to generate two independent sLCRs that respond to the same signaling (see examples).

[0068] In a further preferred embodiment of the invention, the method is characterized in that the organization of the genomic subregions in h) is such that the genomic subregion containing the transcription start site is assembled adjacent to and upstream of the sequence encoding the reporter gene, and the genomic subregion not containing the transcription start site is assembled preferably further upstream of the nearest transcription start site. In this case, the method allows annotating all genomic subregion elements (e.g. 150 bp elements) containing the natural transcription start site and those that do not contain a transcription start site, and it is particularly preferred to start ranking from the genomic subregions containing a transcription start site. After choosing the best ranked genomic subregions containing a transcription start site, ranking of additional genomic subregions can be performed independently of whether these genomic subregions contain a transcription start site or not.

[0069] According to the present invention, in some embodiments, the term "generating a cell type specific expression cassette" relates to the design and physical creation of a nucleic acid molecule. In some embodiments, the term "generating a cell type specific expression cassette" relates to the design of a cell type specific expression cassette without physically creating a corresponding nucleic acid molecule, e.g. the method may be a computer implemented method or may comprise one or more computer implemented steps of a method. In some embodiments, the method is or comprises computer implemented elements, resulting in an in silico design, production, simulation and / or computer representation of said construct as output of the method. Thus, the "generation" of a cassette or construct may in some embodiments be performed in a computer, i.e. in computer software, e.g. the output may be a nucleic acid sequence, nucleic acid sequence information, i.e. in a computer readable format.

[0070] The methods of the present invention may in some embodiments relate to a computer program product, such as a software product.

[0071] The software can be configured to run on a general computing device and is configured to perform one or more of steps a) to h) of the methods described herein. Thus, the computer program product of the present invention also encompasses features described in the methods provided herein and directly related thereto. Further details on the preferred computer-based approach are given in the Examples and relevant references described herein. When the method is implemented in a computer program, for example using simulation or computer design of the cassettes of the present invention, in some embodiments, the sequences can be subsequently synthesized in the laboratory by methods known to those skilled in the art and utilized for either in vitro or in vivo applications, if desired.

[0072] The present invention also relates to a system for performing the methods described herein comprising one or more computing devices, data storage devices and / or software as system components, where said components may be connected, preferably in close proximity to each other or by a data connection, e.g. through the internet, and configured to interact with one or more of said components and / or to perform the methods described herein. The system may comprise computing devices, data storage devices and / or suitable software, e.g. individual software modules that interact with each other to perform the methods described herein.

[0073] Regarding computer implementation, Step a) relating to the preparation of the gene expression profile of the cell type of interest can be performed by a computer, i.e. information about the gene expression profile of the cell type of interest is provided in a computer readable format which is preferably adapted to be processed in the further steps of the method.

[0074] Step b) relating to the preparation of genomic sequence data of the cell type of interest can be performed by a computer, i.e. the information of the genomic sequence data is preferably provided in a computer readable format that is adapted to be processed in the further steps of the method.

[0075] Step c) relating to the selection of a set of signature genes from the gene expression profile, where said signature genes are (i) differentially regulated compared to a reference cell type or (ii) selected according to gene expression levels, is preferably performed by a computer. In a preferred embodiment, the genes and their expression profiles are represented as information in a format that is adapted to be processed by a computer device, and a specific group of genes can be selected based on this information. This step can be automated or performed manually depending on the selection characteristics used / required or the skills of the user.

[0076] Step d) relating to the identification of genes encoding transcription factors in the set of signature genes selected in c) is preferably performed in a computer-implemented manner in which genes are annotated by function, and the function of the transcription factors in any one or more of the identified signature genes can be (optionally) automatically interrogated. Suitable databases mentioned herein as examples can be used.

[0077] Step e) relating to the determination of a set of genomic regions from the genomic sequence data, where each genomic region comprises a sequence encoding a signature gene identified in c) and additional genomic sequences adjacent to said sequence encoding the signature gene, is preferably performed in a computer-implemented manner. The skilled person can evaluate and select the genomic sequences adjacent to the gene of interest based on the genomic sequences, i.e., available from a database, using automated selection criteria or by manually evaluating and selecting the adjacent sequences.

[0078] Step f) relating to the identification of multiple genomic subregions of the same size in the set of genomic regions determined in e), said genomic subregions comprising one or more binding sites for one or more of the transcription factors identified in d), is preferably performed using a computer-implemented method. The identification of binding sites for one or more of the transcription factors can be performed using methods established in the art, such as searching and / or interrogating any given sequence for the presence of known binding sites defined by specific sequences or sequence motifs. Software configured to screen sequences for the presence of such known sequences is available to the skilled person.

[0079] Step g) relating to the selection of a minimum set of preferably 2 to 10 genomic subregions from those determined in f), where the set of genomic subregions is selected to contain transcription factor binding sites for a given percentage of the total transcription factors identified in d), is preferably performed using an (optionally) automated computer algorithm. Details on the determination of genomic subregions are presented above. Multiple options are available in the software solution suitable for the selection of the desired genomic subregions, or the selection can be made manually by a skilled user, evaluating various subregions and organizing them to contain binding sites for a certain percentage of the relevant transcription factors identified in step d).

[0080] One skilled in the art can design and / or configure software using established programming, coding and bioinformatics techniques to evaluate genomic subregions for the presence of transcription factor binding sites, compare these binding sites with transcription factors identified as signature genes, and select an arrangement of genomic subregions that covers a predefined percentage of the relevant transcription factors.

[0081] According to step h) of the method, a cell type specific expression cassette is generated comprising the set of genomic subregions selected in step g) operably linked to a reporter gene or an effector gene. As stated above, "generation" above may relate to the computer-implemented creation of nucleic acid sequence information in a computer readable form and / or the synthesis of physical nucleic acid molecules based on and / or comprising said sequences.

[0082] Thus, the present invention further relates to a method for designing and / or producing a nucleic acid molecule corresponding to, comprising or based on the product DNA sequence information obtained from steps a) to g), the method preferably comprising carrying out a method as described herein and subsequently synthesizing, cloning and / or isolating said nucleic acid molecule.

[0083] The term "generating a cassette" in such embodiments may include any relevant molecular biological or chemical techniques for cloning, mutation, recombination, PCR amplification, and / or synthesis used to generate a nucleic acid molecule.

[0084] In a preferred embodiment, the cassettes are synthesized using de novo nucleic acid synthesis based on the information obtained by the methods of the present invention.

[0085] In a further preferred embodiment, the present invention relates to a cell-type specific reporter vector comprising an expression cassette produced by the methods described herein.

[0086] In a further aspect, the present invention relates to a cell type specific reporter vector comprising 2 to 10 genomic subregions of 100 bp to 1000 bp located adjacently without linkers or with a linker sequence of 100 bp or less located between the subregions, said subregions being derived from distinct (non-adjacent) locations in the same genome of a cell type of interest, said subregions comprising a synthetic regulatory region which cumulatively comprises binding sites for at least 5, preferably at least 10, most preferably at least 20 transcription factors, and a reporter or effector gene, said genomic subregions being operably linked to said reporter or effector gene so as to regulate expression of said reporter or effector gene.

[0087] It is particularly preferred to select genomic subregions by the method according to steps a) to g) described herein. The skilled artisan will understand that the preferred embodiments disclosed for the method equally apply to the cell type specific reporter vectors described herein. The method of the present invention provides structural features of vectors that are unique in the field.

[0088] A preferred embodiment of the invention relates to the design of constructs in which the transcription factor binding sites from genomic subregions have a length of 100 bp to 1500 bp or 100 bp to 1250 bp, preferably 100 bp to 1000 bp, more preferably 120 bp to 300 bp, more preferably 130 bp to 170 bp, most preferably essentially 150 bp, in combination with the origin of genomic subregions from non-contiguous regions of the same genome. With this combination, the constructs of the invention are defined by a novel unbiased de novo assembly by bringing together different / separate but highly related regulatory regions that reflect the relevant size of the regulatory information, in particular the size of the histone particle around which the DNA is wrapped, preferably 120 bp to 300 bp, more preferably 130 bp to 170 bp, most preferably 150 bp.

[0089] A preferred embodiment of the present invention relates to the design of constructs where 5 or more transcription factor binding sites are used, i.e. the higher number of TFBS reflects a novel unbiased de novo assembly by bringing together a sufficient number of TFBS to cover a large regulatory portion of the relevant TFs for any given cell type / condition.

[0090] The genomic subregions are characterized in that they are derived from different locations in the same genome of a cell type and cumulatively contain at least 5, preferably at least 10, most preferably at least 20 or more transcription factor binding sites. In some embodiments, 2-10 (i.e. 2, 3, 4, 5, 6, 7, 8, 9 or 10) genomic subregions are organized to form a sLCR that contains at least 5, 10, 15, 20, 25, 30, 35, 40 or more transcription factor binding sites. Thus, the genomic subregions typically cover a large number of transcription factor binding sites that are sufficient to cover the regulatory information of the cell type of interest. It is preferred that the transcription factor binding sites refer to transcription factors that are characteristically expressed in the cell type of interest. For example, steps a) to d) of the method described herein can be used to determine the transcription factors that are characteristically expressed in the cell type of interest.

[0091] The use of synthetic regulatory regions containing 2 to 10 such genomic subregions, ranging from 100 bp to 1000 bp in length, proved to be an optimal regime in terms of minimizing vector size while maintaining the large amount of regulatory information represented by transcription factor binding sites.

[0092] In this respect too, the arrangement of small genomic regions flanked by linkers either without or by linker sequences of less than 100 bp ensures a compact design and efficient transduction of reporter vectors that do not contain a large amount of regulatory information.

[0093] In a particular preferred embodiment of the invention, the vector is characterized in that each of the genomic subregions has a length between 120 bp and 300 bp, more preferably between 130 bp and 170 bp, most preferably 150 bp. Genomic subregions of such length optimally cover relevant transcription factor binding sites enriched for statistical significance relative to background genomic regions. The optimal size of 150 bp may be due to the fact that the circular 146 base pairs (bp) DNA genome is wrapped around a core particle of histones, preventing access to transcription factors. In contrast, nucleosome-free regions (NFRs), which are usually associated with active cis-regulatory DNA, allow accessibility to transcription factors after DNA unwrapping, and are therefore a minimum of 146 bp. The average size of cis-regulatory DNA is generally inferred by the average size of NFRs, also called DNaseI hypersensitive sites, which is around 1000 bp, and usually includes clustering of relevant transcription factor binding sites at these length scales.

[0094] In a further preferred embodiment of the invention, the vector is characterized in that the genomic subregion adjacent to the reporter gene or to the effector gene contains a transcription start site, ensuring that the effector and reporter are in frame and can be positively regulated by an upstream synthetic regulatory region.

[0095] The unique design of the invention described herein has the advantage that a variety of reporter or effector genes can be combined with the synthetic regulatory regions, including genomic subregions, depending on the desired application.

[0096] In a preferred embodiment of the invention, the vector is characterized in that the reporter or effector gene encodes a protein selected from the group comprising fluorescent proteins, suicide genes, luciferase, β-galactosidase, chloramphenicol acetyltransferase, surface receptors, protein tags including but not limited to 6xHis tag, V5 tag, GFP tag, self-processing ribozyme cassettes, mevalonate kinase and its derivatives, biotin ligase including but not limited to BirA and its derivatives, modified peroxidase including but not limited to APEX2 and its derivatives, restriction enzymes, endonucleases or site-specific recombinases including but not limited to Cre, Flp, Tn5, SpCas9, SaCas9, TALEN and their derivatives, genes correcting monogenic diseases, viral antigens such as E1A and E1B for inducing cell type specific vaccination, or adjuvant cytokines / chemokines for enhancing immune recognition such as GM-CSF or IL-12.

[0097] Fluorescent proteins may be particularly useful for any kind of optical measurement of a signal indicative of the expression of a reporter gene, and for this purpose the method may benefit from the use of state-of-the-art microscopic and / or fluorescence activated cell sorting equipment and quantification techniques.

[0098] Furthermore, the present invention can be easily used with different types of vector systems and can be easily adapted to the cells of interest.

[0099] In a preferred embodiment of the invention, the vector is a viral vector, preferably a lentiviral vector or an adeno-associated viral vector.

[0100] In a further preferred embodiment of the invention the vector comprises a nucleic acid sequence according to SEQ ID NO: 1-6 or a nucleic acid sequence having at least 80%, preferably at least 90% identity to any one of SEQ ID NO: 1-6.

[0101] As described herein, the present invention allows for the provision of cell type specific vector constructs that mediate reliable expression of desired reporter or effector genes in a cell type of interest without the need for prior knowledge. Thus, the vector constructs enable a variety of different applications ranging from basic research to clinical studies or therapeutic strategies.

[0102] For example, vector constructs can be used to identify cell types or determine the specific cell state or developmental state of a cell. Vectors can also allow for studying how cells react to external signals or chemicals. Furthermore, vectors can be used in diagnostics, for example to determine whether a cancer state or type, such as epithelial or mesenchymal glioblastoma, is present, allowing for more effective treatment guidance. Furthermore, vectors can also be used as pharmaceuticals themselves, for example in gene therapy approaches.

[0103] A preferred embodiment of the invention relates to the use of vectors to transform cells for gene and viral therapy, drug discovery or validation and / or to determine the properties of cells, preferably cell type, state or fate.

[0104] The presence of the vectors or sLCR described herein in cells that are already transformed is encompassed by embodiments of the invention.

[0105] In one embodiment, the present invention provides a method for producing a method for treating a cancer cell comprising: a. providing a cell type specific reporter vector as described herein; b. providing cells; c. transducing the cell with the vector; d. measuring a signal indicative of expression of the reporter gene or the effector gene; wherein the amount of said signal is indicative of a property of said cell, preferably a cell type, state or fate transition; The present invention relates to a method for determining a characteristic, preferably a cell type, state or fate transition, of a cell, comprising:

[0106] Any suitable measurement method can be used, for example the reporter or effector gene can be a fluorescent protein, in which case a microscope device can be used to quantitatively assess the fluorescent signal and thus the expression of the reporter or effector gene in the investigated cells.

[0107] In one embodiment, the present invention provides a method for producing a method for treating a cancer cell comprising: a. providing a cell type specific reporter vector as described herein; b. Providing cells in which a specific cellular state may or may not exist, or may be optionally induced; c. transducing a cell with the vector; d. Optionally inducing the cells; e. measuring a signal indicative of expression of the reporter gene; Furthermore, the amount of signal indicates the unique cellular state of each of the cells; The present invention relates to a method for determining a specific cell state, comprising:

[0108] In one embodiment, the present invention provides a method for producing a method for treating a cancer cell comprising: a. providing a cell type specific reporter vector as described herein; b. Providing cells that have undergone fate conversion in response to an external signaling and / or chemical perturbation; c. transducing a cell with the vector; d. exposing the cell to an external signaling and / or chemical perturbation; e. measuring a signal indicative of expression of the reporter gene; Furthermore, the amount of signal suggests cell fate conversion; The present invention relates to a method for determining cell fate transition, comprising:

[0109] In one embodiment, the present invention provides a method for producing a method for treating a cancer cell comprising: a. providing a cell type specific reporter vector as described herein; b. providing cells that have undergone fate conversion in response to reprogramming factors, including transcription factors, external signaling, and / or chemical perturbations; c. transducing a cell with the vector; d. exposing the cell to a transcription factor, an external signaling and / or a chemical perturbation; e. measuring a signal indicative of expression of the reporter gene; Furthermore, the amount of signal indicates the factor that induces cell fate conversion; The present invention relates to a method for determining a cell fate reprogramming factor, comprising:

[0110] In one embodiment, the present invention provides a method for producing a method for treating a cancer cell comprising: a. providing a cell type specific reporter vector as described herein; b. Providing cells in vivo having a unique signature; c. transducing a cell with the vector reflecting the signature; d. exposing the cells to a range of biological and chemical agents; e. measuring a signal indicative of a phenotype of interest; Furthermore, the amount of signal is indicative of the phenotype; The present invention relates to a method for determining the minimum requirements for in vitro cell growth of a phenotype of interest, comprising:

[0111] In one embodiment, the present invention provides a method for producing a method for treating a cancer cell comprising: a. providing a cell type specific reporter vector as described herein; b. Providing a cell having an inherent pathological condition that can be corrected by the expression or elimination of a given gene in the given cell; c. transducing the cells with said vector directing expression of said disease correcting gene, or suicide gene, or endonuclease; d. exposing the cells to a disease-correcting gene, suicide gene, or drug that activates the endonuclease; e. measuring a signal indicative of expression of the reporter gene and a signal indicative of disease correction; The present invention relates to a method for targeted correction of diseased cells, comprising:

[0112] In one embodiment, the present invention provides a method for producing a method for treating a cancer cell comprising: a. providing a tumor cell type specific reporter as described herein; b. Providing a vector encoding an oncolytic virus genome, including adenovirus, Maraba virus, VSV, HSV-1, measles virus, reovirus, retrovirus, and vaccinia virus, which can be engineered to express a tumor associated antigen (TAA) and / or a molecular adjuvant under the expression of a tumor sLCR by gene transfer; c. generating viral particles containing the vector; d. Transducing the viral particles into a target organism to infect tumor cells; e. Measuring viral genetic material in the tumor tissue that is not in the surrounding tissue; The present invention relates to a method of oncolytic virus therapy comprising:

[0113] The methods described herein, eg, methods for determining a property of a cell, preferably a cell type, state or fate transition, can be used in a variety of biological, biotechnological or pharmaceutical (screening) contexts.

[0114] Further embodiments of the present invention relate to the use of DNA methylation and / or ATAC-seq profiles as input for the discovery of signature genes.

[0115] ATAC-seq (Assay for Transposase-Accessible Chromatin by Sequencing) is a technique used to assess genome-wide chromatin accessibility by probing open chromatin with a hyperactive mutant Tn5 transposase that inserts sequencing adapters into open regions of the genome. The mutant Tn5 transposase excises any sufficiently long DNA in a process called tagmentation, where DNA is simultaneously fragmented and tagged by Tn5 transposase pre-integrated with sequencing adapters. The tagged DNA fragments are then purified, amplified by PCR, and sent for sequencing. Sequencing reads can then be used to infer regions of increased accessibility as well as to map regions of transcription factor binding sites and nucleosome positions.

[0116] Chromatin accessibility of several classes of cis-regulatory elements is a predictive marker of in vivo DNA binding by transcription factors. The repertoire of all accessible sites in chromatin is the strongest predictor of cell identity. Indeed, in cancer, chromatin accessibility is the strongest predictor of cancer type similarity and can be used to identify subtype identity in the common dimensional space of individual cancer types. To investigate whether the epigenetic heterogeneity exhibited by sLCR is accompanied by changes in genome-wide chromatin accessibility, ATAC-seq can be performed and cells can be sorted according to the expression levels of reporter constructs described herein. Thus, differential analysis of chromatin accessibility can reveal many genes undergoing remodeling. These results, described in the Examples below, highlight the effectiveness of sLCR to reveal, for example, intratumor heterogeneity and enable thorough cellular and molecular characterization of tumor models together with primary cancer data.

[0117] Further embodiments of the present invention relate to target discovery and validation for drug targets in the field of stress response (e.g. killing of cells with high ER stress or inflammatory signaling) and senolytics (e.g. killing of senescent cells).

[0118] Using the methods of the present invention, specific regulatory profiles can be identified for any given cell state, and reporter constructs can be effectively generated. In some embodiments, sLCRs can be generated for cell types / states that have high ER stress or inflammatory signaling, or are undergoing senescence. Such reporters can then be used to measure whether any given drug candidate applied during screening results in a change in the cell state.

[0119] Further embodiments of the present invention relate to target discovery and validation for drug targets in the field of cell identity / fate change. As described in detail herein, specific regulatory profiles can be identified for any given cell identity or state before and after identity or fate change, effectively generating reporter constructs. In some embodiments, sLCRs can be generated for cell types before and after identity change. Such reporters can thus be used to measure whether any given drug candidate applied during screening results in a change in cell state.

[0120] Further embodiments of the present invention relate to target discovery and validation for synthetic peptides using the methods and constructs described herein.

[0121] Further embodiments of the present invention relate to target discovery and validation for therapeutic exosomes and antisense oligonucleotides using the methods and constructs described herein.

[0122] Further embodiments of the present invention relate to the discovery of therapeutic potential of drug candidates in immunotherapy, including but not limited to the role of innate immune cells in therapeutic response and resistance, and the use of sLCR to engineer therapeutic adaptive immune cells (T cells, NK) against exhaustion and primary target specificity.

[0123] In some embodiments, sLCR can be generated as a readout of immune cell activity and / or target specificity, and candidate molecules can be tested and changes in the sLCR readout measured to assess whether immune cells (T cells, NK) can counteract depletion when enhanced / treated with the candidate compound.

[0124] In a further embodiment, the present invention relates to a computer implemented method for determining the sequence of a synthetic locus control region (sLCR), comprising steps a) to g) of the method described herein. Accordingly, the present invention also relates to a computer software product capable of and adapted to perform method steps a) to g) as described herein, and to a computer program for use in the method described herein, comprising instructions for causing a computer to perform steps a) to g) of the method described herein, when the program is executed by a computer.

[0125] The present invention is further illustrated by the accompanying drawings, which are not intended to limit the scope of the invention, but rather depict preferred embodiments of aspects of the invention presented for further illustration of the invention described herein. [Brief description of the drawings]

[0126] [Figure 1-1] FIG. 1 : Generation and validation of synthetic locus control regions (sLCRs). [Figure 1-2] FIG. 1 : Generation and validation of synthetic locus control regions (sLCRs). [Figure 1-3] FIG. 1 : Generation and validation of synthetic locus control regions (sLCRs). [Figure 1-4]FIG. 1 : Generation and validation of synthetic locus control regions (sLCRs). [Figure 2-1] FIG. 1 shows intrinsic and adaptive responses in MES-GICs and PN-GICs revealed by sLCR. [Figure 2-2] FIG. 1 shows intrinsic and adaptive responses in MES-GICs and PN-GICs revealed by sLCR. [Figure 2-3] FIG. 1 shows intrinsic and adaptive responses in MES-GICs and PN-GICs revealed by sLCR. [Diagram 3] FIG. 1 shows GBM subtyping and reprogramming using sLCR. [Figure 4-1] FIG. 1 shows tissue-independent epithelial-mesenchymal homeostasis revealed by sLCR. [Figure 4-2] FIG. 1 shows tissue-independent epithelial-mesenchymal homeostasis revealed by sLCR. [Figure 4-3] FIG. 1 shows tissue-independent epithelial-mesenchymal homeostasis revealed by sLCR. [Figure 5-1] FIG. 1 shows heterogeneous mesenchymal transdifferentiation revealed by sLCR in vivo. [Figure 5-2] FIG. 1 shows heterogeneous mesenchymal transdifferentiation revealed by sLCR in vivo. [Figure 6-1] FIG. 1 shows selection of subtype-specific genes for MES GBM subtypes. [Figure 6-2] FIG. 1 shows selection of subtype-specific genes for MES GBM subtypes. [Figure 7-1] FIG. 1 shows automated synthetic locus control region (sLCR) generation. [Figure 7-2] FIG. 1 shows automated synthetic locus control region (sLCR) generation. [Figure 8] FIG. 1 shows intrinsic and adaptive responses in MES-GICs and PN-GICs revealed by sLCR. [Figure 9]FIG. 1 shows transcription factors that bind to MGT#1 cis-regulatory DNA. [Figure 10] FIG. 1 shows the homeostatic maintenance of MGT#1 expression in breast cancer cells. [Figure 11-1] FIG. 1 shows that MGT#1 reflects the contribution of TGFB and GSK126 alone and in combination to EMT. [Figure 11-2] FIG. 1 shows that MGT#1 reflects the contribution of TGFB and GSK126 alone and in combination to EMT. [Figure 12] FIG. 1 shows that MGT#1 allows screening of cell fate transitions induced by external signaling and / or chemical perturbations. [Figure 13-1] FIG. 1 shows intrinsic and adaptive responses (proliferation) in MES-GICs and PN-GICs revealed by sLCR. [Figure 13-2] FIG. 1 shows intrinsic and adaptive responses (proliferation) in MES-GICs and PN-GICs revealed by sLCR. [Figure 13-3] FIG. 1 shows intrinsic and adaptive responses (proliferation) in MES-GICs and PN-GICs revealed by sLCR. [Figure 14-1] FIG. 1 shows heterogeneous mesenchymal transdifferentiation (in vivo expansion) revealed by sLCR. [Figure 14-2] FIG. 1 shows heterogeneous mesenchymal transdifferentiation (in vivo expansion) revealed by sLCR. [Figure 15-1] FIG. 1 shows that sLCR facilitates discovery of therapeutic relevance of non-cell-autonomous crosstalk between tumor and immune cells. [Figure 15-2] FIG. 1 shows that sLCR facilitates discovery of therapeutic relevance of non-cell-autonomous crosstalk between tumor and immune cells. [Figure 15-3] FIG. 1 shows that sLCR facilitates discovery of therapeutic relevance of non-cell-autonomous crosstalk between tumor and immune cells. [Figure 16]FIG. 1 shows detailed characterization of the synthetic locus control region (sLCR). [Figure 17] FIG. 1 shows further examples of adaptive responses revealed by sLCR. [Figure 18] FIG. 1 shows that induction of the MES-GBM state as measured by sLCR in GICs is specific and reversible. [Figure 19-1] FIG. 1 shows MES-sLCR to analyze the role of ionizing radiation and NFkB signaling in MES-GBM. [Figure 19-2] FIG. 1 shows MES-sLCR to analyze the role of ionizing radiation and NFkB signaling in MES-GBM. [Figure 20-1] FIG. 1 shows further evidence supporting the use of sLCR in phenotypic CRISPR / Cas9 forward genetic screens. [Figure 20-2] FIG. 1 shows further evidence supporting the use of sLCR in phenotypic CRISPR / Cas9 forward genetic screens. [Figure 20-3] FIG. 1 shows further evidence supporting the use of sLCR in phenotypic CRISPR / Cas9 forward genetic screens. [Figure 20-4] FIG. 1 shows further evidence supporting the use of sLCR in phenotypic CRISPR / Cas9 forward genetic screens. [Figure 21-1] FIG. 13 shows further evidence supporting hMG cells inducing MGT#1 expression in hGICs and differential sensitivity to therapeutics and hMG cells. [Figure 21-2] FIG. 13 shows further evidence supporting hMG cells inducing MGT#1 expression in hGICs and differential sensitivity to therapeutics and hMG cells. [Figure 21-3] FIG. 13 shows further evidence supporting hMG cells inducing MGT#1 expression in hGICs and differential sensitivity to therapeutics and hMG cells. [Figure 21-4]FIG. 13 shows further evidence supporting hMG cells inducing MGT#1 expression in hGICs and differential sensitivity to therapeutics and hMG cells. [Figure 22] FIG. 1 shows further evidence supporting the use of sLCR in phenotypic CRISPRi screens. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0127] The present invention relates to methods for generating cell type specific expression cassettes, cell type specific vectors employing such expression cassettes and applications of such vectors. Before the present invention is described with reference to examples, it is to be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to limit the scope of the invention.

[0128] All cited references, both patent and non-patent, are incorporated herein by reference in their entirety. All terms are to be given their ordinary technical meaning unless otherwise specified herein.

[0129] As used herein, the term "expression cassette" refers to a nucleic acid construct that contains sufficient nucleic acid elements for expression of a gene product. Expression cassette also encompasses an electronic representation of an expression cassette as described herein. Typically, an expression cassette contains a nucleic acid (sequence) that encodes as a gene product a reporter gene or a functional effector operably linked to a selected genomic subregion that contains a transcription binding site that serves as a regulatory element for expression of the gene product.

[0130] As used herein, the term "synthetic cis-regulatory DNA", "synthetic regulatory region" or "synthetic locus control region (sLCR)" refers to an arrangement of multiple genomic subregions that contain verified and / or potential (putative / predicted) cis-regulatory sequences arranged contiguously (with or without spacers) in a non-naturally occurring order (i.e., not occurring in that order or arrangement in a naturally occurring genome). Examples of cis-regulatory sequences are transcription factor binding sites (TFBS), promoters, enhancers, silencers, or other regulatory sequences that can cis-act on the expression of a coding region. These regulatory regions, when arranged in a synthetic regulatory region, are usually characteristic of a cell type. In the methods described herein, these regulatory regions are preferably assembled into a set of genomic subregions that contain the relevant portions of the transcriptional regulatory sequence information in the cell type of interest.

[0131] As used herein, the term "reporter vector" refers to a nucleic acid construct comprising an expression cassette and additional nucleic acid elements that allow for the introduction of the expression cassette into a cell, either in vitro or in vivo. The terms "reporter vector", "vector" and "effector vector" may be used interchangeably. A "vector" may have one or more restriction endonuclease recognition sites (whether type I, type II or type IIs) at which sequences can be cleaved in a determinable manner without losing the essential biological function of the vector at that site and at which nucleic acid fragments can be spliced ​​or inserted to trigger its replication and cloning. A vector may contain one or more recombination sites that allow for the exchange of nucleic acid sequences between two nucleic acid molecules. A vector may further provide, for example, primer sites for PCR, transcription and / or translation initiation and / or control sites, recombination signals, replicons, selectable markers, etc. A vector may further contain one or more selectable markers suitable for use in identifying cells transformed with the vector. Vectors known in the art and commercially available vectors (and variants or derivatives thereof) can be used with the expression cassettes described herein. Such vectors are available from, for example, Vector Laboratories Inc., Invitrogen, Promega, Novagen, NEB, Clontech, Boehringer Mannheim, Pharmacia, EpiCenter, OriGenes Technologies Inc., Stratagene, PerkinElmer, Pharmingen and Research Genetics, or can be distributed free to scientists by Addgene.

[0132] As used herein, the term "viral vector" refers to a nucleic acid vector construct that contains at least one element of viral origin, has the ability to be packaged into a viral vector particle, and encodes at least a foreign nucleic acid. The vector and / or particle can be utilized to transfer any nucleic acid into a cell, either in vitro or in vivo. Many forms of viral vectors are known in the art. The term virion is used to refer to a single infectious viral particle. "Viral vector", "viral vector particle" and "viral particle" also refer to the complete viral particle with its DNA or RNA core and protein coat when present outside the cell.

[0133] The term "transfection" preferably refers to the delivery of DNA into a eukaryotic (e.g., mammalian) cell. The term "transformation" preferably refers to the delivery of DNA into a prokaryotic (e.g., E. coli) cell. The term "transduction" preferably refers to infecting a cell with a viral particle. The nucleic acid molecule may be stably integrated into the genome as is commonly known in the art. However, the terms "transduction", "transfection" and "transformation" may be used interchangeably herein and refer to the process of introducing a vector containing an expression cassette into a cell.

[0134] As used herein, the term "cell type specific" refers to the specificity of expression of a reporter gene or effector gene when an expression cassette as described herein is introduced into a cell of interest, compared to other cells (e.g., a reference cell). The term cell type specific encompasses expression (levels) that are specific to the cell type and its cell state or fate of the cell of interest. Thus, the term cell type specific expression cassette or vector also encompasses cell state specific and cell fate specific expression cassettes or vectors.

[0135] The terms "reporter", "effector" or "reporter or effector gene" as used herein refer to gene products encoded by nucleic acids contained in the expression constructs provided herein that can be detected by assays or methods known in the art, thereby "reporting" the expression of the construct and / or "effecting" the state or fate of the cell expressing them. Reporters and effectors, as well as nucleic acid sequences encoding reporters, are known in the art. Reporters or effectors include fluorescent proteins, such as green fluorescent protein (GFP), blue fluorescent protein (BFP), yellow fluorescent protein (YFP), red fluorescent protein (RFP), enhanced fluorescent protein derivatives (e.g., eGFP, eYFP, mVenus, eRFP, mCherry, etc.), enzymes (e.g., enzymes that catalyze a reaction that produces a detectable product, such as luciferase, β-glucuronidase, chloramphenicol acetyltransferase, aminoglycoside phosphotransferase, aminocyclitol phosphotransferase, or puromycin N-acetyltransferase), and surface antigens. Suitable reporters or effectors will be apparent to those skilled in the relevant art.Preferred proteins are selected from the group comprising fluorescent proteins, thymidine kinase, luciferase, β-galactosidase, suicide genes including but not limited to chloramphenicol acetyltransferase, surface receptors, protein tags including but not limited to 6xHis tag, V5 tag, GFP tag, self-processing ribozyme cassettes, mevalonate kinase and its derivatives, biotin ligase including but not limited to BirA and its derivatives, modified peroxidase and its derivatives including but not limited to APEX2, restriction enzymes, endonucleases or site-specific recombinases including but not limited to Cre, Flp, Tn5, SpCas9, SaCas9, TALEN and their derivatives, genes correcting monogenic diseases, tumor associated antigens, or genes encoding immune modulating components facilitating immunotherapy including but not limited to MAGEA3m GM-CSF, IFNγ, IFNβ, CXCL-9-10-11.

[0136] The term "gene" essentially means a coding nucleic acid sequence that is transcribed (DNA) and translated (mRNA) into a polypeptide in vitro or in vivo when operably linked to appropriate regulatory sequences. A gene may or may not include regions preceding and following the coding region, such as 5' untranslated (5'UTR) or "leader" sequences and 3'UTR or "trailer" sequences, as well as intervening sequences (introns) between individual coding segments (exons).

[0137] "Gene expression" as used herein refers to the absolute or relative level of expression of a gene and / or the pattern of expression. Gene expression can be measured at the level of DNA, cDNA, RNA, mRNA, protein, or a combination thereof. Gene expression can also be inferred from protein expression.

[0138] "Gene expression profile" refers to the level of expression of multiple different genes measured for a cell type of interest. Gene expression profiles can be measured in samples, such as samples containing different cell types, different tissues, different organs, or bodily fluids (e.g., blood, urine, cerebrospinal fluid, sweat, saliva, or serum), by a variety of methods, including, but not limited to, RNA-SEQ by Massively Parallel Signature Sequencing (MPSS), Serial Analysis of Gene Expression (SAGE) technology, microarray technology, microfluidic technology, in situ hybridization methods, quantitative and semi-quantitative RT-PCR methods, or mass spectrometry.

[0139] Any method available in the art for detecting gene expression is encompassed herein. By "detecting expression" is intended to determine the amount or presence of an RNA transcript or its expression product, e.g., at the protein level.

[0140] As used herein, the term "expression level," when applied to a gene, refers to a normalized level, e.g., a normalized value, of a gene product that is determined at the RNA expression level of the gene or the polypeptide expression level of the gene.

[0141] The term "gene product" or "expression product" is used herein to refer to the RNA transcription products (transcripts) of a gene, including mRNA, and the polypeptide translation products of such RNA transcripts. A gene product can be, for example, unspliced ​​RNA, mRNA, splice variant mRNA, microRNA, fragmented RNA, polypeptides, post-translationally modified polypeptides, splice variant polypeptides, etc. The term "RNA transcript" as used herein refers to the RNA transcription products of a gene, including, for example, mRNA, unspliced ​​RNA, splice variant mRNA, microRNA, and fragmented RNA.

[0142] Methods for detecting the expression of the genes of the present invention, i.e., gene expression profiling, include methods based on polynucleotide hybridization analysis, methods based on polynucleotide sequencing, immunohistochemistry, and proteomics-based methods, which generally detect the expression product (e.g., mRNA) of the gene.

[0143] Many expression detection methods use isolated RNA, and the starting material is typically total RNA isolated from biological samples, such as a cell type of interest and a reference cell type, respectively.

[0144] General methods for RNA extraction are known in the art and are disclosed in standard textbooks of molecular biology, including Ausubel et al., ed., Current Protocols in Molecular Biology, John Wiley & Sons, New York 1987-1999. Methods for RNA extraction from paraffin-embedded tissues are disclosed, for example, in Rupp and Locker (Lab Invest. 56:A67, 1987) and DeAndres et al. (Biotechniques 18:42-44, 1995). In particular, RNA isolation can be performed using purification kits, buffer sets and proteases from commercial manufacturers such as Qiagen (Valencia, Calif.) according to the manufacturer's instructions.

[0145] The isolated RNA can be used in hybridization or amplification assays, including, but not limited to, PCR analysis and probe arrays. One method of detecting RNA levels involves contacting the isolated RNA with a nucleic acid molecule (probe) that can hybridize to the mRNA encoded by the gene to be detected. The nucleic acid probe can be, for example, a full-length cDNA or a portion thereof, for example, at least 7, 15, 30, 60, 100, 250 or 500 nucleotides in length, and an oligonucleotide sufficient to specifically hybridize to the specific gene of the present invention, or any derivative DNA or RNA, under stringent conditions. Hybridization of the mRNA with the probe indicates that the specific gene in question is expressed.

[0146] An alternative, the level of gene expression in a cell type of interest involves a process of nucleic acid amplification using, for example, RT-PCR (U.S. Pat. No. 4,683,202), ligase chain reaction (Barany, Proc. Natl. Acad. Sci. USA 88:189-93, 1991), self-sustained sequence replication (Guatelli et al., Proc. Natl. Acad. Sci. USA 87:1874-78, 1990), transcriptional amplification systems (Kwoh et al., Proc. Natl. Acad. Sci. USA 86:1173-77, 1989), Q-beta replicase (Lizardi et al., Bio / Technology 6:1197, 1988), rolling circle replication (U.S. Pat. No. 5,854,033), or any other nucleic acid amplification method, followed by detection of the amplified molecules using techniques known to those of skill in the art. These detection schemes are especially useful for the detection of nucleic acid molecules if present in very low numbers.

[0147] In particular, gene expression can be assessed by quantitative RT-PCR. Many different PCR or QPCR protocols are known in the art. In general, in PCR, a target polynucleotide sequence is amplified by reaction with at least one oligonucleotide primer or oligonucleotide primer pair. The primer(s) hybridize to a complementary region of the target nucleic acid, and DNA polymerase extends the primer(s), amplifying the target sequence. Under conditions sufficient to produce a product of polymerase-based nucleic acid amplification, nucleic acid fragments of a certain size will dominate the reaction products (the target polynucleotide sequence, which is the amplified product). The amplification cycle is repeated to increase the concentration of a single target polynucleotide sequence. The reaction can be carried out in any thermocycler commonly used for PCR. However, a cycler with real-time fluorescence measurement capability is preferred.

[0148] Quantitative PCR (QPCR) (also called real-time PCR) is preferred under certain circumstances because it provides not only quantitative measurement, but also reduced time and contamination. As used herein, "quantitative PCR" (or "real-time QPCR") refers to the direct monitoring of the progress of PCR amplification without the need for repeated sampling of reaction products. In quantitative PCR, reaction products can be monitored by a signaling mechanism (e.g., fluorescence) that is generated and tracked after the signal is higher than background levels but before the reaction plateaus. The number of cycles required to achieve a detectable or "threshold" fluorescence level varies directly with the concentration of amplifiable target at the start of the PCR process, allowing for the measurement of signal intensity that provides a measurement of the amount of target nucleic acid in a sample in real time.

[0149] Furthermore, microarrays can be used for gene expression profiling. By "microarray" is intended an ordered arrangement of hybridizable array elements, e.g., polynucleotide probes, on a substrate. The term "probe" refers to any molecule capable of selectively binding to a target biomolecule of particular interest, e.g., a nucleotide transcript or protein encoded by or corresponding to a unique gene. One skilled in the art can synthesize probes or obtain them from appropriate biological preparations. Probes can be specifically designed to be labeled. Examples of molecules that can be utilized as probes include, but are not limited to, RNA, DNA, proteins, antibodies, and organic molecules.

[0150] DNA microarrays provide a method for simultaneously measuring the expression levels of multiple genes. Each array consists of a reproducible pattern of capture probes attached to a solid support. Labeled RNA or DNA is hybridized to complementary probes on the array and then detected by laser scanning. The hybridization intensity of each probe on the array is determined and converted to a quantitative value that represents the relative gene expression level. See, for example, U.S. Patent Nos. 6,040,138, 5,800,992, 6,020,135, 6,033,860, and 6,344,316. ​​High-density oligonucleotide arrays are particularly useful for determining the gene expression profile of multiple RNAs in a sample.

[0151] Serial analysis of gene expression (SAGE) is a method that allows for the simultaneous quantitative analysis of many gene transcripts without the need to prepare individual hybridization probes for each transcript. First, short sequence tags (approximately 10 bp to 14 bp) are generated that contain enough information to uniquely identify a transcript, as long as the tag is derived from a unique location within each transcript. Many transcripts are then linked together to form a long continuous molecule that can be sequenced to reveal the identity of multiple tags simultaneously. The expression pattern of any population of transcripts can be quantitatively assessed by determining the abundance of individual tags and identifying the gene that corresponds to each tag. For more details, see, for example, Velculescu et al., Science 270:484-487 (1995) and Velculescu et al., Cell 88:243-51 (1997).

[0152] Nucleic acid sequencing techniques are a preferred method for analyzing gene expression. The principle underlying these methods is that the number of detections of a cDNA sequence in a sample is directly related to the relative expression of the mRNA corresponding to that sequence.

[0153] These methods are sometimes referred to by the term Digital Gene Expression (DGE), which reflects the discrete numerical properties of the data obtained. Early methods that applied this principle were Serial Analysis of Gene Expression (SAGE) and Massively Parallel Signature Sequencing (MPSS). See, e.g., S. Brenner, et al., Nature Biotechnology 18(6):630-634 (2000).

[0154] With the advent of "next-generation" sequencing technologies, DGE has become simpler, more high-throughput, and less costly. As a result, more laboratories can use DGE to screen the expression of more genes in more cell types of interest than was previously possible. See, e.g., J. Marioni, Genome Research 18(9): 1509-1517 (2008); R. Morin, Genome Research 18(4):610 621 (2008); A. Mortazavi, Nature Methods 5(7):621-628 (2008); N. Cloonan, Nature Methods 5(7):613-619 (2008).

[0155] Next generation sequencing typically allows for much higher throughput than traditional Sanger approaches. See Schuster, Next-generation sequencing transforms today's biology, Nature Methods 5:16-18 (2008); Metzker, Sequencing technologies the next generation. Nat Rev Genet. 2010 January; 11(1):31-46. These platforms may allow single molecule sequencing of clonally spread or unamplified nucleic acid fragments. Certain platforms include, for example, sequencing by ligation of dye-modified probes (including cyclic ligation and cleavage), pyrosequencing, and single molecule sequencing. Nucleotide sequence species, amplified nucleic acid species, and detectable products generated therefrom can be analyzed by such sequence analysis platforms. Next generation sequencing can be used in the methods of the invention, for example, to determine gene expression profiles or genomic sequence data of a cell type of interest.

[0156] RNA sequencing (RNA-Seq) uses massively parallel sequencing to allow transcriptome analysis of genomes, typically at a much higher resolution than is available using, for example, Sanger sequencing and microarray-based methods. In RNA-Seq methods, complementary DNA (cDNA) generated from the RNA of interest is directly sequenced using next-generation sequencing techniques. RNA-Seq has been successfully used to accurately quantify transcript levels, confirm or correct the 5' and 3' ends of previously annotated genes, and map exon / intron boundaries (Eminaga et al., 2013. Quantification of microRNA Expression withNext-Generation Sequencing. Current Protocols in Molecular Biology. 103:4.1 7.1-4.1 7.14).

[0157] Thus, as used herein, "sequencing" refers to any technique known in the art that allows identification of at least some consecutive nucleotides of a nucleic acid. Exemplary sequencing methods include Illumina™ sequencing, direct sequencing, random shotgun sequencing, Sanger dideoxy termination sequencing, whole genome sequencing, massively parallel signature sequencing (MPSS), RNA-seq (also known as whole transcriptome sequencing), sequencing by hybridization, pyrosequencing, capillary electrophoresis, gel electrophoresis, double stranded sequencing, cycle sequencing, single base extension sequencing, solid phase sequencing, high throughput sequencing, and the like. Examples of sequencing techniques include massively parallel signature sequencing, emulsion PCR, reversible dye terminator sequencing, paired-end sequencing, near-term sequencing, exonuclease sequencing, sequencing by ligation, short-read sequencing, single molecule sequencing, sequencing by synthesis, real-time sequencing, reverse-terminator sequencing, nanopore sequencing, 454 sequencing, Solexa Genome Analyzer sequencing, SOLiD™ sequencing, Illumina Hiseq4000, Illumina NextSeq500, Illumina MiSeq and Miniseq, MS-PET sequencing, mass spectrometry and combinations thereof.

[0158] Gene expression profiles can also be inferred from information about the proteome. The term "proteome" is defined herein as the totality of proteins present in a cell type at a particular time. Proteomics specifically includes the study of global changes in protein expression in a sample (also referred to as "expression proteomics"). Proteomics typically involves the following steps: (1) separation of individual proteins in a sample by 2-D gel electrophoresis (2-D PAGE), (2) identification of individual proteins recovered from the gel, e.g., by my mass spectrometry or N-terminal sequencing, and (3) analysis of the data using bioinformatics.

[0159] The term "genome", as used herein, generally refers to a complete set of genetic information in the form of one or more nucleic acid sequences, including text or computerized representations. A genome may contain either DNA or RNA depending on its organism of origin. Most organisms have DNA genomes, but some viruses have RNA genomes. As used herein, the term "genome" need not include a complete set of genetic information. The term may also refer to at least a majority of a genome, such as at least 50%-100% of the total genome, or any integer or fractional percentage therebetween.

[0160] The term "genomic sequence data" refers to data relating to a genome, including text or computer representations, and again, the genomic sequence data may relate to a genome, preferably a substantial portion of the genome, for example at least 50%-100% of the entire genome, or any integer or fractional percentage therebetween.

[0161] Provision of genomic sequence data may involve actual sequencing of the genome of the cell type of interest or reliance on publicly available databases of genomic sequence data, such as the Annotated Genome Sequence Database (GSDB) maintained by the National Center for Genome Resources (NCGR). Provision of genomic sequence data for many species is made publicly available through the UCSC Genome Browser, created by the UCSC Genome Browser Group at UC Santa Cruz (CA, USA).

[0162] The term "genomic region" as used herein generally refers to a region of a genome. Typically, a genomic region refers to a contiguous stretch of nucleic acid sequence in the genome of a cell type of interest that contains at least one gene.

[0163] The term "genomic subregion" refers to a portion of a genomic region that has been identified as containing one or more binding sites for one or more of the transcription factors identified as signature genes based on the gene expression profile(s) as described herein.

[0164] The term "nucleic acid" refers to any nucleic acid molecule, including, but not limited to, DNA, RNA, and hybrids or modified variants and polymers thereof ("polynucleotides") in either single- or double-stranded form. Unless specifically limited, the term encompasses nucleic acids containing known analogs of natural nucleotides that have similar binding properties as the reference nucleic acid and are metabolized in a manner similar to naturally occurring nucleotides. Unless otherwise specified, a particular nucleic acid molecule / polynucleotide also implicitly encompasses conservatively modified variants thereof (e.g., degenerate codon substitutions) and complementary sequences, as well as the sequence explicitly indicated. In particular, degenerate codon substitutions can be achieved by generating sequences in which the third position of one or more selected (or all) codons is substituted with mixed-base and / or deoxyinosine residues (Batzer et al., Nucleic Acid Res. 19: 5081 (1991); Ohtsuka et al., J. Biol. Chem. 260: 2605-2608 (1985); Rossolini et al., Mol. Cell. Probes 8: 91-98 (1994)). Nucleotides are designated by their bases according to the following standard abbreviations: adenine (A), cytosine (C), thymine (T) and guanine (G).

[0165] "Foreign nucleic acid" or "foreign genetic element" refers to any nucleic acid introduced into a cell that is not a component of the "original" or "native" genome of the cell. Foreign nucleic acid may be integrated or non-integrated, or may refer to stably transfected nucleic acid.

[0166] A "functional variant" or "functional analog" refers to a nucleic acid or protein having a nucleotide sequence or amino acid sequence, respectively, that is preferably "identical," "essentially identical," "substantially identical," "homologous," or "similar" to a reference sequence, which may be, as non-limiting examples, the sequence of an isolated nucleic acid or protein, or a consensus sequence obtained by comparison of two or more related nucleic acids or proteins, or a group of isoforms of a given nucleic acid or protein. Non-limiting examples of types of isoforms include isoforms of different molecular weights that arise, for example, as a result of alternative RNA splicing or proteolytic cleavage, and isoforms with different post-translational modifications, such as glycosylation.

[0167] As used herein, the term "variant" or "analog" refers to a nucleic acid or polypeptide that differs from a reference nucleic acid or polypeptide but retains essential properties thereof. In general, a variant is overall very similar and in many regions identical to the reference nucleic acid or polypeptide. Thus, a "variant" form of a transcription factor is overall very similar and is capable of binding to DNA and activating gene transcription.

[0168] As used herein, the term "sense strand" refers to the DNA strand of a gene that is translated or translatable into a protein. When a gene is oriented in a nucleic acid sequence in a "sense orientation" relative to a promoter, the "sense strand" is located at the 5' end downstream of the promoter, with the first codon of the protein being proximal to the promoter and the last codon being distal to the promoter. The opposite is referred to as the "antisense" strand.

[0169] As used herein, the term "operably linked" refers to a regulatory element in a nucleic acid construct that is configured to allow functional coupling between the regulatory element and a gene, resulting in expression of the gene, i.e., the regulatory element is preferably in-frame with the nucleic acid encoding the protein or peptide.

[0170] As used herein, the terms "comprising" or "comprises" are used in reference to expression cassettes, reporter vectors and their respective component(s), which may include elements not specifically specified.

[0171] The term "consisting of" refers to the expression cassettes, reporter vectors and their respective component(s) described herein, not including any elements not recited in the description of that embodiment.

[0172] The term "signature gene" refers to a gene selected from the genes of a cell type of interest, which is characteristic of the expression profile of the cell type of interest. Differentially regulated signature genes can be selected, for example, by identifying genes that are up-regulated or down-regulated compared to the expression level in a reference cell type, or by ranking gene expression levels for the cell type of interest and selecting signature genes based on a threshold level or a predetermined number of genes (e.g., most highly or least expressed).

[0173] As used herein, the term "transcription factor" refers to a protein that binds to a specific DNA sequence, thereby controlling the transfer (or transcription) of genetic information from DNA to mRNA. The function of a transcription factor is primarily to regulate the expression of genes. Transcription factors can function alone or in complexes in combination with additional proteins by promoting (as activators) or blocking (as repressors) the recruitment of RNA polymerase to specific genes. Transcription factors contain at least a DNA-binding domain that attaches to a specific DNA sequence ("binding site"), usually adjacent to the genes they regulate.

[0174] The term "microscopy device" relates to a device that comprises means for the microscopic analysis of cells. The microscopic analysis can be performed by, but is not limited to, optical microscopes, binocular stereo microscopes, bright field microscopes, polarizing microscopes, phase contrast microscopes, differential interference contrast microscopes, automated microscopes, fluorescence microscopes, confocal microscopes, total internal reflection fluorescence microscopes, laser microscopes (laser scanning confocal microscopes), multiphoton excitation microscopes, structured illumination microscopes, transmission electron microscopes (TEM), scanning electron microscopes (SEM), atomic force microscopes (AFM), scanning near-field optical microscopes (SNOM), X-ray microscopes, ultrasound microscopes. The microscopy device may additionally comprise, for example, a camera and / or a detector for recording images of the cells and a computer system for controlling the microscopy device.

[0175] The presence and / or intensity of a signal produced by a reporter gene can be determined using microscopy equipment as well as other equipment capable of detecting a signal generated by a reporter gene, such as, but not limited to, a flow cytometer, a luminometer, a spectrometer, a photometer, or a colorimeter.

[0176] As used herein, the term "topologically associated domain" preferably refers to a self-interacting genomic region, meaning that DNA sequences within the topologically associated domain physically interact with each other more frequently than sequences outside the topologically associated domain, thereby forming a three-dimensional chromosome structure. Topologically associated domains can vary in size from thousands to millions of DNA bases. A number of proteins, including the protein CTCF and the protein complex cohesin, are known to be associated with the formation of topologically associated domains. In a preferred embodiment, the topologically associated domain refers to a genomic sequence between two CTFC or cohesin binding sites.

[0177] As used herein, the term "generating a cell type specific expression cassette" in some embodiments relates to designing a cell type specific expression cassette without physically creating a corresponding nucleic acid molecule, e.g., the method may be a computer-implemented method or may include one or more computer-implemented steps of a method.

[0178] As used herein, the term "generating a cell type specific expression cassette" in some embodiments relates to the design and physical creation of a nucleic acid molecule, preferably by de novo synthesis of the nucleic acid molecule.

[0179] Artificial gene synthesis (or de novo synthesis) is the preferred method of generating the cassettes of the present invention and relates to methods used in synthetic biology to create any given nucleic acid sequence. In some cases based on solid-phase DNA synthesis, artificial synthesis differs from molecular cloning and polymerase chain reaction (PCR) in that the user does not need to start with an existing DNA sequence. It is therefore possible to create fully synthetic double-stranded DNA molecules that are not significantly limited in either nucleotide sequence or size. Gene synthesis approaches may be based on a combination of organic chemistry and molecular biology techniques, and allow the synthesis of entire genes "de novo" without the need for precursor template DNA. This method has been used to generate functional bacterial chromosomes containing approximately one million base pairs. Gene synthesis has become an important tool in many areas of recombinant DNA technology, including heterologous gene expression, vaccine development, gene therapy, vector construction and various forms of molecular engineering. The synthesis of nucleic acid sequences is often more economical than classical cloning and mutagenesis procedures. A variety of techniques are well established and known to those skilled in the art.

[0180] The term "gene therapy" refers to the transfer of DNA into a subject, preferably to treat a disease. Strategies for performing gene therapy using gene therapy vectors are known to those skilled in the art. Such gene therapy vectors are optimized to deliver foreign DNA to the host cells of a subject. In a preferred embodiment, the gene therapy vector can be a viral vector. Viruses have a naturally developed strategy for integrating DNA into the genome of a host cell and can therefore be used advantageously. Preferred viral gene therapy vectors can include, but are not limited to, retroviral vectors such as Moloney murine leukemia virus (MMLV), adenoviral vectors, lentiviral vectors, adenovirus-associated virus (AAV) vectors, poxvirus vectors, herpes simplex virus vectors or human immunodeficiency virus vectors (HIV-1). However, non-viral vectors, such as plasmid DNA expression vectors driven by eukaryotic promoters or plasmid DNA sequences with homology to the host genome, can also be used in gene therapy to directly integrate an expression cassette into the genome of a subject at a preferred location. DNA transfer can also be performed using liposomes or similar extracellular vesicles. Furthermore, the preferred gene therapy vector may refer to a method of DNA transfer, such as electroporation or direct injection of nucleic acid into a subject. Those skilled in the art know how to select a preferred gene therapy vector according to the needs of the application and how to incorporate a nucleic acid construct, such as an expression cassette, into a gene therapy vector as described herein (P. Seth et al., 2005; N. Koostra et al. 2009; W. Walther et al. 2000; Waehler et al. 2007).

[0181] The methods, systems or other computer-implemented aspects of the invention may, in some embodiments, include and / or use one or more conventional computing devices having a processor, input devices such as a keyboard or mouse, memory such as a hard drive and volatile or non-volatile memory, and computer code (software) for the functions of the invention.

[0182] The system may comprise one or more conventional computer devices preloaded with the required computer code or software, or may comprise custom-designed software and / or hardware. The system may comprise multiple computer devices performing the steps of the invention. In certain embodiments, multiple clients, such as desktop, laptop or tablet computers, may be connected to the server, for example so that multiple users can provide data or perform calculations at the various steps of the method. The computer system may be networked with other computers, or with required databases, such as genome databases, by a local area network (LAN) connection or by an internet connection. The system may also comprise a back-up system that keeps a copy of the data obtained by the invention. The data connections required between the various steps of the method may be made or configured by any suitable data transmission means, either wired or wireless, for example by a local area network (LAN) connection or by an internet connection.

[0183] A client or user computer may have its own processor, input means such as a keyboard, mouse or touch screen, and memory, or may be a terminal that does not have its own independent processing capabilities but relies on the computational resources of another computer, such as a server to which it is connected or networked. Depending on the particular implementation of the invention, the client system may include the computer code necessary to take control of the system should such a need arise. In one embodiment, the client system is a tablet or laptop.

[0184] The components of the computer system for carrying out the method may be conventional, but the system may be custom configured for each particular implementation. The computer-implemented method steps or system may be executed on any particular architecture, such as personal / microcomputer, minicomputer, or mainframe system. Exemplary operating systems include Apple Mac OS X and iOS, Microsoft Windows and UNIX / Linux; SPARC, POWER, and Itanium-based systems; and z / Architecture. Computer code for carrying out the invention may be written in any programming language or model-based development environment, such as, but not limited to, C / C++, C#, Objective-C, Java, Basic / VisualBasic, MATLAB, R, Simulink, StateFlow, Lab View, or Assembler. The computer code may include subroutines written in a proprietary computer language specific to the manufacturer of the circuit board, controller, or other computer hardware component used with the invention.

[0185] The information processed and / or generated by the method, i.e. as a digital representation of a list of specific sequence elements such as nucleic acid sequences, gene expression profiles, genes and / or TF binding sites, can be in any type of file format used in the industry. For example, the digital representation can be stored in a proprietary format, a DXF format, an XML format, or other formats used in the present invention. Any suitable computer readable medium can be utilized. A computer usable or computer readable medium can be, for example, but not limited to, an electronic, magnetic, optical, electromagnetic, infrared or semiconductor system, apparatus, device or propagation medium. More specific examples (non-exhaustive list) of computer readable media include: an electrical connection with one or more cables, a portable computer diskette, a hard disk, a random access memory (RAM), a read-only memory (ROM), an erasable programmable read-only memory (EPROM or flash memory), optical fiber, a portable compact disk read-only memory (CD-ROM), an optical storage device, a transmission medium such as a transmission medium supporting the Internet or an intranet, cloud storage or a magnetic storage device.

[0186] Table 1 lists the nucleotide sequences of preferred embodiments of a minimal set of genomic subregions (ie, synthetic locus regions) for cell-type specific reporter vectors.

[0187] Table 1: Nucleotide sequences of preferred synthetic locus regions for cell type specific reporters: [Table 1-1] [Table 1-2] JPEG2024156849000004.jpg215147 [Table 1-3] JPEG2024156849000006.jpg232164 [Table 1-4]

[0188] Thus, in one embodiment, the present invention provides a method for producing a composition comprising: a) a nucleic acid molecule comprising or consisting of a nucleotide sequence according to SEQ ID NO: 1 to 6, b) a nucleic acid molecule complementary to the nucleotide sequence according to a); c) a nucleic acid molecule comprising a nucleotide sequence having sufficient sequence identity to be functionally similar / equivalent to a nucleotide sequence according to a) or b), preferably having at least 70%, 80%, preferably 90%, more preferably 95% sequence identity with the nucleotide sequence according to a) or b); d) Nucleic acid molecules according to the nucleotide sequences of a) to c) which have been modified by deletions, additions, substitutions, translocations, inversions and / or insertions and which are functionally similar / equivalent to the nucleotide sequences according to a) to c); The present invention also includes a vector comprising a nucleic acid molecule selected from the group consisting of:

[0189] Functionally similar sequences preferably refer to the ability of the synthetic regulatory region to promote transcription of an operably linked reporter or effector gene in a cell type of interest.

[0190] In one embodiment, the present invention provides a) a nucleic acid molecule comprising or consisting of a nucleotide sequence according to SEQ ID NO: 1 to 6, b) a nucleic acid molecule complementary to the nucleotide sequence according to a); c) a nucleic acid molecule comprising a nucleotide sequence having sufficient sequence identity to be functionally similar / equivalent to a nucleotide sequence according to a) or b), preferably having at least 70%, 80%, preferably 90%, more preferably 95% sequence identity with the nucleotide sequence according to a) or b); d) Nucleic acid molecules according to the nucleotide sequences of a) to c) which have been modified by deletions, additions, substitutions, translocations, inversions and / or insertions and which are functionally similar / equivalent to the nucleotide sequences according to a) to c); e) a nucleic acid molecule produced according to the method; The present invention also encompasses a vector for oncolytic virus therapy comprising a nucleic acid molecule selected from the group consisting of:

[0191] Functionally similar sequences refer to the ability of the synthetic regulatory region to promote transcription of viral essential genes and / or effector genes, such as costimulatory molecules (e.g., cytokines / chemokines), preferably in target cells of the disease of interest but not in non-diseased cells.

[0192] Detailed description of the drawings: Figure 1: Generation and validation of synthetic locus control regions (sLCRs). a) Schematic of sLCR generation starting from differentially regulated genes (DRGs). b) Pairwise correlation heatmap of TFBS motifs significantly detected at genomic GBM subtype-specific loci. The number of TFBS and DRGs analyzed is indicated above each panel. c) Schematic of sLCR and experimental steps to generate reported glioma initiating cells (GICs). d) Left; confocal images of 293T transfected with MGT#1 or (right) cryosections of lentivirally transduced MES-hGIC neurospheres. Scale = 10 μM. e) Representative mVenus FACS profiles of MES-hGICs and PN-hGICs modified with sLCR and FACS sorted for H2B-CFP. MES-hGICs express higher levels of MGT#1 (arrows). f) Representative quantification of response to tumor necrosis factor alpha (TNFa) treatment in the indicated GICs. MES-hGICs express higher levels of MGT#1 (arrows). MES=mesenchymal; PN=proneural; CL=classical. MGT#1-2=MES gene tracking#1-2. tmd=PDRGFRa transmembrane domain. g) Dual IF and smRNA-FISH. Merged (left) and separate channel (right) images are shown. Overlapping signals in yellow and arrows indicate colocalization of MED1 with mVenus induced by MGT#1. h) mVenus FACS profiles of MES-hGICs and PN-hGICs transduced with the indicated sLCRs and FACS sorted for H2B-CFP. Gating and arrows indicate MES-hGICs expressing higher levels of MGT#1 than PN-hGICs.

[0193] Figure 2: Intrinsic and adaptive responses in MES-GICs and PN-GICs revealed by sLCR. a) TNFa is the major signaling contributing to the mesenchymal GBM phenotype. Left, TNFa identified as a top regulator as an activator of two independently designed MES-GBM reporters (MGT#1-MGT#2) in MES-hGICs by adaptive response screening with the indicated cytokines for up to 48 h. Data are normalized to control. MES-hGICs express higher basal levels of MGT#1 compared to PN-hGICs. b) Cooperation of IL-6 with microglial cells in MGT#1 induction. Live cell imaging of MGT#1 expression in MES-hGICs after indicated treatments. c) Immunoblotting for the indicated conditions and antibodies. d and e) Differential MGT#1 activation informs about differential adaptive responses to TNFa. Changes in expression of genes regulated by TNFa in either MES-hGICs or PN-hGICs as measured by RNA-seq and hierarchical sample clustering. f) RT-qPCR validation of indicated genes in response to tumor necrosis factor alpha (TNFa) treatment in indicated GICs. n=3 biologically independent samples, ANOVA test; **** P<0.0001; g) Cooperation between TNFα and therapy-induced mesenchymal commitment revealed by MGT#1 expression. FACS quantification of mesenchymal transdifferentiation after indicated stimuli. h) Immunoblotting for indicated conditions and antibodies. MES=mesenchymal; PN=proneural; CL=classical. MGT#1-2=MES gene tracking#1-2. FBS=fetal bovine serum, CBD=cannabidiol. IRR=ionizing radiation.

[0194] Figure 3: GBM subtyping and reprogramming using sLCRs. a) Schematic of the use of GBM subtype-specific sLCRs to determine unique GBM subtypes and enhance subtype identity using cell reprogramming or external signaling. b) Enhancement of proneural identity in conventional glioma cell lines. T98 cells were transduced with either proneural or mesenchymal sLCRs that induce mCherry as a reporter and transfected with master regulators of PN subtype identity specification. 50 Representative photomicrographs (left) and FACS plots (right) of T98 cells showing high intrinsic TF-induced expression of PNGT#2 but not MGT#2 reporter in T98 cells; scale = 100 μM.

[0195] Figure 4: Tissue-independent epithelial-mesenchymal homeostasis revealed by sLCR. a) MGT#1 reveals intrinsic cell fate differences in breast cancer cells. Left, representative expression of MES-GBM reporter MGT#1 transduced in epithelial (top) and mesenchymal (bottom) breast cancer cells. FACS plot showing higher intrinsic expression of reporter in MDA-231 than MCF7 cells. Note that reporter expression is independent of mesenchymal inducer 10 pM TGFβ2. Scale = 100 μM. b) MGT#1 reveals adaptive responses to chemicals / morphogens in lung cancer cells. Left, representative MGT#1 expression in A549 cells seeded in 96-well and grown for the indicated times. 300000 cells / plate were grown in RPMI medium. 10 pM TGFβ1+2 and 5 μM GSK126 were added at 0 and 48 h. Fluorescence was measured and representative micrographs (right) were captured by an IncuCyte imaging system. Error bars represent standard deviation of independent wells (n=3). c) CRISPRi and MGT#1 reveal mechanistic regulators of lung cancer EMT. Schematic diagram showing the screen. Dox, doxycycline. d) Immunoblotting of representative mid-time points of the CRISRPi screen. MGT#1 fluorescence micrographs were taken before lysis. e) FACS sorting gating strategy for purification of MGT#1 high and low populations. f) MA plot showing relative enrichment of gRNAs in the MGT#1 high-MGT#1 CRISPRi screen. Note the two dropout gRNAs identifying known and novel regulators of EMT. g) FACS validation of MGT#1 expression following CRISPR-mediated knockout of ARID1A and CNKSR2 with two independent gRNAs. h) Immunoblotting of EMT markers in wild-type and ARID1A and CNKSR2 KO cells.

[0196] Figure 5: Heterogeneous mesenchymal transdifferentiation revealed by sLCR in vivo. a) MES-hGIC in NSG mice (n=10) with human endpoint; MGT#1-mVenus dimRepresentative coronal forebrain images of xenografts. Left, HE staining; right, progressive insets showing enlargements of GFP, tubulin and DAPI counterstained tissue. high b) Representative mixed MGT#1-mVenus high / MGT#1-mVenus neg c and d) Representative H2B-CFP expression (arrows) in MGT#1 positive and negative lesions, respectively. e) MES-hGIC in NSG mice or in vitro; MGT#1-mVenus dim Representative flow cytometry plots showing CD133 and MGT#1-mVenus expression in xenografts (left). Individual components are shown on the right. Note the profile shift from in vitro to in vivo. f) Schematic representation of the data given in a-e.

[0197] Figure 6: Selection of subtype-specific genes for MES GBM subtypes. a) Heatmap representing fold changes for selected genes from the TCGA ranked Significance Analysis of Microarrays (SAM) list for the indicated pairwise comparisons. Below, color code showing GBM subtype expression profile associated with metadata. b) Heatmap representing expression levels for selected genes showing expression and fold change in primary biopsies and glioma stem-like cells (GSCs) derived therefrom. Below, color code showing GBM subtype expression profile associated with metadata. All genes had absolute CPMs greater than 4, and most genes showed fold changes in GSCs, suggesting that they also contribute cell-autonomously to their expression. Spearman rank correlation was used for samples and Pearson correlation for genes.

[0198] Figure 7: Automated synthetic locus control region (sLCR) generation. a) Top left (I), schematic of identification of cis-regulatory elements (CREs) associated with specific gene signatures; top right (II), annotation of CREs to genomic locations; bottom (III), iterative selection of 150 bp CREs based on TFBS diversity and score [Σ-log10(p-value)+TFBS number]. sLCR generation includes assembly of n CREs from the closest CRE to the natural TSS to the furthest terminal CRE with up to >50% of TFBS diversity (example MES-GBM). b) Spearman correlation of individual sLCRs based on TFBS score / diversity. (A) shows sLCRs generated by the automated algorithm.

[0199] Figure 8: Intrinsic and adaptive responses in MES-GICs and PN-GICs revealed by sLCR. Representative live cell imaging of MGT#1 expression in GICs from Figure 2a.

[0200] Figure 9: Transcription factors binding to MGT#1 cis-regulatory DNA. a) Top, schematic of MGT#1 sLCR. Bottom, list of TFs for which ChIP-seq signals can be observed in the ENCODE public database in any of the cell lines used.

[0201] Figure 10: Homeostatic maintenance of MGT#1 expression in breast cancer cells. a) Schematic of the two hypotheses tested: MGT#1 statically reflects cell state, or MGT#1 dynamically reflects cell homeostasis, with in vitro homeostatic regulation reconstituted after perturbation (i.e. FACS purification of MGT#1 dim population). The green dashed circle highlights the results in Figure 4a, which shows that MCF7 and MDA-231 have inherent low or high MGT#1 expression, respectively, due to their cellular identity. b) MCF7 and MDA231 were FACS sorted based on best comparable MGT#1 intensity and expanded in vitro before FACS analysis shown in 4a.

[0202] Figure 11: MGT#1 reflects the contribution of TGFB and GSK126 alone and in combination to EMT. a) FACS profile of MGT#1 expression in A549 cells exposed to the indicated treatments for 5 days. A minimum of 10,000 cells were acquired per sample. b) FACS profile of MGT#1 expression and cell morphology in A549 cells exposed to the indicated treatments for 5 days. Note the TGFB-dependent changes in cell shape and cooperativity between TGFB1+2 and GSK126.

[0203] Figure 12: MGT#1 allows screening of cell fate transitions induced by external signaling and / or chemical perturbations. Principal component analysis (PCA) of data obtained from the screen is shown. Two components PC1 and PC2 explain the largest variation in the experiment. To generate the data, A549-MGT#1 cells were grown and cell images were taken at the end of the procedure for naive epithelial A549-MGT#1 and GSK126 treated cells. Note the mesenchymal transition, which is consistent with previously published data. Hierarchical clustering was performed on normalized fluorescence data from grown A549-MGT#1 cells and scanned fluorescent bottom readings using a SPARM20M TECAN plate reader. Pearson correlation was used for clustering. Color code indicates fold change in fluorescence intensity (blue-white-red) and biological replicates (yellow / orange=vehicle, green=GSK126). Live cell imaging was performed showing the response to LPS in GSK126-treated and control A549-MGT#1 cells.

[0204] Figure 13: Intrinsic and adaptive responses in MES-GICs and PN-GICs revealed by sLCR. a) Schematic of phenotypic screening with sLCR (top) and bubble plot visualization of results (bottom). For each GIC and sLCR, the size of the bubble indicates the magnitude of change of each treatment relative to the control (log2-fold change) and the color of the bubble indicates the sign of the change (red or orange for enrichment, light blue for depletion). b) FACS validation of the phenotypic screen. Surface expression of CD133 and PNGT#2 were endogenous markers of cell identity. Note the higher MES-hGIC MGT#1 expression compared to PN-hGICs. c) Representative FACS quantification of mesenchymal transdifferentiation after the indicated stimuli. d) Experimental design for functional analysis of MGT#1 activation. e) Volcano plot of drug-associated sgRNAs from the screen in d (red, positive regulators; blue, negative regulators; grey, non-significant). All MGT#1 high Fold change for fractions (n=3, mean of naïve, TMZ+IR, TNFa+FBS) for all MGT#1 low Calculated for fractions and unsorted controls (n=6). Padj was calculated by DeSeq2 (see Methods). Selected sgRNA-compound pairs are highlighted. f) RT-qPCR of indicated genes after indicated treatments and sequential treatment with TNFa. Padj is shown for representative comparisons, with results from global 2-way ANOVA and Dunnett's multiple comparisons. MES=mesenchymal; PN=proneural; MGT#1-2=MES gene tracking#1-2. FBS=fetal bovine serum, TNFa=tumor necrosis factor-alpha. IR=ionizing radiation. TMZ=temozolomide.

[0205] Figure 14: Heterogeneous mesenchymal transdifferentiation in vivo revealed by sLCR. a) Scatter plot of ATAC-seq profiles for the indicated conditions indicated by yellow and blue boxes in 5e), highlighting open chromatin at the TNF receptor superfamily (TNFRS) locus. b) UCSC genome browser view of the FADD / TNFRS6 locus. MGT#1 in vitro and in vivo highChanges in accessibility between cells are indicated by arrows and colors (red-up, gray-neutral). c) Unsupervised t-SNE on ATAC-seq profiling of the PanCancer dataset and the indicated conditions. Each dot represents a given sample or a merge of all technical replicates when available. The analysis includes the top principal components for the 250000 most variable peaks across all samples. Grey dots are all TCGA cancer types except GBM / LGG, colored together with glioma stem cells from (Park et al., 2017, Cell Stem Cell21, 209-224 August 3, 2017) and GICs from this study. Circles indicate dimensions occupied by primary GBM / LGG and GICs / GSCs. d) Unsupervised t-SNE on ATAC-seq profiling restricted to samples within the glioma dimension.

[0206] Figure 15: sLCR facilitates discovery of therapeutic relevance of cell-non-autonomous crosstalk between tumor and immune cells. a) Brightfield and IF of representative MES-hGICs with indicated reporters grown as spheroids or organoids with immortalized human microglia (hMGs; top and bottom panels, respectively). Scale bar = 50 µm. b) Schematic of non-contact hGIC-hMG co-culture. Left; Brightfield images of hGICs and MGs in co-culture. c) MES-hGIC-MGT#1 alone or stimulated with TNFa or hMG co-culture. highRepresentative FACS profiles and gating strategy for. Bottom, Venn diagram of NFkB-related genes by Ingenuity Pathway Analysis of DRG for the indicated conditions. DRG are enriched compared to control GICs (FC>1, padj<0.05). d) Venn diagram of hMG-induced MES GBM signature overlapping with that of patients. Note the high degree of overlap with Neftel et al. compared to others. e) Heatmap of DRG for the indicated conditions. RNA-seq reads were normalized as Log2-transformed and Z-scored transcripts per million. Statistical significance was assessed using the R package LIMMA (control, n=3, hMG, n=3; TNFa n=2; padj<0.05). f) MA plots for the indicated comparisons. Significant DRGs are highlighted and color coded. g) MES-hGIC-MGT#1 high h) Left, Schematic of chemosensitivity profiling assay for sLCR high and low states. Right, FACS sorted MES-hGIC-MGT#1 in response to increasing concentrations of the indicated drugs. high and MES-hGIC-MGT#1 low LogIC50 values ​​calculated for fraction viability.

[0207] Figure 16: Detailed characterization of the synthetic locus control region (sLCR). Single molecule RNA FISH quantification of gene expression induced by MGT#1 and PGK. Arrows / yellow indicate cytoplasmic colocalization.

[0208] Figure 17: Further examples of adaptive responses revealed by sLCR. Representative MGT#1 activation after the indicated stimuli.

[0209] Figure 18: Induction of the MES-GBM state as measured by sLCR in GICs is specific and reversible. a and b) Bar graphs showing individual responses to the indicated factors / sLCR after 48 hours of induction. c and d) Line graphs showing longitudinal expression of the indicated factors / sLCR.

[0210] Figure 19: MES-sLCR to analyze the role of ionizing radiation and NFkB signaling in MES-GBM. a) Right, dose response between IR and MGT#1 activation. An example of the experimental setup is shown on the left. b) Representative FACS quantification of mesenchymal transdifferentiation after the indicated stimuli.

[0211] FIG. 20: Further evidence supporting the use of sLCR in phenotypic CRISPR / Cas9 forward genetic screens. a) Genome-wide CRISPR screening using MGT#1 for gRNA amplification. high and MGT#1 low b) FACS plots for the indicated conditions before sorting. b) Box plots showing data quality assessment by comparing the distribution of highly informative essential gRNAs and all non-essential or non-targeting gRNAs in the unsorted screening conditions (P-value = Student's t-test). c) Distribution of sgRNA fold change values ​​between the Brunello library and unsorted MES-hGIC + Brunello conditions for the indicated gRNA sets (see Methods). d) Representative MA plots of sgRNA abundance (x-axis) and fold change (y-axis). Naïve MES-hGICs harboring the Brunello library were sorted into MGT#1 high and MGT#1 low The indicated gRNAs were FACS sorted in 100% genomic DNA and were normalized to the largest dataset and Log2 transformed (see Methods). highfraction. e) Ingenuity Pathway Analysis (IPA) top 25 toxicity categories (FC ± 1.5; padj < 0.05) of all hits from the CRISPR / Cas9 KO screen. Only "positive regulators" exceed the statistical cutoff. Categories in bold are associated with retinoic acid receptor signaling. IPA Upstream Regulator Analysis (FC ± 1.5; padj < 0.05) of all hits from the CRISPR / Cas9 KO screen. Positive and negative regulators of the MES-GBM phenotype are colored light blue and red, respectively. Grey indicates significant categories with no directional enrichment. f) Volcano plot of top regulated sgRNAs from the screen in e. All MGT#1 high The fold change for fractions (n=3, average of naïve, TMZ+IR, TNFa+FBS) was calculated for all MGT#1 low Calculated for fractions and unsorted controls (n=6). Padj was calculated by DESeq2 to highlight FDA approved compound pairs of selected sgRNAs (see Methods).

[0212] Figure 21: Further evidence supporting hMG cells inducing MGT#1 expression in hGICs and differential sensitivity to treatments and hMG cells. a) Detailed schematic of the co-culture experiment in Figure 4; see Methods for detailed medium composition. b) MES-hGIC-MGT or PN-hGIC-MGT#1 alone or co-cultured with human microglia (hMG) or human CD34+ derived myeloid-derived suppressor cells (MDSCs). high c) Principal component analysis of the indicated RNA-seq profiles. Distances were calculated based on the average expression levels of selected human MG markers from Gosselin et al. 2017. d) FACS-sorted MES-hGIC-MGT#1 in response to increasing concentrations of the indicated drugs. high and MES-hGIC-MGT#1 lowFraction viability. e) Scatter plot and gene set enrichment analysis (GSEA) for the indicated gene list showing that hMG cells induce MES-GBM and suppress DNA damage transcriptional signature genes.

[0213] Figure 22: Further evidence supporting the use of sLCR in phenotypic CRISPRi screening. a) Cumulative plot distribution for all samples (n=42) in the kinome screen including technical replicates and biological conditions: plasmid library, A549-H1944 input, A549-H1944+GSK126 high, med, low-control-A549-H1944+GSK126+dox high, med, low and A549-H1944+doxhigh, med, low-GSK126-induced EMT and homeostatic EMT screens, respectively. All gRNAs (n=6615) were normalized by total number per million reads, log transformed by percentile normalization (75th percentile) and converted by conversion to z-score. b and c) Scatter plots for all gRNAs (n=6615) in the screens of Fig. 3c-f, and GSEA for non-essential sgRNAs (n=483) and essential genes (n=352), respectively. Depletion of essential genes is significant by t-test and Kolmogorov-Smirnov with FC<-1 and padj<0.001. d and e) Scatter plots for all gRNAs (n=6615) in the combined A549+H1944+GSK126+dox screen, and GSEA for non-essential sgRNAs (n=483) and essential genes (n=352), respectively. Depletion of essential genes is significant by t-test and Kolmogorov-Smirnov with FC<-0.5 and padj<0.001. EXAMPLES

[0214] The present invention is further illustrated by the following examples, which are not intended to limit the scope of the present invention, but rather represent preferred embodiments presented for further illustration of the invention described herein. The examples demonstrate that the methods and reporter vectors described herein allow cell type specific expression of reporter and effector genes in various cell types of interest.

[0215] Materials and methods used in the examples: Generation of sLCRs and discovery of TFBS: High affinity TF binding sites in defined genomic regions (DRG loci; Table X) were identified using FIMO (PMID:21330290) with --output-pthresh 1e-4 --no-qvalue. A database of 1818 models representing known transcription factor binding preferences (position weight matrix, PWM) was generated from the literature (Portales-Casamar et al., 2010; Badis et al., 2009; Berger et al., 2008; Bucher, 1990; Jolma et al., 2010). PWMs were preselected based on subtype-specific TFs. Regions corresponding to DRGs were retrieved from the UCSC genome browser (hg19; Refseq table downloaded on October 5, 2012) and scanned in windows of 150 bp and 50 bp steps (hereafter referred to as cis units). The scanned regions around each signature gene were delimited by two distal CTCF sites located >10 kb away from the TSS or TES. Subtype-specific PWMs were mapped to genomic regions using FIMO. PWMs are the most significantly overrepresented regions (adjusted p-value <0.01; multiple backgrounds). For each window, if multiple matches were identified with the same PWM, the p-value of the best match was considered as a proxy for the affinity of that TF across the region. Given a region, an overall score was calculated based on the sum of the best -log10(p-value) for each PWM considered. Significantly overrepresented regions (multiple backgrounds) were determined by comparing motifs / backgrounds (empirical p-value <0.01). For the TFBS pairwise correlation heatmap in Figure 1a, the top 500 regions were used in terms of score as defined above. Genomics coordinate vs. TFBS correlation heatmaps, including the representative one in Figure 1a, were generated using the top 100 scoring regions.

[0216] Automation of sLCR generation: In order to focus on cell-specific gene signatures, a pilot approach excluded genes with low expression in GBM stem-like cells (GSCs) from our previous experiments, but the current implementation of the method involves focusing on validated glioma-specific signatures. 20 The first sLCR was designed by manual selection of the top scoring cis units based on PWM score and diversity. Selection of TSS-containing regions was also performed manually. The automated sLCR generation was written in python (URL GitHub / GitLab). The script takes as input a list of TFs, PWMs and phenotypic gene signatures. Using these, cis units are generated from defined cis-regulatory regions (default parameters: 150 bp window / 50 bp step). The selection of the best cis units for any given phenotype is generated using an algorithm based on defined selection rules. The algorithm first generates a ranking and selection of the best cis units by applying the following formula: [sum of score-log10(p-value) x diversity (number of different TFBSs)]. Iteratively, TFBSs included in the selected cis units are filtered out. To increase the chance of successful transcription firing, the algorithm also ranks the cis units based on 5'CAGE data. The ranked list is the output of the algorithm. The automated procedure returned the duplicate results by manual selection (Figure 7). The heatmaps in Figures 1a and 1b were generated using the heatmap.2 function from the gplots R package.

[0217] RNA-seq generation: RNA was extracted using Trizol (Invitrogen), precipitated with isopropanol, and purified with RNACleanXP beads. The RNA-seq libraries generated for this study were constructed using the TruSeq Stranded Total RNA library prep kit. A bead-based approach was used for rRNA depletion (Ribo-Zero Gold; Illumina), and PCR amplification was performed according to the manufacturer's protocol. Final libraries were analyzed on a Bioanalyzer or TapeStation, and barcoded libraries were pooled and sequenced on an Illumina HiSeq2500 or HiSeq4000 platform using either a single-read 51 bp or paired-end 100 base protocol. Illumina adapters were trimmed with Cutadapt using raw reads, and raw reads were aligned against the human genome (Hg19 or Hg38) with TopHat. HTSeq was used to assess the number of uniquely assigned reads for each gene. Expression values ​​were then scaled by 10 7 Data were normalized to total reads and log2 transformed to obtain counts per million (CPM).

[0218] Analysis: For the heatmap in Fig. 2d, Seqmonk v1.42 was used. Briefly, BAM files were aligned to Hg38 using HISAT2 and transcripts were quantified by RNA-Seq pipeline quantification of transcript count reads across exons correcting for feature length. Opposite strand specific libraries were assumed by percentile normalization supplemented by matching distributions following quantification, log transformation and graphical display with alignments.

[0219] In Fig. 15e, data were analyzed using SeqMonk and reads were normalized, DNA contamination corrected, raw counts were generated by standard analysis pipeline and DESeq2 differential analysis was performed. The same pipeline with log transformation was used for visualization. Standard SeqMonk settings: significance was determined using p<0.05 after Benjamimi (Benjamini) and Hochberg correction with independent intensity filtering applied. Quantification was performed as above. NFKB-related genes in MG vs. GIC and TNFa vs. GIC were determined using IPA and MES GBM signatures were obtained by respective publications and plots were generated using Venny. GSEA significance was determined as FC>0.5-fold with padj=0 for MES-GBM, FC<-0.4 with padj=0 for PN and FC>1-fold with padj=0 for SREBP. The interaction map in FIG. 15e was generated using a functional Ingenuity upstream regulator of IPA for the comparison of MGT#1High TNFa vs. MGT#1High C20MG cocultures.

[0220] ATAC-seq: ATAC-seq on FACS-sorted populations was performed on 20-50000 cells from in vivo experiments and 50-100000 cells from in vitro experiments. Cells were centrifuged in PBS and pellets were gently resuspended in 50 μl of master mix (25 μL 2x TD buffer, 2.5 μL transposase and 22.5 μL nuclease-free water, Nextera DNA Library Prep, Illumina) and incubated for 60 min at 37°C with moderate shaking (500 rpm-800 rpm). Transposition was stopped with 5 μl proteinase K and 50 μl AL buffer (Qiagen), incubated for 10 min at 56°C and DNA was purified using 1.8xvol / vol AMPure XP beads and eluted in 18 μl. The optimal number of PCR cycles for library amplification was determined using 2 μl of template for each sample, followed by qPCR amplification using heat-activated Kappa Hifi polymerase and EvaGreen 1x. Final amplifications were performed in 50 μl qPCR volumes and 8 μl–12 μl of template DNA. Primers were previously described (Buenrostro et al. 201). Libraries were individually quantified using Qubit (Life Technologies) and appropriate ladder distributions were determined on a TapeStation (Agilent) using HighSensitivity D1000 ScreenTapes. Sequencing was performed on an Illumina NextSeq 500 with V2 chemistry for 150 cycles (paired-end 75 nt). ATAC-seq variance analysis in Figure 14a was performed using SeqMonk using TSS ±5 kb as probe and final annotation in ENSEMBL mRNA. Normalization used Read Count Quantitation, where reads were corrected for total probe-only counts per million reads, and the log-transformed snf was further transformed by size factor normalization.

[0221] ATAC-seq analysis: Reads were adapter removed using trim-galore v0.6.2 --nextera and then mapped using bowtie2 v2.3.5 (reference) default parameters. ATAC-seq analysis was performed using SeqMonk using probe TSS ±5 kb, final annotation in ENSEMBL mRNA (2019 assembly). Counts were normalized using the Read Count Quantitation function, and reads were corrected for total probe-only counts per million reads, log transformed, and further transformed by dimension factor normalization. The integration of sLCR ATAC-seq and TCGA ATAC-seq in Figure 14c was generated following established protocols.

[0222] Vector generation: sLCRs were synthesized initially by IDT and later by GenScript. MGT#1-mVenus was cloned into the PacI-BsrGI fragment of the mammalian expression lentivirus FUGW (gift of David Baltimore; Addgene#14883). For MGT#1 with additional modifications such as swapping mVenus with mCherry, or all other sLCRs, either restriction enzyme digestion or Gibson cloning was used. sLCR vectors are third generation lentiviral systems and have been used with pCMV-G (Addgene#8454), pRSV-REV (Addgene#12253) and pMDLG / pRRE (Addgene#12251). Sall2 (ccsbBroad304_11117) and Pou3f2 (ccsbBroad304_14774) were obtained from the CCSB-Broad Lentiviral Expression Library.

[0223] The cell lines: MES-hGIC and PN-hGIC were generated by our laboratory and are described elsewhere. Briefly, PN-hGIC was generated by transforming human NPC with pLenti6.2 / V5-IDH1-R132H, TP53R173H and TP53R273H (point mutations introduced into TP53ccsbBroad304_07088 from the CCSB-Broad Lentiviral Expression Library) and pRS-Puro-sh-PTEN(#1). MES-hGIC was generated by transforming human NPC pRSPURO-sh-PTEN(#1), pLKO.1-sh-TP53(TRCN0000003754) and pRS-shNF1. These lines were subjected to genetic, transcriptional and epigenetic characterization, as well as in vivo tumorigenicity and phenotypic mimicry. In vitro, GICs were grown as described with one modification. 76 In addition to EGF (20 ng / ml; R&D), bFGF (20 ng / ml; R&D), heparin (1 μg / ml; Sigma), and 5% penicillin and streptomycin, PDGF-AA (20 ng / ml; R&D) is also added to RHB-A (Takara Bio Inc.). This medium composition is referred to as RHB-A complete medium. hGICs were cultured at 37°C in an incubator with 5% CO2, 3% O2, and 95% humidity.

[0224] T98G and U87MG (kindly provided by the vanTellingen lab, NKI) were grown in EMEM medium. For the experiment in Fig. 13a, T98G were switched to RHB-A supplemented with EGF (20 ng / ml), bFGF (20 ng / ml), heparin (1 μg / ml), and 5% penicillin and streptomycin, and grown first on standard tissue culture treated plastic and then in ultra-low binding plastic (CORNING).

[0225] MCF7, MDA-231, A549 and H1944 cell lines (kindly provided by Rene Bernards lab, NKI) were cultured in RPMI medium. All cell lines were supplemented with 10% FBS and 5% penicillin and streptomycin at 37°C in a 5% CO2-95% air incubator.

[0226] Immortalized primary human microglia C20 were cultured in RHB-A medium (Takara Bio Inc.) supplemented with 1% FBS, 2.5 mM glutamine (Thermofisher; 35050038), 1 μM dexamethasone (Sigma; D1756), and 1% penicillin and streptomycin at 37°C in an incubator with 5% CO2, 19% O2, and 95% humidity.

[0227] Donor-derived CD34 cells were grown in SFEM II (StemCell), SCF, FLT3-L, TPO, IL6 (all 100 ng / ml; easyexperiments.com), UM171 (Selleck, 0.035 μM), SR1 (Selleck, 0.75 μM), and 19-deoxy-9-methylene-16,16-dimethylPGE2 (Cayman, 10 μM).

[0228] Genome-wide CRISPR knockout in vitro screen: For the genome-wide pooled CRISPR knockout screen, we utilized the Brunello library, which consists of 77441 sgRNAs targeting 19114 genes (an average of 4 sgRNAs per gene) and 1000 non-targeting controls. A total of 16 × 10 sgRNAs were used to achieve a library representation of over 100-fold. 6 MES-hGIC-MGT#1 low Cells were transduced at an MOI of approximately 0.5 and allowed to grow for 10 days before treatment was introduced. On day 10, cells were treated with TNFα (10 ng / ml) and FBS (0.5%), temozolomide (50 μM) and irradiation (20 Gy), or left untreated. FACs sorting of each condition was performed prior to gDNA extraction, and MES-hGIC-MGT#1 low, MES-hGIC-MGT#1 high and unsorted populations were collected. Genomic DNA was extracted by lysing cell pellets in AL buffer (Qiagen) supplemented with proteinase K (Invitrogen) and RNase A (Thermo Scientific) for 10 min at 56 °C, followed by purification with AMPure beads and elution in EB buffer (Qiagen). NGS libraries were constructed in a two-step PCR setup, where PCR1 was used to amplify sgRNA scaffolds and insert staggered sequences to increase library complexity across flow cells, and PCR2 introduced Illumina-compatible adapters with unique P7 barcodes to allow sample multiplexity. For PCR1, 5 μg of each gDNA sample was split into five parallel reactions, which were subsequently pooled and purified with AMPure beads. The optimal cycle number for PCR2 was determined individually for 1 μl of each PCR1 by performing qPCR amplification with KAPA HiFi HotStart Ready Mix (Roche) and 1x EvaGreen (Biotium). 10 μl of purified PCR1 from each sample was used as input for the final PCR2. Both PCR1 and PCR2 were performed using KAPAHiFi HotStart Ready Mix. Primers are available upon request. Quality control of the final libraries was performed using Qubit dsDNA HS kit (Invitrogen) for quantification and TapeStation High SensitivityD1000 ScreenTape (Agilent) for PCR fragment size determination. Barcoded libraries were pooled in equimolar concentrations and sequenced on an Illumina NextSeq500 using V2 chemistry (1 × 75 nt single read mode) for 75 cycles.

[0229] Transwell co-cultures: Co-cultures of hGICs and immortalized primary human microglia C20 were set up using hydrophilic PTFE 6-well cell culture inserts with 0.4 μm pore size (Merck). Human microglia were cultured at 1.5 × 10 5 Cells / well were seeded in respective medium on 6-well plates for 24 h. Medium was aspirated and cells were washed once with PBS before adding 1 ml of RHB-A complete medium. Transwell inserts were placed in the plates and 5 × 10 cells ... a total volume of 1 ml of RHB-A complete medium. 5 Single hGICs were plated onto the insert surface. hGICs and C20 human microglia were harvested after 48 hours of co-culture for further analysis.

[0230] Transfection-transduction: Transfection and transduction have been described in detail previously. Briefly, 12 μg of DNA mix (lentivector, pCMV-G, pRSV-REV, pMDLG / pRRE) was incubated with FuGENE-DMEM / F12 mix for 15 min at room temperature and added to antibiotic-free medium covering 293T cells, and the first-tap of viral supernatant was harvested 40 h post-transfection. Titers were assessed using the Lenti-X p24 Rapid Titer Kit (Takara Bio Inc.) according to the manufacturer's instructions. Viral particles were applied to target cells in the appropriate complete medium supplemented with 2.5 μg / ml protamine sulfate. After 12-14 h of incubation with viral supernatant, the medium was refreshed with the appropriate complete medium.

[0231] Preparation of frozen sections: Tumor masses were allowed to settle by gravity and fixed with freshly prepared formaldehyde (1.0%) in PBS, which was blocked with 140 mM glycine 2M and rinsed with 30% sucrose, followed by addition of freezing medium (OCT / cryomold). Frozen blocks were obtained by dry ice freezing and stored at -80°C until use. Blocks were cut with a Leica CM 1950.

[0232] Immunohistochemistry: Tissues or tumor-like masses were fixed in 4% PFA for 20 min. After fixation, dehydration was performed with graded EtOH from 70% to 100%, xylene, and overnight paraffin incubation. Paraffin-embedded samples (PES) were sectioned using a HM 355S microtome (ThermoScientific). Hematoxylin / eosin (HE) staining was performed as standard, and images of slides were acquired with an automated microscope (Keyence Corporation).

[0233] Immunofluorescence: Cells were grown on cover slips at room temperature or spheroids were spun down on glass and subsequently fixed with 4% paraformaldehyde (PFA, 16005-Sigma Aldrich) in PBS for 10 min, washed (3 times) for 5 min in PBS, permeabilized with 0.5% triton X100 in PBS for 5 min, blocked with 4% BSA (3854.4ROTH) for 15 min, stained with primary and secondary antibodies and 20 μm / ml Hoechst 33258 (16756-50, Cayman) and mounted on glass slides with nail polish and Vectashield (H1000-Linaris). Paraffin-embedded tissues were deparaffinized and citrate antigen retrieval was performed by standard protocols. Permeabilization was performed with Triton 0.25% in PBS and endogenous peroxidase was blocked with 3% H2O2 in water when appropriate. Blocking was usually performed with 5% normal goat serum (NGS). Primary antibodies were anti-GFP (Anti-GFP ab6556, 1:000), anti-MED1 (Abcam ab64965, 1:500), and anti-tubulin (BD T5168, 1:2000). Secondary antibodies were A31573, A11055, and A31571 Alexa Fluor 647, A21206 Alexa Fluor 488, and A31570 Alexa Fluor 555.

[0234] RNA FISH and double FISH-IF: Cells were permeabilized with 70% ethanol (RNA FISH only) or 0.5% triton X-100 (double IF-RNA FISH), fixed with RNase-free PBS (1x, Life Technologies, AM9932), 20% Stellaris RNA FISH Wash Buffer A (Biosearch Technologies, Inc., SMF-WA1-60) and 10% deionized formamide (EMD Millipore, S4117) in RNase-free PBS for 5 min at room temperature. IgK-MGT#1-mVenus and H2B-CFP were probed with SMF-1084-5 CAL Fluor™ Red 635 and SMF-1063-5 Quasar™ 570 custom Stellaris™ FISH Probe (oligo sequences available upon request) in 100 μL of 31.5 μM 10% deionized formamide, 90% Stellaris RNA FISH Hybridization Buffer (Biosearch Technologies, SMF-HB1-10) transferred to coverslips and hybridized at 37° C. in the dark. After overnight incubation, slides were washed (3 times) for 5 min with RNase-free PBS. Primary / secondary staining, if any, was performed as described.

[0235] Imaging: The microscopes used were Zeiss LSM800, Leica SP5-7-8, and Nikon Spinning Disk. The confocal images in Fig. S41(?) were acquired with a Leica SP5. mVenus fluorescence was acquired using Ex=488 nm, Em=535 nm, and the images in Fig. 1d were acquired with a Zeiss LSM800 using Ex=558 nm, Em=575 nm for mVenus-QUASAR570, Ex=653, Em=668 for BRD4-AF647 or MED1-AF647, respectively. For H2B-CFP-QUASAR670, Ex=631, Em=670 were used. Images were processed using ImageJ or Photoshop.

[0236] Phenotypic screening: Tumor cells were grown as above until screening. Then, 15000 cells / 50 μl / well were seeded in 384-well plates (Corning) in Gibco FluoroBrite DMEM medium supplemented with appropriate growth factors. Cells were dispensed into each well as a 50 μl suspension using the SPARK20M Injector system (50 μl injection volume; 100 μl / sec injection speed). For non-adherent cells (e.g. GICs), cells were further centrifuged at 1500 rpm at 37°C for 1 h 30 min. Fluorescent bottom readings were scanned using a SPARM 20M TECAN plate reader at 37°C in 5% CO2-95% air (3% for GICs) in a humidified cassette with the following settings for mVenus: Monochromator, Ex 505 nm ± 20 nm, Em 535 nm ± 7.5 nm, manual gain: 198, flash: 35, integration time: 40 μs. In independent replicates, cell viability was measured using a 0.02% AlamarBlue solution in FluoroBrite medium with the following settings: fluorescence top read, monochromator, Ex 565 nm ± 10 nm, Em 592 nm ± 10 nm, manual gain: 88, flash: 30, integration time: 40 μs.

[0237] DMSO soluble compounds such as GSK126 were robotically dispensed using a D300e and cytokines were robotically dispensed into each well using an Andrew pipetting robot (AndrewAlliance). The following concentrations were used:

[0238] [Table 2]

[0239] Data were imported into PRISM7 (GraphPad). Fluorescence intensity of control dead cells was subtracted from all values ​​as background. Individual values ​​were normalized to the mean of controls and expressed as fold change.

[0240] Drug dose response screening: Transduced hGICs from transwell co-culture experiments were harvested into single cell suspensions and sorted into mVenus high and low populations using a BD FACS Aria III. Cells were counted and 7000 cells / 50 μl / well were seeded in RHB-A complete medium on 384-well black-walled plates using a SPARK20M Injector system (50 μl injection volume; 100 μl / sec injection rate). Drugs were typically dissolved as 10 mM stocks in DMSO and dispensed using a D300e multi-function printer (TECAN) for plate randomization and targeted dose response with DMSO normalization. After 72 hours of incubation, cell viability was measured after 2-6 hours of incubation with 10 μl of Cell-Titer-Blu(Blue) (Promega) assay reagent with the following settings: fluorescence top read, monochromator, Ex 565 nm ± 10 nm, Em 592 nm ± 10 nm, gain settings: optimal scanning, flash: 30, integration time: 40 μs. Data was imported into PRISM7 (GraphPad). Fluorescence intensity of blank wells was subtracted from all values ​​as background. Concentrations were log10 transformed to log[M] scale and individual values ​​were normalized to the mean of untreated positive and SDS-treated negative control conditions. Dose-response curves and IC50 values ​​were derived using a nonlinear regression model (log(inhibitor) vs. normalized response--variable slope).

[0241] [Table 3]

[0242] Irradiation of hGICs: Irradiation was performed using a XenX irradiator platform (XStrahl Life Sciences) equipped with a 225 kV X-ray tube for targeted irradiation. hGICs cultured in either 6-well or 96-well plates were placed in the focal plane of the beamline and exposed to irradiation for a specific time depending on the target dose calculated using built-in calculation software.

[0243] Generation of Matrigel Organoids: To generate organoids by co-culture of C20 human microglia with hGICs, growth factor-reduced, phenol red-free Matrigel (BD; 734-1101) droplets were used as the extracellular matrix support. Target cells were harvested and cultured at 1.5 × 10 in a volume of 500 μl. 5 3.5 x 10 C20 human microglia and 3.5 x 10 5 Single cell suspensions containing 1000 hGICs were prepared. 30 μl of Matrigel, thawed on ice, was added to each well of cold 60-well Minitrays (Thermofisher; 439225) using pre-chilled consumables and pipette tips. 5000 cells per droplet were injected into each organoid using 5 μl of the prepared cell suspension and mixed by pipetting. Droplets were cultured at 37°C in an incubator with 5% CO2, 3% O2 ​​and 95% humidity for up to 14 days, with RHB-A complete medium changed every 2-3 days. Live cell imaging was performed on day 10 using a Leica SP8 confocal microscope.

[0244] RT-qPCR: cDNA was generated using 20 μL of SuperScript™ VILO™ MasterMix RNA (0.5 μg-2.5 μg) incubated at 25° C. for 10 min, 42° C. for 60 min, and 85° C. for 5 min. RT-qPCR was performed with 10 ng cDNA / well using 10 μl / well of 1× PowerUp SYBR Green Master Mix (Applied Biosystems) in a 384-well ViiA™ 7 System. Primers are available upon request.

[0245] Tissue dissection and cell surface staining: Brain tumor dissection has been described in detail previously. 77Briefly, tissues were dissected with a scalpel and digested in Accutase / DNaseI (947 μl Accutase, 50 μl DNase I buffer, 3 μl DNase I) at 37°C until required. They were first filtered through a 120 μm cell strainer and then through a 40 μm cell strainer before RBC lysis (NH4Cl, 155 mM; KHCO3, 10 mM; EDTA, pH 7.4, 0.1 mM). After washing in cold PBS, viability and cell number were automatically assessed by 0.4% trypan blue staining using a TECAN SPARK20M.

[0246] After assessing surface markers, typically 200000 cells / antibody were used in a 15 ml Falcon. Staining volume was 50 μl in RHB-A medium with primary antibody (e.g., CD133-APC; Miltenyi) for 30 min on ice in the dark. Unbound antibody was removed by two PBS washes. Depending on whether cells were analyzed or sorted, data acquisition was performed on a BD LSR Fortessa or cells were sorted using a BD Aria II or Astrios Moflo. Appropriate laser-filter combinations were chosen depending on the fluorophore analyzed. Typically, events were first gated based on shape and granularity (FSC-SSC) to exclude dead cells, and either AnnexinV or the LIVE / DEAD Fixable Aqua Dead Cell Stain Kit was used as viability dye (depending on the fluorophore analyzed). Analysis was performed on a FlowJo_V10.

[0247] FACS analysis: Analysis was performed with FlowJo_V10.

[0248] FACS sorting: Transduced hGICs were harvested into single cell suspensions, resuspended in cold RHB-A complete, and filtered into FACS tubes. Sorting was performed using BD FACS Aria III or Fusion. Appropriate laser-filter combinations were chosen depending on the fluorophore being sorted. Typically, events were first gated based on shape and granularity to exclude dead cells (FSC-A vs. SSC-A) and doublets were excluded (FSC-A vs. FSC-H). A positive gate was established with PGK-induced, constitutively expressed H2B-CFP as the sorting reporter to sort populations with low to moderate intensity sLCR-dependent fluorophore expression.

[0249] Immunoblotting: Cell pellets were lysed in RIPA buffer (20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% NP-40) supplemented with 1x protease inhibitor cocktail (Roche), 10 mM NaPPi, 10 mM NaF and 1 mM sodium orthovanadate. Lysates were sonicated as required and electrophoresed using NuPAGE Bis-Tris precast gels (Life Technologies) in NuPAGE MOPS SDS Running Buffer (50 mM MOPS, 50 mM Tris base, 0.1% SDS, 1 mM EDTA). Proteins were transferred to nitrocellulose membranes in transfer buffer (25 mM Tris-HCl (pH 7.5), 192 mM glycine, 20% methanol) at 120 mA for 1 h. Protein transfer was assessed by staining with Ponceau Red for 5 min followed by two washes in TBS-T. Membranes were blocked with 5% BSA in PBS for 1 h at room temperature. Dilutions of primary antibodies were prepared in PBS+5% BSA and the membranes were incubated overnight at 4°C. After 3 washes with TBS-T for 5 min, dilutions of appropriate HRP-conjugated secondary antibodies were prepared in PBS+5% BSA and the membranes were incubated for 45 min at room temperature. After 3 washes with TBS-T for 5 min, ECL detection reagent (Sigma; RPN2209) was applied and the membranes were exposed to ECL Hyperfilm (Sigma; GE28-9068-37) to detect chemiluminescent signals.

[0250] antibody: [Table 4]

[0251] IncuCyte: IncuCyte automated longitudinal imaging was performed in 96-well black-walled plates (Greiner). 300,000 cells per plate were seeded to reach optimal confluence at the end of the experiment. GSK126 was sorted using a D300e and TGFB1+2 was sorted manually into each well. Both were refreshed every 2 days. The last time point was independently verified using a plate reader (BMC (BMG) Clariostar).

[0252] CRISPRi Screening: For CRISPRi screening, A549-MGT#1±GSK126±Dox cells were sorted with Astrios Moflo. We aimed for 1000x (>6 million cells) library representation in the bottom 10% (dim) and top 10% (bright) cells within each population. Intermediate populations were also sorted and included in the screening analysis as controls. Cells were lysed in AL+ProteinaseK buffer (Quiagen) for 10 min at 56°C, followed by DNA extraction using AMPure beads (Agencourt) and RNase A treatment. PCR amplification and barcode tagging of CRISPRi libraries were performed essentially as described, including the composition of the PCR buffer. 77 For each sample in PCR1, 20 μg of DNA was used split across 10 parallel reactions including from the input control, and 0.1 ng of DNA was required for the plasmid library in PCR1. Parallel PCR1 reactions were mixed and 5 μl was used as template for PCR2. Phusion polymerase (NEB), GC buffer and 3% DMSO were used in both PCR1 and PCR2. Primers are available upon request.

[0253] Library concentrations were measured and barcoded libraries were pooled and sequenced on an Illumina HiSeq2500 sequencer. Reads were mapped to computational libraries using custom scripts (available upon request) to generate read counts that were subsequently used as input for Seqmonk. Custom genomes were used for Seqmonk analysis (available upon request), samples were normalized to RPM, Log transformed to generate MA plots, and DEseq2 with padj<0.001 was performed on raw read counts. Two independent CRISPRi screens in A549 and one additional screen in H1944 were performed.

[0254] CRISPR / Cas9 KO: A549-MGT#1 was knocked out for CNKSR2 and ARID1A using the Cas9RNP Synthego kit according to the manufacturer's instructions. Electroporation was performed on A549 cells in PBS using BioRad XCell with standard pulse. The optimal gRNA from the kit was first evaluated using T7E1 and TIDE calculations (https: / / tide.nki.nl / ). Bulk evaluation of MGT#1 fluorescence was then performed using flow cytometry as well as low confluence plating and manual cloning selection.

[0255] Animal experiments: All mouse studies were performed in accordance with protocols approved by the Animal Care and Use Committee and in accordance with European Union regulations. Orthotopic glioma xenograft studies were performed as previously described with modifications. 76 NOD-SCID-IL2Rg / (NSG) mice were purchased from The Jackson Laboratory and maintained under specific pathogen-free (SPF) conditions. Male and female mice aged 7 to 12 weeks were used.

[0256] Gene knockout: Gene knockout was performed using the Synthego Gene Knockout Kit. sgRNA was dissolved in nuclease-free 1X Te buffer to a stock concentration of 30 μM. RNP complexes were formed by mixing Cas9 nuclease-gRNA at a 6:1 ratio. Each RNP complex was electroporated into 250K A549-MGT1#1 in 1x PBS in a 2 mm cuvette using a Biorad GenePulser xCell (150 volts, 10 ms). After electroporation, cells were cultured in RPMI supplemented with 10% fetal bovine serum and 1% penicillin / streptomycin. Approximately 7 days after electroporation, gDNA was extracted using an Invisorb spin tissue isolation kit (Stratec), eluted in 50 μl elution buffer, and PCR was performed against the target gene of interest using 800 bp–1200 bp products centered around the gRNA target locus (primers available upon request). Knockout efficiency was calculated using TIDE (NKI) and T7EI assays. Individual clones were established or bulk KO cells were directly assayed by FACS using BD LSRFortessa and FlowJo programs.

[0257] Example 1: Design of expression cassettes containing subtype-specific synthetic locus control regions (sLCRs) for glioblastoma multiforme (GBM) tumor cells High degree of cellular and molecular heterogeneity is thought to contribute to resistance to standard therapies in solid tumors and poses an obstacle to the development of targeted approaches. Glioblastoma multiforme (GBM), the most common primary adult brain tumor, is highly heterogeneous and resistant to therapy. 13 GBM is also one of the cancers with the most extensive genomic and epigenomic characterization. 14~16 Based on the transcriptome, GBM tumors have been repeatedly classified into three subtypes, mesenchymal and proneural, with most cross-validation. 52,53,54Several studies have discussed the correlation between subtype-specific gene expression signatures and differential response to therapy and overall patient survival, suggesting that GBM subtype identity and fate alterations may have therapeutic potential. Within GBM tumors, tumor cells with predominant subtypes and distinct subtype identities may coexist. 17,18 Furthermore, tumors may change their dominant expression profile upon relapse. 19,20 .

[0258] Previous lineage tracing has had a profound impact on our understanding of GBM biology in mouse models, particularly the cellular origin of individual subtypes. 5 , and how abnormal homeostatic regulation may affect responses to standard treatments in vivo. 10 gave information regarding.

[0259] This example describes a systems biology approach to genetically label and design synthetic systems to test any cellular state or transition in complex developmental and disease contexts to arrive at the biological principles underlying the molecular subtypes of human GBM.

[0260] We first hypothesized that subtype-specific GBM genes substantially possess the regulatory activities (i.e., cis-regulatory elements) required to specify subtype identity. We further hypothesized that the transcription factor genes (TFs) expressed in each subtype are primarily responsible for establishing and maintaining subtype identity.

[0261] To design gene cassettes that would disrupt minimal signaling and regulatory information, we determined the subtype-specific GBM genes with the highest fold change compared to all other subtypes in the TCGA dataset. 16Calling of MES, CL and PN subtype-specific genes can be achieved using any stringent cutoff (i.e. Log2 FC > 6; Figure 6). Similarly, TFs can be identified using less stringent cutoffs (i.e. Log2 FC > 0) and standard pathway analysis tools (e.g. Ingenuity Pathway Analysis, DAVID, etc.). First, we discarded genes with low expression (e.g. counts per million (CPM) < 4) in GBM stem-like cells (GSCs) from our previous experiments as a measure to focus on cell autonomous regulation (Figure 6). In the current implementation of the method, we use single-cell RNA-seq profiles as glioma-specific signatures, e.g. 14 .

[0262] To identify genomic regions with high intrinsic cis-regulatory potential in differentially regulated genes (DGRs) across subtypes, we calculated all pair frequencies for the best position weight matrices (PWMs) associated with TFs expressed in each subtype (Fig. 1a). Given that cis-regulatory DNA is often a nucleosome-free region (NFR; >147 bp) and contains, on average, approximately 1000 bp, 21 To precisely locate these elements, a sliding window approach of 1 kb with 150 bp steps was set up. The search for cis units potentially regulating DRGs was arbitrarily set at a distance of >10 kb from the gene start / end and separated by two external CTCF binding sites determined by the ENCODE consortium. 22,23 These criteria are believed to contain the majority of contacts within cis-regulatory elements for a given locus and approximate the functional definition of a topological association domain (TAD) using CTCF as the boundary protein. 24 .

[0263] To assemble synthetic cis-regulatory elements that induce subtype-specific expression using the above TFBS analysis, such synthetic locus control regions (sLCRs) should ideally contain a minimal set of cis-units with maximum number (i) and diversity (ii). Ideally, at least one cis-unit that constitutes one sLCR also contains a natural transcription start site (TSS) and is located immediately upstream of the reported element (Fig. 1a). Using these criteria, we generated sLCRs for gene tracking of MES, CL and PN GBMs, hereafter MGT, CLGT and PNGT. An algorithm can be used to minimize decisions and automate sLCR generation (Fig. 7a). Pairwise correlation of TFBS potentially regulating these genes reveals that some TFs cluster away from other TFBS clusters (Fig. 1b). This observation is consistent with experimental observations from ChIP-seq experiments, indicating that our procedure returned results in tune with the principles of functionally and structurally related genome regulation. Furthermore, ENCODE ChIP-seq data in multiple cell lines also support the binding of actual TFs to individual cis units (Figure 9). Importantly, the distinct MGT#1 and MGT#2 sLCRs, only 827 pb and 1015 bp in length, respectively, assembled primarily by independent individual cis units, can account for up to 60% of the global regulatory potential.

[0264] Example 2: Genetic tracking of mesenchymal fate in human glioma-initiating cells using lentiviral vectors containing MGT#1 as the sLCR A typical lentiviral vector carrying a sLCR such as MGT#1 induces expression of a subtype of the fluorescent reporter mVenus or mCherry. To facilitate gene tracking in vivo, mVenus is targeted to the cell membrane (by Igk leader and platelet-derived growth factor receptor (PDGFR) transmembrane sequence tagging; Fig. 1c) and mCherry is translocated to the nucleus by an NLS. To allow fluorescent visualization and sorting of the sLCR independently of reporter expression, we also included a second cassette expressing an H2B-CFP fusion driven by the ubiquitous PGK promoter (Fig. 1c).

[0265] As a prototype test, we produced lentiviral particles in HEK293T cells using MGT#1-mVenus sLCR and used the viral particles to infect human glioma-initiating cells with the MES genotype (MES-hGIC).Membrane mVenus expression was observed in both transiently transfected and frozen sections of stably transduced tumor-like masses (Figure 1d).

[0266] Next, the near-isogenic characterized MES-hGICs and PN-hGICs were transduced with MGT#1 lentiviral particles. PN-hGICs have a combination of IDH1 and TP53 point mutations found only in PN GBMs, while MES-hGICs have a triple knockdown of TP53, PTEN, and NF1 that characterizes the MES GBM background. Interestingly, a minor but measurable increase in basal fluorescence in MES-hGICs was observed, suggesting that MGT#1 reflects higher intrinsic basal signaling in these cells (Figure 1e). TNFα is considered a key MES-GBM signaling pathway, as it can induce PN to MES conversion. 20 , then MES-hGIC-MGT#1 low and PN-hGIC-MGT#1 low We tested whether MGT#1 faithfully recapitulates MES GBM signaling by exposing either MGT#1 or MES-hGIC-MGT#1 to TNFα. In the presence of TNF, it has previously been shown that at least two cis units of the MGT#1 sLCR directly engage NFkBTF induced by TNF. It was reaffirmed that TNFα induced an increase in fluorescence in both cell types compared to the respective parental controls. Interestingly, MES-hGIC-MGT#1 was not associated with a basal level of MGT#1 expression, even though the FACS sorting step confirmed that identical basal levels of MGT#1 expression were present in both cell types. low MES-hGIC-MGT#1 high Instead, PN-hGIC-MGT#1 low PN-hGIC-MGT#1 medlevels (Figures 1e and 1f), demonstrating MES GBM subtype-specific expression of the MGT#1 reporter and leveraging this system to provide evidence that the adaptive response of hGICs is imprinted on their tumor genotype.

[0267] Human GICs and GSCs are consistently grown under "NBE" conditions, which stands for serum-free Neurobasal medium supplemented with basic FGF and EGF 25 Because PDGF-AA is the signaling pathway most frequently amplified in GBM, adding PDGF-AA to GICs may be an effective treatment for GBM. 26 To investigate the basal state of MES-GBM signaling using our genetic strategy, we cultured MES-hGIC-MGT#1 low and PN-hGIC-MGT#1 low We performed a medium-throughput cytokine screen in cells. GICs were grown under standard conditions and replated in a 384-well format. GICs were then stimulated with individual cytokines in biological and technical replicates, followed by continuous fluorescent bottom readings in a given time-course experiment. In a typical experiment, MGT#1 fluorescence emission upon stimulation was acquired longitudinally for up to 48 hours, after which fluorescence was normalized to naive GICs. Consistent with previous reports and the experiments described above, MES-hGIC-MGT#1 low MES-hGIC-MGT#1 in the presence of TNFα signaling high (Fig. 2a, Fig. 8). Thus, MGT#1 provides information on the differential response to external signaling between tumor cells with different genotypes. Furthermore, MGT#1 was found to be able to inhibit the MES-hGIC-MGT#1 low and PN-hGIC-MGT#1 low This is the solid basis for a screening format to identify relevant signaling that supports cell growth and subtype identity.

[0268] Example 3: Use of MGT#1 and MGT#2 sLCR as a readout to investigate intrinsic and adaptive responses in GICs Under the same experimental conditions, a second independent reporter (MGT#2) showed consistent results supporting the ability to generate functional sLCR starting from gene expression profiles (Fig. 2a). Interestingly, both MGT#1 and MGT#2 reporters showed that FBS was able to induce mesenchymal differentiation, which, unlike the case of TNFα, was accompanied by GIC differentiation as judged by visual inspection and flow cytometry (data not shown). This finding can indeed only be partially explained by the presence of TGFB1, a known component of FBS. Indeed, TGFB1, although a mesenchymal inducer, does not strongly induce MGT#1 and does not promote differentiation when used as a purified cytokine in the same time frame (Fig. 2a). Perhaps more interestingly, this observation with FBS is in excellent agreement with the TCGA report that the MES GBM signature was not found in any of the mouse brain cells, but only in FBS-cultured astrocytes. 16 .

[0269] The in vivo source of TNFα in mouse models of glioma appears to be the tumor microenvironment (TME), specifically glioblastoma-associated microglia / monocytes (GAM). 27 TNFα expression has also been observed in hGAM. 28 Interestingly, IDH1 wild-type GBM invasion by GAM has recently been associated with NF1 deficiency and MEG GBM subtype identity. 14 To obtain experimental support for the hypothesis that GAM recruited to GBM induces MES differentiation in NF-deficient GBM cells, we performed in vitro coculture of IDH1 wild-type and NF1-depleted MES-hGIC-MGT#1dim cells with MACS-purified CD11b cells purified from GBM patients. Remarkably, coculture of hGIC-MGT#1dim cells with CD11b+hGAM induced MGT#1 expression in the presence of IL-6 stimulation (Fig. 2b). IL-6 is a potent inhibitor of GAM. 29 It has been previously shown to stimulate GSCs 30 or mesenchymal stem cells derived from the TME 31Notably, hGAM can be produced by either TLR4 or tenascin-C (TNSC), another GSC-derived proinflammatory factor, even in the unstimulated state. 32 ) was insufficient to induce MGT#1 expression in MES-hGICs. 33 Moreover, TNFα induced MGT#1 induction in MES-hGICs regardless of the presence of hGAM (Fig. 2b). Thus, our data reveal a potential cellular crosstalk in the GBM TME that revolves around IL6 signaling and leads to MES GBM specification. These data also highlight the potential of sLCR to mechanistically dissect cell-nonautonomous interactions ex vivo.

[0270] Our data support the sLCR as a valid readout for investigating intrinsic and adaptive responses in GICs, but do not exclude the possibility that this readout is largely limited to reporter sole regulation. To understand whether reporter regulation involves differences in cell identity, we used MES-hGIC-MGT#1 low and PN-hGIC-MGT#1 low Immunoblotting, global gene expression profiling and targeted mRNA validation were performed on the cells. All experimental procedures tested showed that MES-hGIC-MGT#1 cells were significantly different in expression of the IL-16 / ... low and PN-hGIC-MGT#1 lowThe cells consistently showed limited but measurable signaling pathway activation and basal differences in gene expression (Fig. 2c-def). Of note, TNFα stimulation induced phosphorylation of NFkB-p65, STAT3 and p38-MAPK in both cell types, but this resulted in significantly different gene expression outputs (Fig. 2c-def). Thus, MGT#1 is informative about the impact of active signaling (e.g. TNFα) and reflects similar cell fate transitions even when pre-existing context-dependent differences are in place (e.g. mesenchymal signaling amplification or transition). Interestingly, both global and targeted gene expression profiling suggested that TNFα directs PN-hGICs towards a state closer to naive MES-hGICs (Fig. 2c-def).

[0271] Example 4: Use of MGT#1 to functionally test whether external stimuli (e.g., ionizing radiation) can induce mesenchymal transdifferentiation in a GBM cell-autonomous manner Mesenchymal differentiation in GBM was originally described as a key event in recurrence after radiation therapy. 19 , which was subsequently linked to acquired radioresistance via TNF-induced NFKB activation. 20 Correlative evidence repeatedly supports the link between inflammatory signaling, EMT and radiation resistance 34 To functionally test whether irradiation can induce mesenchymal transdifferentiation in a cell-autonomous manner, MES-hGIC-MGT#1 low and PN-hGIC-MGT#1 low Cells were exposed to ionizing radiation (IR) alone or in combination with TNFα. This experiment revolved around delivering a single radiation dose of 10 Gy for two reasons: (i) this was experimentally determined to be sublethal (alone and in combination with other treatments including TNFα or temozolomide; data not shown), and (ii) 10 Gy is close to the dose experimentally demonstrated to elicit a secondary response in multiple human GSCs as a means of enhancing their inherent radioresistance and repair capacity. 34,35Phosphorylation of the residual DNA damage marker H2A 24 hours after irradiation confirmed the occurrence of both double-strand breaks and repair. However, only a small number of GICs from either genetic background were found to be MGT#1. high The state did not change (Figure 2g and Figure 2h). Rather, MES-hGIC-MGT#1 low and PN-hGIC-MGT#1 low Both types of cells showed enhanced mesenchymal differentiation in combination with TNFα, indicating that TNF signaling and IR coordinately induce this cell fate specification. Collectively, these data support the conclusion that sublethal IR cooperates with other mechanisms to induce mesenchymal transition in GBM. The data also support the speculation that NFKB activation is enhanced as a result of non-canonical signaling triggered by genotoxic stress. 36 .

[0272] Example 5: GBM subtyping and reprogramming using sLCR Proneural GBM is a common GBM progenitor subtype and is thought to represent the cell of origin of oligodendrocytes. 26,37 Previous studies have demonstrated that prolonged growth in FBS affects the phenotypic identity of individual cell lines. 25,16 To test whether PN sLCR reflects a proneural state, we decided to induce FBS-induced reprogramming of conventional cell lines into PN-GICs using master TFs responsible for PN identity. 38 For this purpose, we transduced either MGT#1 or PNGT#2 into the T98G cell line (https: / / portals.broadinstitute.org / ccle), which is characterized by a TP53 mutation likely associated with the PN phenotype. 16Consistent with genotypic predictions, T98 cells showed basal expression of PNGT#2 but not MGT#1 when switched from FBS to NBE growth conditions (Fig. 3a and 3b). Importantly, transient overexpression of SALL3, SOX2 and POU3F2 further enhanced PNGT#2 activation but was neutral on MGT#1 expression (Fig. 3b). Of note, these sets of experiments were performed using mCherry fluorescent protein with nuclear localization signaling, ruling out that fluorescent protein intensity (mCherry is brighter than mVenus), localization and stability (mVenus is membrane-spanning and stabilized) play a major role in the observed phenotypic conversion.

[0273] Overall, these experiments demonstrate that multiple endogenous and external triggers known to play important roles in GBM biology can be disrupted by individual sLCRs in GBM cells using the systems and synthetic biology approaches described herein.

[0274] Example 6: Analysis of epithelial-mesenchymal transition in breast and lung cancer cells using MGT#1 Mesenchymal transdifferentiation is a physiological process that is hijacked by multiple tumors of epithelial origin 39 To investigate whether our gene tracking strategy leads to deviations from GBM homeostasis, we next transduce MGT#1 into well-characterized epithelial and mesenchymal breast cancer cells.

[0275] Tumor subtypes are genetically imprinted in breast cancer cells 40After the first lentiviral transduction, epithelial MCF7 cells consistently showed lower MGT#1 expression compared to MDA-231 cells that appeared to have undergone EMT (Fig. 10a and 10b). To confirm that MGT#1 expression reflected its actual breast cancer subtype identity, the top MCF7-MGT#1 expressing cells and the intermediate MDA-231-MGT#1 expressing cells were FACS-sorted and subcloned. Nevertheless, further expansion of the FACS-sorted population reconstituted the homeostatic pre-sort, with MCF7 expressing lower levels of MGT#1 than MDA-231. Such levels appeared to be stable, as short-term treatment with the EMT inducer TGFB2 did not strongly alter basal MGT#1 fluorescence in either MCF7 or MDA-231 (Fig. 4a).

[0276] Ezh2 inhibition can support Kras-induced EMT in some mouse and human lung cancer cells 41 In this context, we tested the use of sLCR to reflect cellular and molecular responses to biological and chemical stimuli. Consistent with previous findings, longitudinal measurements in epithelial A549 cells revealed that high MGT#1 fluorescence was cooperatively induced by the Ezh2 inhibitor GSK126 and TFGB signaling (Figure 4b).

[0277] Epithelial lung cancer cells exposed to TFGB signaling readily changed their morphology and began to express high levels of MGT#1 as judged by flow cytometry (Fig. 11a and 11b). Interestingly, at early time points, flow cytometry revealed that TFGB signaling and Ezh2 inhibition by GSK126 induced molecular transformation to a similar extent, but GSK126 did not induce changes in cell morphology. In a combined situation, TFGB signaling and GSK126 synergistically induced MGT#1 activation, and moderate morphological changes were also observed (Fig. 11a and 11b), raising the intriguing possibility that GSK126 contributes to EMT by additional mechanisms other than as an amplifier over TFGB signaling.

[0278] Example 7: Use of Ezh2 inhibition and MGT#1 to investigate the signaling and genetic basis of epithelial-mesenchymal transition in NSCLC cells To utilize Ezh2 inhibition and MGT#1 as a framework to clarify the signaling basis of EMT in NSCLC cells, we next investigated the effect of Ezh2 inhibition on A549-MGT#1 cells treated with GSK126 and vehicle. low A cytokine screen was performed in cells. Consistent with the above data and our recently published observations (Serresi et al., J. Exp. Med, 2018, doi:10.1084 / jem.20180801), TNFα was also proven to be the major signaling for MGT#1 expression in epithelial lung cancer cells, with a modest additive effect of GSK126 on the high overall fluorescence output measured in a longitudinal medium-throughput microplate reader screen. At the same time, it was confirmed that A549 cells respond differently to TLR stimulation with bacterial LPS in the presence of GSK126, indicating that even under these experimental conditions, TGFB1 induces MGT#1 more substantially in combination with GSK126. A systematic analysis of the screens with several cytokines and their combinations reveals that Ezh2 inhibition enhances the transcriptional response to external signaling to EMT (Figure 12). Taken together, the MGT#1 response indicates that multiple signaling pathways can converge during EMT and suggests that transcriptional inhibition controls cellular metastability.

[0279] We next sought to utilize Ezh2 inhibition and MGT#1 as a framework for a high-throughput screen to clarify the genetic basis of EMT in NSCLC cells. First, A549 and H1944 Kras-induced NSCLC cells were transduced with the MGT#1 reporter. Both cell lines were then transduced with Tet-inducible KRAB-dCas9 and a library of sgRNAs targeting the entire human kinome (543 genes, 5901 gRNAs in total; approximately 5 gRNAs / gene). In addition, we included gRNAs targeting essential and non-essential genes to serve as controls for the screening procedure. This system allows for the systematic knockdown of individual genes in individual cells (Figure 4c). By applying GSK126 treatment as previously described, we FACS-purified NSCLC cells that showed improved or impaired ability to support expression of the fluorescent reporter and exhibited an epithelial or mesenchymal phenotype (Figure 4d and Figure 4e). Gene set enrichment analysis supported the overall quality of the screen as judged by the significant in vitro depletion of essential but not non-essential genes in both cell lines compared to the input population (data not shown). low and H1944-MGT#1 low The MGT#1 high By comparing with their counterparts, we found only a few gRNAs (14 / 5912, 0.24%) that were statistically differently enriched or depleted in either one of the two conditions in both cell lines, indicating that most human kinases are dispensable for GSK126-induced EMT. However, two gRNAs, both with statistically significant, high fold changes and A549-MGT#1 low and H1944-MGT#1 low We demonstrated that Ezh2-dependent NF-kB-induced EMT is associated with NF-kB-dependent NF-kB-dependent EMT in lung cancer cells, and their expression could result in transcriptional repression of kinase-related genes that enable lung cancer cell EMT upon Ezh2 inhibition (Fig. 4e). Interestingly, one gRNA targeted ACVR1 receptor, which has previously been reported to enhance NF-kB-induced EMT. 42In this study, a gRNA targets CNKSR2, a scaffolding protein involved in RAS-dependent signaling that was an unobvious candidate for regulating EMT in lung cancer. We validated the results of the screen using conventional CRISPR / Cas9 technology and found that two independent CNKSR2 KO clones showed enhanced epithelial features compared to parental controls similar to ARID1A KO, which is expected to be required for the Ezh2 loss-of-function phenotype (Figure 4f). RAS-induced EMT has previously been shown to occur through the Hippo pathway. 43 Our data generated using the capabilities of the sLCR reveal additional mechanisms by which RAS / MAPK-dependent signaling may directly contribute to EMT.

[0280] Taken together, the results obtained by epithelial-mesenchymal transition in three different cancer types highlight the tissue-independent ability of our sLCR to unleash such homeostasis in tumors.

[0281] Example 6: MGT#1 as a genetic tracking reporter of tumor homeostasis in vivo Having demonstrated the utility of the sLCR in analyzing cellular and molecular states ex vivo, we next sought to test the role of MGT#1 as a genetic reporter of tumor homeostasis in vivo. dim Cells were implanted intracranially in NSG mice and tumor formation was monitored longitudinally. At the onset of high-grade neurological signs, animals were sacrificed for histochemical and immunohistochemical as well as intrinsic and surface marker analysis. Histologically, all tumors appeared as grade IV GBM, with malignant cells infiltrating most of the mouse brain, showing extensive proliferation and invasion (Figure 5a). For each animal (n=10), image-guided tumor resection was used to generate single-cell preparations while preserving the invaded brain tissue. Immunohistochemical staining revealed that MGT#1-expressing cells were distributed randomly in the tumor mass but were fairly well restricted to the invasive front (Figure 5a and 5b).

[0282] Assuming that responses to the virus, chromatin modifications, and gene silencing could all potentially affect sLCR expression, two approaches were used to confirm that MGT#1 reflects functional intratumoral heterogeneity and to exclude that MGT#1-expressing cells are simply escapers. First, we examined all dense regions where MES GBM signaling is absent for other markers and expression of MGT#1-independent H2B-CFP. Immunostaining with tubulin staining confirmed that the antigen was accessible in the majority of stained tumor tissues, and some MGT#1 "dark" cells, whose active proliferation could be presumed by chromatin condensation, were indeed H2B-CFP positive (Figure 5c and Figure 5d). Second, we performed parallel in vitro / in vitro surface marker and endogenous analysis by flow cytometry. Consistent with immunohistochemical staining, endogenous mVenus fluorescent expression showed a significant level of heterogeneity in vivo. In vitro expanded MES-hGIC-MGT#1 dim Compared with the MGT#1 cells, the xenograft-derived tumor cells showed a small population of bright MES-hGIC-MGT#1 cells, with the majority of tumor cells being MGT#1. low or dark (Figure 5e). The cell surface receptor CD133, which is routinely used to label tumor-propagating cells in patient-derived xenografts, increased overall CD133 in vitro. high The CD133 expressing cells showed a similar switch from the population to a low or negative state. Notably, CD133 expressing cells contained comparable proportions of MGT#1 expressing and non-expressing cells, supporting the ability of MGT#1 to exhibit functional heterogeneity (Figure 5e).

[0283] Overall, our experiments highlight the ability of sLCR to account for intratumor heterogeneity (FIG. 5f).

[0284] Further experiments demonstrating the feasibility and implementation of the present invention: Example 7: Further characterization of the synthetic locus control region (sLCR) sLCRs are designed to mimic endogenous CREs, such as the α-globin LCR, which exhibit position-independent cell-type and developmental stage-specific expression and are involved in transcription factories. These elements are often defined as super-enhancers and condense into coactivator puncta. To test whether sLCRs share characteristics with endogenous LCRs, we measured nascent RNA in MGT#1-transduced cells by RNA-FISH and searched for BRD4 or MED1 condensates using IF. Dual IF and RNA-FISH identified colocalization between BRD4 or MED1 and MGT#1 nascent RNA in fixed MGT#1-expressing tumor cells (Figure 1g). Furthermore, while both inducible MGT#1-induced mVenus and "housekeeping" PGK-induced H2B-CFP mRNA were present in the cytoplasm of tumor cells, only mVenus was detectable in the nucleus (Figure 16), indicating an intensity difference between the two CREs.

[0285] We then transduced spontaneously immortalized human neural progenitor cells with proneural (PNGT#1-2) and mesenchymal (MGT#1-2) sLCR lentiviral particles that had acquired high copy numbers of PDGFRA, c-Myc, and CDK4. To recapitulate the common PN and MES GBM genetic background, PTEN was depleted and IDH1 was upregulated. R132 and TP53 R273H Further modification of hGICs to carry point mutations or further deplete TP53 and NF1 generated PN-hGICs and MES-hGICs, respectively. These cells showed similar DNA methylation profiles to GBM patients and acquired subtype-specific gene expression in vivo, thus representing two distinct GBM subtypes. Under growth factor-defined conditions in vitro, PNGT#1-2 showed strong expression in both cell types, while MGT#1-2 showed low overall expression in both genotypes, highlighting the design specificity for different regulatory networks. Notably, MGT#1 had higher basal expression in MES-hGICs compared to PN-hGICs, indicating a genotype-specific response (Figure 1h).

[0286] We therefore devised a method to systematically generate synthetic LCRs that reflect a given cell identity while retaining key features of the endogenous CRE.

[0287] Example 8: Additional evidence supporting functional reporter activity by sLCR MES-hGIC-MGT#1 low and PN-hGIC-MGT#1 low To investigate the adaptive response of cells to external signaling, we next performed a phenotypic screen. hGICs grown in NBE were stimulated with selected factors (cytokines, growth factors, compounds) and FACS analyzed 48 hours after stimulation (Figure 13b). When normalized to naive hGICs, sLCR was significantly increased in MES-hGIC-MGT#1 cells compared with control cells. low and PN-hGIC-MGT#1 low In the present study, we showed common and distinct responses to human serum or FBS and activin A as MES-GBM regulators, highlighting TNFα signaling. This result was reproducible in two independent MES-GBM sLCRs (MGT#1-2) and follow-up validation. Instead, the PN phenotype appeared to be less responsive to changes induced by external signaling (Fig. 13b and Fig. 13c and Fig. 17). MES GBM specification appeared to be additive to the existing intrinsic phenotype as judged by the surface expression of CD133 and PNGT#2. Indeed, TNFα has been previously reported as an inducer of a key MES-GBM signaling pathway and of PN to MES conversion. Furthermore, NFkB, a known TNF-induced TF, was found to engage at least two of the CREs contained in the MGT#1 sLCR upon TNFα stimulation (Fig. 9b). MES-hGIC-MGT#1 low FACS-sorted PN-hGIC-MGT#1 with comparable levels of MGT#1 expression low Still, MES-hGIC-MGT#1 did not achieve a similar response to TNFα (Fig. 2g, Fig. 8, and Fig. 13a). Consistently, despite being grown under the same signaling conditions, MES-hGIC-MGT#1 low and PN-hGIC-MGT#1 lowThe cells showed differences in endogenous expression and activation of selected signaling pathways (Figure 2). TNFα stimulation induced phosphorylation of NFkB-p65, STAT3 and p38-MAPK in both cell types, but this resulted in significantly different gene expression outputs (Figure 2d). These analyses suggest that TNFα induces the MES GBM signature in MES-hGICs, whereas PN-hGICs develop a state similar to naive MES-hGICs (Figures 2e and 2f). Collectively, our results indicate that sLCR MGT#1-2 reflects the endogenous mesenchymal GBM gene expression program and captures the activation state of signaling pathways (e.g., TNFα) and any pre-existing context-dependent differences (e.g., MES vs. PN background).

[0288] The observation that differentiation-promoting signaling (i.e., human serum or FBS) induces reporter activation is consistent with previous findings showing that the MES-GBM signature can be generated by astrocytes cultured with FBS but not by any of the mouse brain cells. Notably, washout experiments suggest that the MES-GBM state is reversible over a time frame of several days (Figure 18), indicating that the MES GBM state can be achieved and reversed.

[0289] Mesenchymal transdifferentiation in GBM has been found to be a key event during relapse after standard treatment and has been associated with acquired radioresistance through TNF-induced NFkB activation. Substantial correlative evidence supports the link between inflammatory signaling, EMT, innate immune cell infiltration, and radioresistance. To experimentally test whether irradiation can induce mesenchymal transdifferentiation in a cell-autonomous manner, we used MES-hGIC-MGT#1 low and PN-hGIC-MGT#1 low Cells were exposed to ionizing radiation (IR) alone or in combination with TNFα. MGT#1 activation showed a dose response to increasing IR, whether single or split doses (Figure 2g and Figure 19). MES-hGIC-MGT#1 low and PN-hGIC-MGT#1 lowBoth cells showed enhanced mesenchymal transdifferentiation in combination with TNFα. A single radiation dose of 10 Gy is sublethal in multiple human GSCs. Similarly, our GSCs, whether alone or in combination with other treatments (e.g., TNFα or temozolomide), remained compatible 24 hours after irradiation and showed phosphorylation of the residual DNA damage marker γH2AX, confirming that double-strand breaks had occurred and were under repair (Figure 2h).

[0290] Canonical NFkB activation can result in downstream TNFα signaling and by non-canonical genotoxic stress. To provide experimental confirmation for the importance of NFkB in intrinsic and acquired MES-GBM states, we deleted p65 / RELA using CRISPR / Cas9 in MES-hGICs, resulting in a significant downregulation of intrinsic MGT#1 expression (Fig. 13c). Notably, the ability of TNFα to induce MES-GBM signaling was significantly impaired in polyclonal and monoclonal RELA KO cells, while the IkB kinase (IKK) inhibitor-16 further restricted the adaptive response to TNFα. In monoclonal RELA KO GICs, compensation was excluded as a result of the RELA KO escaper, suggesting that other NFkB transcription factors in RELA KO cells may transduce TNF signaling (Fig. 19b).

[0291] In patients, the GBM stem cell state dominates the gene repertoire in maintaining tumor homeostasis. We next sought to test whether sLCRs could be used to discover genes that regulate the MES GBM state by performing a genome-wide pooled CRISPR / Cas9 screen. MES-hGIC-MGT#1 lowGenetic screens in were performed in their naive state or when MES-GBM conditions were induced by external signaling or genotoxic stress (i.e., FBS+TNFα or TNZ+IR, respectively; Fig. 13d). Of the 73179 gRNAs, the phenotypic screen returned 333 and 1164 gRNAs associated with MGT#1 high and low factions, respectively (Fig. 13e). The effect of libraries and treatments on MGT#1 expression, the average statistical depletion of genes associated with fitness but not those of the controls, as well as the depletion of two sgRNAs targeting RELA in the naive state (Fig. 20a-d) all suggested that functional genes could be uncovered by this screen. Interestingly, several clinically relevant drug targets, such as PARP1 and EED, were key regulators of MGT#1 activation in all conditions but did not appear to be important for proliferation. PARP1 activity has been reported to be required for IR-induced NF-kB activation, and polycomb repressive complex 2 scaffold EED inhibition promotes EMT in other contexts. To test whether this approach could be used to prioritize pharmacological treatments that result in cell fate changes, we searched for regulators upstream of the hits. Notably, several gRNAs have been previously associated with downstream RAR / RXR agonist and MEK1 inhibitor targets with statistical trends of enrichment in MGT#1 low and high fractions, respectively (Figure 13e and Figure 20). To confirm the prediction that both drugs may have effects on cell fate decisions, MES-hGIC-MGT#1 were exposed to MEK1 selective inhibitors TAK-733 or All-trans-retinoic acid (ATRA). In both cases, MES-hGIC-MGT#1 responded to short-term TNFα stimulation (4 hours) with higher upregulation of both MGT#1 and MES-GBM endogenous markers compared to TNFα alone (Figure 13f), indicating that pretreatment sensitized these cells to MES GBM program activation. ATRA and TAK-733 sensitized MGT#1 more than the EED / EZH2 inhibitor GSK126, supporting the specificity of the treatment.Thus, the sLCR provides a phenotypic layer of pharmacogenomic information that is superior to previous large-scale studies based on compatibility alone.

[0292] Overall, these results provide experimental evidence of mesenchymal GBM as a transient and reversible cellular state, supporting the robustness and efficacy of engineered sLCRs in phenotypic screening applications.

[0293] Example 9: sLCRs allow discrimination of molecularly diverse entities Primary cancer types can be grouped based on their molecular profiles. Chromatin accessibility is the strongest predictor of cancer type similarity and can be used to identify subtype identity in the common dimensional space of individual cancer types. To investigate whether the acquired heterogeneity exhibited by sLCR is accompanied by changes in genome-wide chromatin accessibility, we performed in vitro and in vivo characterization of MES-hGIC-MGT#1 high We performed ATAC-seq on MES-hGIC-MGT#1 cells. Differential analysis of chromatin accessibility revealed many genes undergoing remodeling, especially at the PN-to-MES conversion driver WWTR1 (TAZ) and several TNF receptor gene loci, providing a genetic trace of remodeling events that occur only in a physiologically relevant tumor microenvironment (Figures 14a and 14b). Integration of ATAC-seq data from TCGA and glioma stem cells revealed that MES-hGIC-MGT#1 cells were remodeled using ATAC-seq. high It further became clear that the cells represent specific entities within a common glioma space (Fig. 14c). Importantly, unsupervised chromatin profiling of GICs divided by MGT#1 high and low expression shows that samples are grouped into defined clusters (Fig. 14d), highlighting the acquisition of unique patterns in chromatin accessibility with MGT#1 expression. These results highlight the effectiveness of sLCR to reveal intratumoral heterogeneity and enable thorough cellular and molecular characterization of tumor models together with primary cancer data.

[0294] Example 10: sLCR facilitates discovery of therapeutic relevance of cell-non-autonomous crosstalk between tumor cells and immune cells Although IDH1 wild-type GBM infiltration by glioblastoma-associated microglia / monocytes (GAMs) has recently been associated with NF1 deficiency and MES-GBM subtype identity, whether there is a causal relationship between GAMs and MES-GBMs remains unresolved. To experimentally test the hypothesis that innate immune cells are responsible for, rather than recruited by, MES transdifferentiation in NF1-deficient GBM cells, we investigated IDH1 wild-type and NF1-depleted MES-hGIC-MGT#1 cells. low The cells were co-cultured in vitro with an immortalized human microglial cell line (hMG; cl.C20).

[0295] First, we compared both PN-sLCR expression by single cells in GBM tumor masses and multicellular organoid culture conditions, and found that spheroid cultures support the proliferation of stem and progenitor cells with limited spontaneous differentiation and cell death, whereas MES-sLCR expression by single cells in GBM tumor masses and multicellular organoid culture conditions supports .... 50,51 Thus, glioma organoids give rise to phenotypically diverse cell populations. Similar to the in vivo expression patterns (Fig. 14a), we found that MES-hGICs exhibited heterogeneous PN-sLCR and MES-sLCR expression patterns under organoid conditions and in the presence of human microglial cells, in contrast to their homogenous expression in pure spheroid cultures (Fig. 15a).

[0296] Next, we set up a co-culture of homogeneous GBM tumor-like masses with hMG cells using trans-well inserts. Remarkably, hMG cells induced MGT#1 induction in MES-hGIC to the same extent as TNFα (Fig. 15b and Fig. 15c and Fig. 21). Consistent with previous experiments, hMG also activated MGT#1 to a lesser extent in PN-hGIC. In contrast, myeloid-derived suppressor cells (MDSCs) obtained by human CD34+ in vitro only lightly stimulated MGT#1 expression in both lines (Fig. 21). MES-hGIC-MGT#1 by both conditions highGlobal transcriptome analysis of the cells revealed common and distinct NFkB-related gene activation, providing evidence that adaptive immune cells induce a specific MES-GBM state that largely shares targets with the patient signature (Fig. 15d). Interestingly, no evidence of TNFα expression by either cell type was found. Rather, metabolic transcriptome remodeling characterizing genes in the cholesterol biosynthetic pathway appeared to constitute a MES-hGIC signature specific to coculture with hMG cells (Fig. 15e-g). These data indicate that activation of NFkB in tumor cells is primarily attributable to innate immune cells. Indeed, inflammatory mediators IFNγ and IL-2 derived from the adaptive immune system, as well as stromal-derived IL-6, did not induce direct MGT#1 activation to the same extent (Fig. 17). Taken together, we provide experimental insight into the cascade of events that lead to the MES-GBM state in vivo.

[0297] EMT has been associated with resistance to chemotherapy but also offers therapeutic opportunities. DNA damage stress is a major therapeutic component of the standard treatment in GBM, also called the Stupp protocol. The TNF-NFkB signature in GBM has previously been associated with a mesenchymal state and radioresistance in large patient cohorts and PDX models. Therefore, we next exploited the ability of sLCR to identify MES homeostasis to validate the therapeutic relevance of microglia-induced GBM states.

[0298] For this purpose, MGT#1-2 was used after hMG-induced transformation. high and MGT#1-2 low We FACS-sorted MES-hGIC and PN-hGIC cells and exposed these cells to a range of selected standard and targeted chemotherapeutic agents. Remarkably, in contrast to their sLCR low counterparts, MES-hGIC-MGT#1 high or MES-hGIC-MGT#2 highBoth of these cells proved to be more resistant to DNA damage-based therapeutic agents (olaparib, ATR inhibitor VE-821, topotecan, mitomycin C) and LXR623, an LXR agonist that regulates cholesterol efflux (Figures 15h and 21). Importantly, MES-hGIC-MGT#1 high The cells retained a similar sensitivity profile to targeting agents such as BAY11-7085 (IκB) and WP1066 (STAT3; Fig. 15h and Fig. 21). MES-hGIC-MGT#1 high The change in the chemosensitivity profile of MES-hGIC-MGT#1 high Consistent with the gene expression changes induced by hMG cells, including a decrease in DNA damage gene signature expression in cells, the cell cycle profile shifts with the overexpression and cholesterol biosynthesis signature of patient-derived MES-GBM (Figure 21). Similar results were obtained with proneural genotypes, demonstrating that hMG cells can separate hGICs into two functionally and therapeutically distinct states, supporting the use of sLCR in target discovery platforms that orchestrate complex responses associated with tumor heterogeneity.

[0299] Taken together, our results provide a serendipitous link between innate immune cells and the MES-GBM state and highlight the potential of the sLCR to mechanistically dissect relevant cell-nonautonomous interactions in vivo and ex vivo.

[0300] Further advantages and implementations of the present invention: Our understanding of complex cellular and molecular mechanisms at the organismal level is currently highly dependent on in vivo experiments and limited by the technologies available for gene tracing. We established a systems biology framework that allows the generation of synthetic reporters that can disrupt cell-intrinsic and cell-nonautonomous signaling. These sLCRs can be used to explain genotype-to-molecular and cellular phenotype transitions in vitro and in vivo. Experimentally, sLCRs can be used to characterize the molecular mechanisms linking biological, chemical and environmental stimuli to cell fate transitions, including by chemical and forward genetic screens.

[0301] We applied this approach to investigate the cellular and molecular features of GBM subtype expression profiles. Identification of proneural and mesenchymal GBM subtypes was consistent across expression platforms (microarrays, RNA-seq), readouts (gene expression, DNA methylation), and patient populations (Western and Chinese). Despite these significant efforts, the significance of GBM subtypes remains elusive in terms of their origin, location, or spatiotemporal evolution.

[0302] Combining the near-isogenic model with the MES sLCR indicates that the most prominent components for MES-GBM specification are indeed applicable. Although intrinsic MES signaling dictated by genotype exemplified by MES-hGICs is measurable when compared to PN-hGICs, despite showing moderate MES sLCR expression differences, TNF signaling and differentiation-promoting stimuli (e.g., FBS) are major contributors to MES signaling. Interestingly, TNFα and FBS both induce MES transdifferentiation by differentially affecting cell morphology. Both types of responses appear to be imprinted in vivo as inferred by the degree of heterogeneity in MGT#1 expression and markers of undifferentiated self-renewing tumor cells. Our experiments correlate MGT#1 readout in GBM cells with expression of migration-related markers such as CD44, response to proinflammatory microenvironments and resistance to sublethal genotoxic stress, all of which represent hallmarks of tumor progression, including in GBMs, at the single-cell level. 18 These findings illustrate the ability of MGT#1 to elucidate cellular and molecular mechanisms in GBM.

[0303] This technology allows cellular and molecular profiling to be transformed into phenotypic maps, and can meet the experimental needs associated with the continuous mapping of cellular and molecular features in health and disease, including at the single cell level.Indeed, sLCR improves the in vivo phenotypic assays that still represent an essential step for the full understanding of complex cellular and molecular mechanisms at the organism level.As a result, it offers great ex vivo opportunities.

[0304] We show that sLCR, reflecting in vivo regulatory networks, precisely disrupts cell-intrinsic and cell-nonautonomous signaling and has been successfully applied to analyze genotype-to-molecular and cellular phenotype transitions in vitro and in vivo. We demonstrate the utility of this system by investigating the cellular and molecular basis of GBM subtype expression profiles. Identification of proneural and mesenchymal GBM subtypes was consistent across expression platforms (microarrays, RNA-seq and single-cell RNA-seq), readouts (gene expression, DNA methylation) and patient ethnicity (Western and Chinese). Despite these significant efforts, the significance of GBM subtypes remains elusive in terms of their origin, location or spatiotemporal evolution and, more importantly, their therapeutic implications.

[0305] Proneural and mesenchymal GBM programs depend on the activity of specific transcription factors. Here, we have integrated the sLCR with quasi-isogenic models and cell lines, and the results are consistent with PN-GBM, a defined GBM entity that is strongly dependent on RTK signaling and thus promoted by neural stem cell culture conditions. Instead, we show that the most prominent components for MES-GBM specification are indeed adaptable. In the absence of tumor microenvironment, the PN state appears to be inherent even in cells with MEG-GBM genotype (e.g., NF1 depletion), whereas MES identity is rapidly amplified by acute inflammatory and differentiation-promoting stimuli (e.g., TNF signaling and bovine or human serum). Interestingly, in different cell types, MES transdifferentiation, as measured by sLCR, can occur with differentially affected cell morphology. Our experiments correlate MES-sLCR readout in GBM cells with a feed-forward response to a proinflammatory microenvironment, resistance to sublethal genotoxic stress, and expression of migration-related markers such as CD44, all of which represent hallmarks of progression in human cancers, including in GBM, at the single-cell level. These hallmarks appear to be imprinted on tissue homeostasis, as inferred by clustered cell expression patterns ("homeostasis") and heterogeneity in in vivo and ex vivo tumor models.

[0306] Genetic tracing of key components of MES-GBM in three different cancer types highlights the tissue-independent ability of our sLCR to reveal tumor homeostasis and provides further evidence that EMT represents a hijacking of developmental cellular processes. These findings illustrate the versatility of sLCR to elucidate cellular and molecular mechanisms in multifactorial diseases. Furthermore, the use of sLCR in pharmacogenomics may significantly accelerate translational medicine by revealing phenotype-specific dependencies and resistances.

[0307] Finally, sLCR allows for mechanistic analysis of pathophysiologically relevant cell-non-autonomous interactions between innate immune cells and tumor cells. GAMs are thought to constitute a source of TNFα in both glioma mouse models and human tumors. Our results provide experimental validation for the clinical relevance of MES-GBM subtypes to specific immune contexts and reveal a TNFα-independent pathway to MESGBM. Importantly, the identified GAM-induced MES-GBM states show a degree of overlap with patient signatures that are comparable to individual patient signatures themselves.

[0308] In summary, sLCRs have been shown to be useful for characterizing molecular mechanisms by linking biological, chemical and environmental cues, including those by chemical and genetic screens, to cell fate transitions. Previous attempts to generate synthetic reporters using massively parallel sequencing or mixture models have revealed limitations associated with the potential applications and design control of this approach. Our method substantially addresses this issue and lays the foundation for future developments ranging from linear improvement of basic design components (e.g., using curated TFBS and cis-element resources) to systematic generation and validation of large numbers of sLCRs followed by machine learning of successful features. At the same time, robust cell type or state specificity and granularity can be extended by combining sLCRs with DNA barcoding. Tunable manipulation can be achieved by combining sLCR transcriptional inputs with synthetic effector proteins that enable Boolean logic output. This makes gene tracking with sLCRs scalable and extendable to virtually any given system to dissect cell-intrinsic and cell-nonautonomous mechanisms controlling normal and abnormal homeostasis, whether ex vivo or in vivo. References 1. Kretzschmar, K. & Watt, FM Lineage tracing. Cell 148, 33-45 (2012). 2. Barker, N. etal. Identification of stem cells in small intestine and colon by markergene Lgr5. Nature 449, 1003-1007 (2007). 3. Barker, N., Tan, S. & Clevers, H. Lgr proteins in epithelial stem cell biology. Development140, 2484-2494 (2013). 4. Livet, J. et al.Transgenic strategies for combinatorial expression of fluorescent proteins inthe nervous system. Nature 450, 56-62 (2007). 5. Liu, C. et al.Mosaic analysis with double markers reveals tumor cell of origin in glioma. Cell146, 209-221 (2011). 6. Schwitalla, S. etal. Intestinal Tumorigenesis Initiated by Dedifferentiation and Acquisitionof Stem-Cell-like Properties. Cell (2012).doi:10.1016 / j.cell.2012.12.012 7. Schepers, A. G. etal. Lineage tracing reveals Lgr5+ stem cell activity in mouse intestinaladenomas. 337, 730-735 (2012). 8. Driessens, G.,Beck, B., Caauwe, A., Simons, B. D. & Blanpain, C. Defining the mode oftumour growth by clonal analysis. Nature (2012). doi:10.1038 / nature11344 9. Oshimori, N. &Fuchs, E. Paracrine TGF-β Signaling Counterbalances BMP-Mediated Repression inHair Follicle Stem Cell Activation. Cell Stem Cell 10, 63-75(2012). 10. Chen, J. et al.A restricted cell population propagates glioblastoma growth after chemotherapy.Nature (2012). doi:10.1038 / nature11287 11. Zhu, L. et al.Multi-organ Mapping of Cancer Risk. Cell 166, 1132-1146.e7(2016). 12. Church, G. M.,Elowitz, M. B., Smolke, C. D., Voigt, C. A. & Weiss, R. Realizing thepotential of synthetic biology. Nat Rev Mol Cell Biol 15, 289-294(2014). 13. Stupp, R. etal. Effects of radiotherapy with concomitant and adjuvant temozolomideversus radiotherapy alone on survival in glioblastoma in a randomised phase IIIstudy: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 10,459-466 (2009). 14. Wang, Q. et al.Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates withImmunological Changes in the Microenvironment. Cancer Cell 32,42-56.e6 (2017). 15. Noushmehr, H. etal. Identification of a CpG island methylator phenotype that defines adistinct subgroup of glioma. Cancer Cell 17, 510-522 (2010). 16. Verhaak, R. G. W. etal. Integrated genomic analysis identifies clinically relevant subtypes ofglioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. CancerCell 17, 98-110 (2010). 17. Sottoriva, A. etal. Intratumor heterogeneity in human glioblastoma reflects cancerevolutionary dynamics. Proc Natl Acad Sci USA 110, 4009-4014(2013). 18. Lee, J.-K. etal. Spatiotemporal genomic architecture informs precision oncology inglioblastoma. Nature Genetics 49, 594-599 (2017). 19. Phillips, H. S. etal. Molecular subclasses of high-grade glioma predict prognosis, delineatea pattern of disease progression, and resemble stages in neurogenesis. CancerCell 9, 157-173 (2006). 20. Bhat, K. P. etal. Mesenchymal Differentiation Mediated by NF-κB Promotes RadiationResistance in Glioblastoma. Cancer Cell 24, 331-346 (2013). 21. ENCODE ProjectConsortium et al. Identification and analysis of functional elements in1% of the human genome by the ENCODE pilot project. Nature 447,799-816 (2007). 22. Thurman, R. E.,Day, N., Noble, W. S. & Stamatoyannopoulos, J. A. Identification ofhigher-order functional domains in the human ENCODE regions. Genome Res 17,917-927 (2007). 23. Kim, T. H. etal. Analysis of the vertebrate insulator protein CTCF-binding sites in thehuman genome. Cell 128, 1231-1245 (2007). 24. Ong, C.-T. &Corces, V. G. CTCF: an architectural protein bridging genome topology andfunction. Nat Rev Genet 15, 234-246 (2014). 25. Lee, J. et al.Tumor stem cells derived from glioblastomas cultured in bFGF and EGF moreclosely mirror the phenotype and genotype of primary tumors than doserum-cultured cell lines. Cancer Cell 9, 391-403 (2006). 26. Ozawa, T. etal. Most Human Non-GCIMP Glioblastoma Subtypes Evolve from a CommonProneural-like Precursor Glioma. Cancer Cell 26, 288-300 (2014). 27. Quail, D. F. etal. The tumor microenvironment underlies acquired resistance to CSF-1Rinhibition in gliomas. Science 352, aad3018 (2016). 28. Szulzewsky, F. etal. Human glioblastoma-associated microglia / monocytes express a distinctRNA profile compared to human control and murine samples. Glia 64,1416-1436 (2016). 29. a Dzaye, O. D. etal. Glioma Stem Cells but Not Bulk Glioma Cells Upregulate IL-6 Secretionin Microglia / Brain Macrophages via Toll-like Receptor 4 Signaling. J.Neuropathol. Exp. Neurol. 75, 429-440 (2016). 30. Inda, M.-D.-M. etal. Tumor heterogeneity is an active process maintained by a mutant EGFR-inducedcytokine circuit in glioblastoma. Genes Dev 24, 1731-1745 (2010). 31. Hossain, A. etal. Mesenchymal Stem Cells Isolated From Human Gliomas IncreaseProliferation and Maintain Stemness of Glioma Stem Cells Through theIL-6 / gp130 / STAT3 Pathway. Stem Cells 33, 2400-2415 (2015). 32. Midwood, K. etal. Tenascin-C is an endogenous activator of Toll-like receptor 4 that isessential for maintaining inflammation in arthritic joint disease. Nat Med15, 774-780 (2009). 33. Jachetti, E. etal. Tenascin-C Protects Cancer Stem-like Cells from Immune Surveillance byArresting T-cell Activation. Cancer Res 75, 2095-2108 (2015). 34. Stanzani, E. etal. Radioresistance of mesenchymal glioblastoma initiating cells correlateswith patient outcome and is associated with activation of inflammatory program.Oncotarget 8, 73640-73653 (2017). 35. Bao, S. et al.Glioma stem cells promote radioresistance by preferential activation of the DNAdamage response. Nature 444, 756-760 (2006). 36. Hinz, M. et al.A cytoplasmic ATM-TRAF6-cIAP1 module links nuclear DNA damage signaling toubiquitin-mediated NF-κB activation. Mol Cell 40, 63-74 (2010). 37. Lei, L. et al.Glioblastoma models reveal the connection between adult glial progenitors andthe proneural phenotype. PLoS ONE 6, e20041 (2011). 38. Rheinbay, E. etal. An Aberrant Transcription Factor Network Essential for Wnt Signalingand Stem Cell Maintenance in Glioblastoma. Cell Rep (2013).doi:10.1016 / j.celrep.2013.04.021 39. Kalluri, R. &Weinberg, R. A. The basics of epithelial-mesenchymal transition. Journal ofClinical Investigation 119, 1420-1428 (2009). 40. Baird, R. D. &Caldas, C. Genetic heterogeneity in breast cancer: the road to personalizedmedicine? BMC Med 11, 151 (2013). 41. Serresi, M. etal. Polycomb Repressive Complex 2 Is a Barrier to KRAS-Driven Inflammationand Epithelial-Mesenchymal Transition in Non-Small-Cell Lung Cancer. CancerCell 29, 17-31 (2016). 42. Wamsley, J. J. etal. Activin upregulation by NF-κB is required to maintain mesenchymal featuresof cancer stem-like cells in non-small cell lung cancer. Cancer Res 75,426-435 (2015). 43. Shao, D. D. etal. KRAS and YAP1 converge to regulate EMT and tumor survival. Cell 158,171-184 (2014). 44. Ohinata, Y., Sano,M., Shigeta, M., Yamanaka, K. & Saitou, M. A comprehensive, non-invasivevisualization of primordial germ cell development in mice by the Prdm1-mVenusand Dppa3-ECFP double transgenic reporter. Reproduction 136,503-514 (2008). 45. Gargiulo, G. etal. In vivo RNAi screen for BMI1 targets identifies TGF-β / BMP-ER stresspathways as key regulators of neural- and malignant glioma-stem cellhomeostasis. Cancer Cell 23, 660-676 (2013). 46. Gargiulo, G.,Serresi, M., Cesaroni, M., Hulsman, D. & Van Lohuizen, M. In vivo shRNAscreens in solid tumors. Nat Protoc 9, 2880-2902 (2014). 47. Li, P., Markson,J.S., Wang, S., Chen, S., Vachharajani, V., and Elowitz, M.B. (2018). Morphogengradient reconstitution reveals Hedgehog pathway design principles. Science 360,543-548. 48. Blankvoort, S., Witter, M.P.,Noonan, J., Cotney, J., and Kentros, C. (2018). Marked Diversity of UniqueCortical Enhancers Enables Neuron-Specific Tools by Enhancer-Driven GeneExpression. Curr Biol 28, 2103-2114.e2105. 49. Takahashi, K., and Yamanaka,S. (2006). Induction of pluripotent stem cells from mouse embryonic and adultfibroblast cultures by defined factors. Cell 126, 663-676. 50. Suva, M.-L., Rheinbay, E.,Gillespie, S.M., Patel, A.P., Wakimoto, H., Rabkin, S.D., Riggi, N., Chi, A.S.,Cahill, D.P., Nahed, B.V., et al. (2014). Reconstructing and Reprogramming theTumor-Propagating Potential of Glioblastoma Stem-like Cells. Cell 51. Frith, M.C., Fu, Y., Yu,L., Chen, J.-F., Hansen, U., and Weng, Z. (2004). Detection of functional DNA motifsvia statistical over-representation. Nucleic Acids Res 32, 1372-1381. 52. Phillips, H.S., Kharbanda,S., Chen, R., Forrest, W.F., Soriano, R.H., Wu, T.D., Misra, A., Nigro, J.M.,Colman, H., Soroceanu, L., et al. (2006). Molecular subclasses of high-gradeglioma predict prognosis, delineate a pattern of disease progression, andresemble stages in neurogenesis. Cancer Cell 9, 157-173. 53. Verhaak, RGW, Hoadley,KA, Purdom, E., Wang, V., Qi, Y., Wilkerson, MD, Miller, CR, Ding, L.,Golub, TR, Mesirov, JP, et al. (2010). Integrated genomic analysisidentifies clinically relevant subtypes of glioblastoma characterized byabnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17, 98-110. 54. Sturm, D., Witt, H., Hovestadt, V., Khuong-Quang, D.-A., Jones, DTW, Konermann, C., Pfaff, E., Tonjes, M., Sill, M., Bender, S., et al. (2012). Hotspot Mutations in H3F3A andIDH1 Define Distinct Epigenetic and Biological Subgroups of Glioblastoma. Cancer Cell 22, 425-437. [Explanation of symbols]

[0309] Drawing translation Figure 1 target phenotype target phenotype Gene expression signature of intrinsic / adaptive state Transcription factor genes signature genes Transcription factor binding sites (TFBS) enrichment genes Correlate positional information with TFBS enrichments genomic position TFBS motif TFBS motif TFBS motif match TFBS motif match Regulatory potential inference Supervised assembly individual cis-elements TFBS (diversity) TFBS (number) TFBS(number) % of TFBS % of TFBS Sum of all cis-elements cis-elements (number) combination of both parameters ranking natural TSS Synthetic Locus Control Region target gene fluorescent reporter, endonuclease, suicide gene, etc. Correlation MGT#1 or MGT#2 MGT#1 or MGT#2 MES-hGICs or PN-hCICs MES-hGICs or PN-hCICs FACS sorting FACS analysis (MGT#1 or #2) Normalized To Mode Normalization to mode Control Ctrl unstim non-stimulation Count Figure 2 Control 96h 96 hours Activin A human Microglia Vinculin Nestin genes fluorescence Fold change Relative mRNA levels Relative normalized expression Figure 3 Unknown GBM phenotype Proneural sLCR Mesenchymal sLCR external signaling Brightfield Fluorescence Empty % of total Figure 4 Brightfield Fluorescence % of total Longitudinal MGT#1 expression Time (hours) lung cancer cells lung cancer cells Epithelial fate Mesenchymal fate dox-inducible KRAB-dCas9 dox-inducible KRAB-dCas9 Kinome sgRNAs library vehicle cell number cell number Fluorescence intensity Cells with low signal Cells with high signal Sequence sgRNAs EMT-required Kinases EMT-barrier Kinases Fluorescent reporter Vinculin Total H3 Total H3 % of total Kinome Screening gRNAs fold-change gRNA relative abundance gRNA relative abundance Required for GSK126-driven EMT E-cadherin Claudin Vimentin Figure 5 Unstained controls % of tot % of total Figure 6 Color Key Row Z-Score Z-score column Figure 7 Generate CRE pool from signature genes Signature genes TF genes genes Generate positional information CRE pool CRE pool Correlate positional information with TFBS enrichments CRExTFBS Matrix CRE×TFBS matrix sLCR selection algorithm Score and Rank CRE CRE scoring and ranking Select best CRE Remove best CRE+TFBS Remove best CRE+TFBS No Yes sLCR selection: CRE natural TSS+CREn sLCR selection:CRE 天然のTSS+CREn Score Diversity Pairwise Corrlation TFBS motif Pairwise correlation of TFBS motif (positive:Correlation) Figure 8 Control 48h 48 hours 24h 24 hours Figure 9 IgK leader Figure 10 Epithelial MCF7 Epithelial MCF7 Mesenchymal MDA-231 FACS sorting FACS analysis (eg Fig. 4a) OR Figure 11 % of total Figure 12 Experiment Vehicle Figure 13 Human Serum Activin A Apelin F-13A Tenascin C Control polyclonal Vinculin Genome-wide CRISPR / Cas9 Genome-wide CRISPR / Cas9 Naive All conditions All conditions Not significant Tretinoin targets Relative mRNA levels (to 18s&CTRL) compound compound 16h 16 hours 4 / 8h 4 / 8h vehicle Figure 14 Scale DNase Clusters Glioma dimension tSNE Dimension this study Figure 15 Brightfield Proneural sLCRs Mesenchymal sLCR merged channels Spheroids culture Organoid culture Transwell insert Microporous membrane Immortalized human Microglia Control MG co-culture MG co-culture Count NFkB-associated MGT#1 high NFkB-related MGT#1 high Private to TNFα Private to TNFα Shared MG / TNFα Shared with MG / TNFα Private to MG this study MG-driven MES-GMB MES-GMB induced by MG Differentially-regulated genes Z-scores SREBF1 / 2 target genes MES or PN-hGICs-MGT#1 MES-hGIC-MGT#1 or PN-hGIC-MGT#1 Olaparib Topotecan Mitomycin C Figure 17 Human Serum Activin A Figure 18 48h 48 hours Fold mVenus FI / untreated mVenus FI multiple / untreated Activin A human serum Apelin F-13A Control washout Fluorescence intensity Days Figure 19 Radiation dose Control Polyclonal Figure 20 Control Naive Unsorted Brunello Input Essential gRNAs Non Essential gRNAs Non targeting gRNAs count Essential nonEssential non-essential others others pre CRISPRcleanR Before CRISPRcleanR density density post CRISPRcleanR After CRISPRcleanR Top IPA Toxicity Ratio Pro-Apoptosis Activation Oxidative Stress Long-term Renal Injury Pro-oxidative Response Panel (Rat) Glutathione Depletion - Phase II Reactions Renal Necrosis / Cell Death Mitochondrial Dysfunction Increases Heart Failure Cardiac Hypertrophy Renal Proximal Tubule Toxicity Biomarker Panel (Rat) Glutathione Depletion - CYP Induction and Reactive Metabolites Genes associated with chronic allograft nephropathy (Human) LPS / IL-1 Mediated Inhibition of RXR Function Liver Necrosis / Cell Death Cell Cycle: G1 / S Checkpoint Regulation Decr. Transmembrane Potential of Mitochondria and Mito. Membrane Decrease in membrane potential of mitochondria and mitochondrial membrane Increases Glomerular Injury Cardiac Fibrosis Vasopressin-induced Genes Inner Med. Renal Coll. Duct Cells (Rat) Incr. Perm. Transition of Mitochondria and Mito. Membrane Increased permeability transition of mitochondria and mitochondrial membrane Cardiac Necrosis / Cell death pvalue P value p-value of overlap Activation Z-score Activation Z-score Not significant MEK1 inhibitor EZH2 inhibitor Figure 21 MES or PN-hGICs-MGT#1 in RHBA+P / S (3%O2) heparin Transwell insert Microporous membrane MDSCs-like in RHB-A hMG-like in RHB-A Adaptation in RHBA (>3 passages) glutamine Dexamethasone Donor-derived hCD34+ in SFEMII+P / S Donor-derived hCD34+ in SFEMII+P / S brain-driven_immortalized hCD11b+(hMG-cl.C20) in BrainPhys+P / S Brain-derived immortalized hCD11b+(hMG-cl.C20) in BrainPhys+P / S % of total ctrl Control Viability Topotecan Mitomycin C Olaparib Temozolomide all mRNAs DDR genes Fig. 22 gRNA relative expression cumulative gRNAs distribution cumulative gRNA distribution Non-essential gRNAs Essential gRNAs all conditions all conditions Input

[0310] The present invention encompasses the following: 1.a) Providing a gene expression profile of a cell type of interest; b) providing genomic sequence data for said cell type of interest; c) selecting a set of signature genes from said gene expression profile; wherein the signature genes are (i) differentially regulated compared to a reference cell type, or (ii) selected according to gene expression levels; d) identifying genes encoding transcription factors in the set of signature genes selected in c); e) determining a set of genomic regions from the genomic sequence data; wherein each genomic region comprises a sequence encoding a signature gene identified in c) and additional genomic sequences adjacent to the sequence encoding the signature gene; f) identifying a plurality of genomic subregions of comparable limited size, preferably the same size, in the set of genomic regions determined in e); wherein the genomic subregion comprises one or more binding sites for one or more of the transcription factors identified in d); g) selecting a minimum set of preferably 2 to 10 genomic subregions from the genomic subregions determined in f); wherein the set of genomic subregions is selected to contain transcription factor binding sites for a predetermined percentage of all transcription factors identified in d); h) generating a cell type specific expression cassette comprising the set of genomic subregions selected in step g) operably linked to a reporter gene or an effector gene; wherein the genomic subregion is configured to regulate expression of the reporter gene or effector gene; A method for generating a cell type specific expression cassette comprising: 2. The gene expression profile comprises the expression levels of genes in the subject's cell types; According to step c)(i), a gene expression profile of a reference cell type comprising expression levels of genes in the reference cell type is prepared, and differentially regulated signature genes are selected by identifying genes that are up- or down-regulated compared to their expression levels in the reference cell type, preferably by selecting genes that are 3-fold to 10-fold up-regulated in the cell type of interest; or 2. A method for generating an expression cassette according to claim 1, comprising ranking the genes of said cell type of interest according to their gene expression levels and selecting signature genes based on expression of a predetermined level or a predetermined number of signature genes, such as the 100 to 1000 most highly expressed genes or the 100 to 1000 least expressed genes in said cell type of interest according to step c)(ii). 3. A method for generating an expression cassette according to claim 1 or 2, wherein the predetermined percentage of transcription factors covered is 30% or more, preferably 40% or more, most preferably 50% or more. 4. A method for generating an expression cassette according to any one of claims 1 to 3, wherein the genomic region determined in e) corresponds to a genomic sequence of a topologically associated domain containing said differentially regulated genes, preferably the topologically associated domain corresponds to a genomic sequence between two CTFC binding sites located outside the coding region of said signature gene, preferably comprising said signature gene. 5. The identification of genomic subregions of the same size in step f) is carried out by a sliding window algorithm of the genomic regions determined in e); Preferably, the window has a length of 500 bp to 5000 bp, preferably 700 bp to 2000 bp, more preferably 800 bp to 1200 bp, most preferably 1000 bp; The sliding step has a length of 100 bp to 1000 bp, preferably 120 bp to 300 bp, more preferably 130 bp to 170 bp, and most preferably 150 bp; A method for producing the expression cassette according to any one of items 1 to 4 above. 6. The selection of a set of genomic subregions in g) comprises, for each genomic subregion identified in f), d) enrichment of binding sites for transcription factors in said genome sequence data; A diversity score for the transcription factors for which binding sites exist; This is done by calculating the genomic subregions are ranked according to the cumulative percentage of transcription factors for which they have binding sites; A minimal set of genomic subregions is selected that contains binding sites for a predefined percentage of all transcription factors identified in d). A method for producing the expression cassette according to any one of items 1 to 5 above. 7. A cell type-specific reporter vector comprising an expression cassette produced by the method according to any one of the preceding paragraphs 1 to 6. 8. A synthetic regulatory region comprising 2 to 10 genomic subregions of 100 bp to 1000 bp adjacently located without a linker or with a linker sequence of less than 100 bp located between the subregions, said subregions being derived from distinct (non-adjacent) locations in the same genome of a cell type, said subregions cumulatively comprising binding sites for at least 5, preferably at least 10, most preferably at least 20 transcription factors; A reporter gene or an effector gene; wherein the genomic subregion is operably linked to a reporter gene or an effector gene so as to regulate expression of the reporter gene or the effector gene. 9. The vector according to the preceding item 8, wherein each of the genomic subregions has a length of 120 bp to 300 bp, more preferably 130 bp to 170 bp, and most preferably 150 bp. 10. The vector according to the preceding item 8 or 9, wherein the genomic subregion adjacent to the reporter gene or effector gene comprises a transcription initiation site. 11. The vector according to any one of the preceding paragraphs 8 to 10, wherein the reporter gene or effector gene encodes a protein selected from the group consisting of a fluorescent protein, a suicide gene, luciferase, β-galactosidase, chloramphenicol acetyltransferase, a surface receptor, a protein tag, including but not limited to, 6xHis tag, V5 tag, GFP tag, a self-processing ribozyme cassette, mevalonate kinase and derivatives thereof, biotin ligase and derivatives thereof, including but not limited to, BirA, modified peroxidase and derivatives thereof, including but not limited to, APEX2, a restriction enzyme, an endonuclease or site-specific recombinase and derivatives thereof, including but not limited to, Cre, Flp, Tn5, SpCas9, SaCas9, TALEN, and a gene that corrects a single gene disease. 12. A vector according to any one of the preceding paragraphs 8 to 10, comprising a nucleic acid sequence according to SEQ ID NOs: 1 to 6 or a nucleic acid sequence having at least 80%, preferably at least 90%, identity to any one of SEQ ID NOs: 1 to 6. 13. Use of a vector according to any one of the preceding paragraphs 8 to 12 for transforming cells and / or determining cell characteristics, preferably cell type, state or fate conversion, for gene therapy and viral therapy, drug discovery or validation. 14.a. preparing the vector according to any one of the preceding paragraphs 8 to 12; b. providing cells; c. transducing the cell with the vector; d. measuring a signal indicative of expression of the reporter gene; wherein the amount of said signal is indicative of a property of said cell, preferably a cell type, state or fate transition; 20. A method for determining a characteristic, preferably a cell type, state or fate transition, of a cell comprising: 15. A computer-implemented method for determining the sequence of a synthetic locus control region (sLCR), comprising steps a) to g) of 1 above.

Claims

[Claim 1] a) providing a gene expression profile of a cell type of interest; b) providing genomic sequence data for said cell type of interest; c) selecting a set of signature genes from said gene expression profile; wherein the signature genes are (i) differentially regulated compared to a reference cell type, or (ii) selected according to gene expression levels; d) identifying genes encoding transcription factors in the set of signature genes selected in c); e) determining a set of genomic regions from the genomic sequence data; wherein each genomic region comprises a sequence encoding a signature gene identified in c) and additional genomic sequences adjacent to the sequence encoding the signature gene; f) identifying a plurality of genomic subregions of comparable limited size, preferably the same size, in the set of genomic regions determined in e); wherein the genomic subregion comprises one or more binding sites for one or more of the transcription factors identified in d); g) selecting a minimum set of preferably 2 to 10 genomic subregions from the genomic subregions determined in f); wherein the set of genomic subregions is selected to contain transcription factor binding sites for a predetermined percentage of all transcription factors identified in d); h) generating a cell type specific expression cassette comprising the set of genomic subregions selected in step g) operably linked to a reporter gene or an effector gene; wherein the genomic subregion is configured to regulate expression of the reporter gene or the effector gene; A method for generating a cell type specific expression cassette comprising:

Citation Information

Patent Citations

  • Method for quickly enriching, separating, identifying and quantifying endogenesis transcription factor and compound thereof by adopting few samples and special device thereof

    CN106546674A

  • Physiology analyzing method and system

    JP2003203078A

  • Method for constructing specific promoters

    JP2014506456A

  • A method for analyzing nucleotide sequence interactions in three-dimensional DNA structures

    JP2016537029A

  • Muscle-specific nucleic acid regulatory elements and methods and uses thereof

    JP2017505126A